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Abstract 
The formation of macromolecular complexes and the solution behaviour of proteins are results of 
protein-protein interactions (PPI) and the nature of the solution components. PPI’s can be divided 
into two broad categories of attractive and repulsive forces. From a formulation perspective, proper 
interaction is critical for the long term stability of a pharmaceutical. Protein complex formation is 
important for extended half-life in vivo and is essential to cellular communication such as the 
induction of the insulin response. 
This thesis focuses on human serum albumin (HSA) as a central player and the ability of small-
angle X-ray scattering (SAXS) to study proteins under diverse solution conditions. HSA is utilized 
in many ways in the pharmaceutical industry such as the formulations of other proteins and in 
particular for half-life extension of peptides, where the long half-life of up to 21 days of HSA is 
deployed.  
The thesis is divided into four parts: 1) Self-interaction of HSA in pharmaceutical relevant systems; 
2) The liraglutide oligomer and interaction with HSA; 3) Conjugation of GLP-1 to HSA and last but 
not least 4) A benchmark study of the implementation of SAXS in RosettaDock. 
HSA is used as a stabilizer in formulation where it is known to decrease adsorption to the air/liquid 
and liquid/container interfaces, thereby reducing the aggregation propensity of the target protein. 
However, with high concentration liquid formulations coming into focus limited information is 
available on the behaviour of HSA in these crowded environments. We have applied SAXS in order 
to shed light on the self-interaction of HSA in pharmaceutical relevant buffer systems on protein 
concentrations up to 150 mg/ml. HSA stabilized by octanoate is observed to interact by purely 
repulsive forces in the investigated concentration ranges while defatted HSA show attractive forces 
at low protein concentration. The tonicity corresponding to isotonicity, is observed to coincide with 
the maximum screening observed in all systems while this is not observed as a function of ionic 
strength, making tonicity an important parameter for protein interaction in the investigated systems. 
Trehalose is seen to provide a screening effect of added NaCl leading us to think that trehalose 
somehow determines the range of interaction of the proteins in solution. Finally it is proposed that 
the stabilizing effect of HSA could be mediated by a repulsive network of HSA molecules 
screening the interaction of other proteins, hereby decreasing the aggregation propensity. 
Glucagon-like peptide 1 (GLP-1) is an incretin hormone used in the treatment of diabetes mellitus 
type 2. Due to its very limited half-life of approximately 3 minutes, Novo Nordisk A/S developed 
an acylated analogue, liraglutide, which due to multimerization and probable interaction with HSA 
in-vivo, makes it applicable for once daily administration. The oligomerization and the interaction 
with HSA were investigated by SAXS and static light scattering (SLS). The oligomeric state of 
liraglutide was approximately heptameric but due to uncertainties, the experimental studies were 
complimented by a series of molecular dynamic (MD) simulations. The results from MD where 
compared to the experimental SAXS data and the combined effort show that the liraglutide 
heptamer was the most probable multimer. The studies of liraglutide with HSA both in a defatted 
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form and a stabilized form, were capable of confirming the presence of a hetero complex though at 
very low concentration. This could be a result of very transient interaction or the consequence of 
non-optimal buffer conditions. 
Another approach to half-life extension is conjugation of molecules to HSA. In this part of the 
thesis, novel GLP-1-albumin conjugates developed by Albumedix A/S where examined by a 
combined approach of pharmacokinetic studies and solution structure determination with SAXS. 
GLP-1 was conjugated to Cys34 of recombinant HSA (rHSA) and two rHSA variants with lower 
(NB) and higher binding (HB) affinity to the neonatal Fc receptor (FcRn). Binding kinetics showed 
that the conjugation had limited effect on the binding properties of the conjugates to FcRn 
compared to the respective rHSA variants. Increased in-vivo half-life of the conjugates was 
observed in NMRI WT mice compared to GLP-1, with the HB-variant displaying ~300 times longer 
half-life, while the potency of GLP-1-albumin was decreased by 3-4 orders of magnitude compared 
to GLP-1. The solution structure of the rHSA variants and the conjugates indicate a flexible nature 
of the conjugate, with the GLP-1 pointing away from the surface of rHSA. The low resolution 
structure from SAXS combined with high resolution structural information from X-ray 
crystallography, explains the pharmacokinetics results, as limited interference is seen between FcRn 
and the conjugate, while albumin steric hindrance explains the decreased potency of the conjugates. 
Structure determination of macromolecular complexes can be challenging by traditional approaches 
such as X-ray crystallography and NMR. An alternative approach is the use of experimental 
knowledge in combination with in-silico modelling to gain knowledge about macromolecular 
complexes. The final part of the thesis regards the benchmarking of the protein docking tool, 
RosettaDock, in combination with SAXS. The RosettaDock protocol is a two-step process 
involving a low resolution rigid body protocol, set up to imitate the initial protein-protein 
encounter, followed by a high resolution protocol where the position of the proteins and amino acid 
side chains are optimized. We applied SAXS as constrain (SAXSconstrain) after the low resolution 
step to filter out complexes with overall shapes which would not match the SAXS data. Since it is a 
rigid body approach larger conformational changes in any part of the complex provides a limit to 
the method either from interface non-complementarity or a resulting shape which deviates from the 
SAXS data. 38 structures from Benchmark 4.0 of different difficulty levels were investigated using 
this approach. In general our result indicate that implementation of  SAXSconstrain reduces the 
sampling space and increases the probability of finding a near-native structure. In a wider 
perspective, the strength of RosettaDockSAXS lies in the combination of low-resolution structural 
information from SAXS experiments and the protein-protein interaction energies obtained from 
RosettaDock which provides means to gain insight to higher resolution information about the 
interface between two protein partners. This allows for the prediction of unknown three-
dimensional atomic structures of protein-protein complexes. 
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Dansk populært resumé  
Dannelse af makromolekylære komplekser og proteiners opførsel i vandige opløsninger er et 
resultat af protein-protein interaktion (PPI) og den kemiske natur af opløsningens komponenter. PPI 
kan deles i to brede kategorier som dækker over attraktive og frastødende kræfter. Fra et 
formulerings perspektiv er den rette interaktion kritisk for den langsigtede stabilitet af et 
lægemiddel. Protein kompleksdannelse er vigtig for forlængelse af halveringstid in vivo og er 
essentiel for cellulær kommunikation såsom induktion af insulinresponset.  
Denne afhandling fokuserer på human serum albumin (HSA) og brugen af småvinkel røntgen 
spredning (SAXS) til at studerer proteiner under forskellige opløsningsbetingelser. HSA benyttes på 
mange måder i den farmaceutiske industri, såsom i formuleringen af andre proteiner og navnligt for 
halveringstids-forlængelse af peptider, hvor den lange halveringstid for HSA på op til 21 dage 
bliver udnyttet.  
Afhandlingen er delt i fire hovedafsnit: 1) Selv-interaktion af HSA i farmaceutisk relevante 
systemer; 2) Liraglutid oligomeren og dennes interaktion med HSA; 3) Konjugering af GLP-1 til 
HSA og sidst men ikke mindst 4) Et benchmark studie af implementering af SAXS i RosettaDock. 
HSA benyttes som stabilisator i formuleringer, hvor det er kendt at den reducerer adsorption til 
luft/væske og væske/beholder grænseflader og hermed reducerer aggregerings tilbøjeligheden for 
mål proteinet. Der er desværre ikke megen information tilgængelig om opførelsen af HSA i mere 
tætpakkede systemer, som ved formuleringen af høj-koncentrations protein opløsninger. Vi har 
benyttet SAXS til at belyse selv-interaktionen af HSA i farmaceutisk relevante systemer i protein 
koncentrationer op til 150 mg/mL. Det ses at når HSA er stabiliseret af oktanoat, er interaktionen 
domineret af frastødende kræfter, mens affedtet HSA viser attraktion ved lav protein koncentration. 
En tonicitet svarende til isotonicitet, er observeret til at koincidere med maksimum screening af 
protein molekyler i vandig opløsning for alle systemer, mens dette ikke er tilfældet som en funktion 
af ionstyrke. Dette gør tonicitet til en vigtig parameter for protein interaktion i de undersøgte 
systemer. Trehalose ser ud til potentielt at screene tilsat NaCl, hvilket føre os til at tænke at 
trehalose på en eller anden måde bestemmer rækkevidden for interaktionen for proteiner i 
opløsning. Til sidst foreslås det at den stabiliserende effekt af HSA ved højere protein 
koncentration, kan opstå ved dannelsen af et netværk af frastødende HSA molekyler, som derved 
screener interaktionen mellem andre proteiner hvorved aggregerings tendensen vil formindskes. 
Glukagonlignende peptid-1 (GLP-1) er et inkretin hormon som benyttes i behandlingen af diabetes 
mellitus type 2. Da GLP-1 har en begrænset halveringstid på ca. 3 minutter, har Novo Nordisk A/S 
udviklet en acyleret analog, liraglutid, som på grund af multimerisering og en tilsyneladende 
interaktion med HSA in-vivo, gør en-gang-daglig administration mulig. Oligomerisering og 
interaktion med HSA var undersøgt ved hjælp as SAXS og statisk lys spredning (SLS). Liraglutid 
oligomeren viste sig at bestå af ca. 7 monomerer (heptamer), men grundet usikkerheder blev de 
eksperimentelle studier komplimenteret af en serie af molekyl-dynamisk (MD) simuleringer. 
Resultaterne fra MD blev sammenlignet med SAXS data og den kombinerede tilgang viste at 
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heptameren var den mest sandsynlige multimer. Studierne af liraglutid med HSA i både en affedtet 
og stabiliseret form, kunne bekræfte eksistensen af et hetero kompleks men ved meget lav 
koncentration. Dette kan være et resultatet af en svag binding af liraglutid til HSA eller af ikke 
optimale pufferbetingelser. 
En anden tilgang til halveringstids-forlængelse er konjugering af molekyler til HSA. I denne del af 
afhandlingen er ny-skabte GLP-1-albumin konjugater udviklet af Albumedix A/S, undersøgt ved en 
kombineret tilgang af farmakokinetik og struktur analyse ved hjælp af SAXS. GLP-1 var konjugeret 
til Cys34 af rekombinant HSA (rHSA) og to HSA varianter med højere (HB) og lavere (NB) 
bindingsevne til neonatal Fc receptoren (FcRn). Affinitets studier viste at konjugeringen havde 
begrænset effekt på bindingsevnen af konjugaterne til FcRn sammenlignet med de respektive rHSA 
varianter. En øget in-vivo halveringstid af konjugaterne var observeret i NMRI WT mus 
sammenlignet med GLP-1, hvor HB varianten viste en omkring 300 gange længere halveringstid, 
mens potensen af GLP-1-albumin var nedsat 3-4 størrelsesordner sammenlignet med GLP-1. 
Strukturen af rHSA og konjugaterne i vandig opløsning indikere at den konjugaterde GLP-1 er 
fleksibel og peger væk fra overfladen af rHSA. Lav-resolutions strukturen fra SAXS kombineret 
med høj-resolutions information fra røntgen krystallografi, kan forklare de farmakokinetiske 
resultater, da begrænset interferens er observeret mellem FcRn og konjugaterne, mens sterisk 
hindring fra albumin kan forklare den nedsatte potens af konjugaterne. 
Struktur bestemmelse af makromolekylære komplekser, ved hjælp af traditionelle tilgange såsom 
røntgen krystallografi og NMR, kan være udfordrende. En alternativ tilgang til information om 
sådanne komplekser er brugen af eksperimentel viden i kombination med in-silico modellering. Det 
sidste kapitel af afhandlingen handler om en benchmarking af protein docking programmet, 
RosettaDock, kombineret med SAXS. RosettaDock protokollen består af to trin, hvor det første trin 
imiterer det indledende møde mellem de to protein partner. Under det næste trin bliver positionen af 
den mindre protein partner og sidekæde positioner mellem de to proteiner, optimeret.  Vi benytter 
SAXS under det første trin (SAXSconstrain) for at begrænse det søgerum der er tilgængeligt for 
RosettaDock. Da det er en ”rigid body” tilgang vil større konformationelle ændringer, enten mellem 
de to proteiner eller på overfladen, begrænse metoden da det kan resultere i en overordnet form som 
ikke svarer overens med SAXS resultaterne. 38 strukturer fra Benchmark 4.0 med forskellige 
sværhedsgrader blev undersøgt. Generelt indikerer vores resultater at implantationen af SAXSconstrain 
begrænser søgerummet og øger chancen for at finde et kompleks af næsten oprindelig struktur. I et 
større perspektiv ligger styrken af RosettaDockSAXS i kombinationen af lav-opløsnings 
information fra SAXS og protein-protein interaktions energierne fra RosettaDock. Dette giver en 
mulighed for højere-opløsnings information om grænsefladen mellem to proteiner og åbner 
muligheden for mere nøjagtig forudsigelse af ukendte protein-protein komplekser. 
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Abbreviations 
 
B22  Osmotic second-virial coefficient 
BSA  Bovine serum albumin 
dG  Interface energy 
dHSA  Defatted HSA 
DLVO  Derjaguin-Landau-Verwey-Overbeek 
Dmax  Maximum diameter of particle 
DPP-IV  Peptide by dipeptidyl-peptidase IV 
FA  Fatty acid 
FcRn  Neonatal Fc receptor 
GLP-1  Glucagon-like peptide 1 
GLP-1R  GLP-1 receptor 
GLP-1-PEG-mal  HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR-
K-(8-amino-3,6,dioxaoctanoyl-
maleimidopropionyl)) 
 
HSA  Human serum albumin 
IRMSD  Interface root mean square deviation 
KD Dissociation constant 
Lir  Liraglutide 
MD  Molecular dynamic 
MSA  Mean spherical approximation 
Mw  Molecular weight 
NMR  Nuclear magnetic resonance 
PEG  Polyethylene glycol 
PPI  Protein-protein interactions 
RG  Radius of gyration 
rHSA  Recombinant HSA 
rTP  Recombinant therapeutic protein 
SANS  Small angle neutron scattering 
SAS Small angle scattering 
SAXS  Small angle X-ray scattering 
SLS  Static light scattering 
SVD  Singular value decomposition 
WT Wild type 
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 Introduction 1
 
 
Biologics is a broad term covering biopharmaceuticals derived from natural sources such as blood 
and products produced via recombinant techniques
1
.  In the pharmaceutical industry, biologics, and 
in particular recombinant therapeutic proteins (rTP) such as monoclonal antibodies and the insulin 
derivative Detemir (Levemir® ) (1, 2), are becoming increasingly important due to the higher 
specificity and efficiency compared to traditional small molecule drugs.  As nothing comes cheap, 
development of these new drugs comes with a high price. Development from concept to specific 
product can take years as small changes in the primary structure of a protein, can have a big impact 
on its specificity, efficacy and stability. Stability of an rTP is critical to its functions as degradation 
can have impact on activity and shelf-life and can possibly induce an allergic reaction in patients, 
rendering the patient immune to subsequent administration. Additionally, rTPs can have potential 
serious side effects, which need to be seen from the point of view of what beneficial effect is gained 
from the pharmaceutical. To this end, regulatory instances such as the FDA (U.S. Food and Drug 
Administration) apply strict rules to biologics before they are allowed on the marked. All together, 
these challenges result in large million dollar investments from pharmaceutical companies without 
guaranties. Elimination of bottlenecks such as upscaling problematics and stability challenges can 
help in reducing both costs and time resulting finally in faster and more efficient development and 
lower cost for patients. 
                                                 
1 http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm 
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The stability of proteins in solution reflects the interplay between water, co-solvent and the nature 
of the protein. The physical-chemical nature of both co-solvent and macromolecule and their effect 
on water all add to the interplay.  
To increase the understanding on the physical-chemical stability and/or overall solution structure of 
a glucagon-like peptide 1 (GLP-1) analogue and to gain insight into the interaction with human 
serum albumin, two strategies were employed. Experimentally by solution characterization using 
small angle X-ray scattering (SAXS) and static light scattering (SLS) and by combining this 
knowledge with in-silico modelling of potential protein complexes using the Rosetta modelling 
suite.  
The results have been divided into four sections after a formal introduction to human serum 
albumin (HSA) strategies and the concept of protein formulation. Each section includes an 
introduction to the theme in question.  
The first part focuses on the self-interaction of HSA due to its ability to stabilize other proteins. 
This section sets particular focus on HSA behaviour at higher protein concentrations as this has not 
received very much attention in the literature. As few methods are available to examine proteins at 
higher concentration the combination of SAXS and static light scattering provides a means to get 
insight into the interaction parameters governing these solutions.  
Second, the focus will be set on the acylated GLP-1 analogue, liraglutide (Victoza® ,Novo Nordisk 
A/S). Here the self-interaction of liraglutide and its potential interaction with HSA in solution will 
be examined by SAXS and static light scattering (SLS).  GLP-1 is used in the treatment of Diabetes 
mellitus type 2 but its utilization is problematic due to the limited in-vivo lifespan (3). In order to 
find a way around the natural fast degradation several different approaches have been employed, 
including acylation and conjugation to larger molecules such as HSA, which has long natural 
plasma half-life. Acylation is believed to increase the half-life, as in the case with Levemir® 
(Norvo Nordisk A/S) by oligomerization of the hydrophobic peptide in combination with 
interaction with HSA in human serum (4, 5).  Introduction of a fatty acid moiety introduces other 
challenges though, as these hydrophobic peptides can be difficult to stabilize in solution.  
Conjugation of GLP-1 to HSA offers another opportunity to utilize the long half-life of HSA. The 
major concerns for conjugations are that a change in structure of both HSA and the peptide can 
affect both potency of the peptides and immunogenicity. As a part of understanding GLP-1 and 
HSA interaction, the solution characterization of GLP-1 conjugated to four recombinant HSA 
(rHSA) variants will be presented. This study is presented in conjunction with pharmacokinetic 
characterization by Albumedix A/S.  
Finally the Rosetta modelling suite was chosen as an instrument to model complexes in solution 
using the results derived from SAXS. As limited information was available regarding the success of 
this combination, the result from benchmarking the Rosetta protein docking protocol, RosettaDock, 
using SAXS as a constrain is presented in chapter 6.    
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1.1 Serum albumin: Structure and drug delivery  
In the human blood plasma several transport proteins are found. The most abundant of these with a 
concentration of up to 50 mg/ml, is human serum albumin (HSA) (6). With a molecular weight of 
66.5 kDa, it is produced in the hepatocytes of the liver and secreted. In blood it transports a variety 
of substances such as fatty acids, ions and small molecule pharmaceuticals, acts as a scavenger and 
helps regulating the colloid osmotic pressure.  
The first reference to albumin can be found dating back to 400 years BC by Hippocrates of Cos (7) 
who noticed foamy urine in patients with chronic liver disease. In the nineteenth century albumin 
was firstly characterized as the soluble part of dialyzed blood plasma and finally crystallized in 
1936 by Hewitt (7), but not until 1990ties did the crystal structure get elucidated. The heart shaped 
structure was published at a resolution of 6 Å by D. C. Carter and X. M. He (8), and a few years 
later by the same group down to 2.8 Å (9). This helped mapping the ligand binding pockets of HSA 
and several structures of complexes of HSA bound with ligands has since been solved. 
HSA STRUCTURE 
HSA is a 585 amino acid long peptide which folds into a mainly a-helical structure. It consists of 
three major domains (I, II and III), Figure 1-1, each consisting of two subunits (termed A and B). 
The structure is stabilized by 17 intra-subdomain disulphide bridges with one free thiol at position 
34. Though characterized as a stable globular protein HSA is actually a rather flexible molecule, 
where movement of the individual domains enhances binding to ligands and/or the neonatal FcRn 
receptor (10–12). From the crystal structures  of defatted HSA; PDBID: 1AO6 (13), Myristic acid 
bound HSA; 1E7G (10) and in complex with the MHC like Fc receptor (FcRn); 4N0F(12), three 
different conformations can be observed.  
The Stephen Curry group identified seven distinct binding sites of longer fatty acids (FAs) (lauric, 
myristic, palmitic and stearic acids), with another putative binding site in domain IA (see Figure 
1-1) and additional binding sites for the smaller capric acid (14). An overview of the myristic acid 
binding sites is presented in Figure 1-1. Subdomain IIA (FA7) and IIIA (FA3 and 4) are also known 
as Sudlow’s drug binding sites 1 and 2  respectively  from the work done by G. Sudlow and 
coworkers (15, 16). 
HSA is a well characterized protein and often used as a standard protein, but its many functions and 
abilities are still intriguing and utilized in the pharmaceutical industry (7, 17). HSA therapy has 
traditionally been used in for example the treatment of shock, burn, hypoalbuminemia and cirrhosis 
of the liver (17). Due to fear of cross contamination from albumin purified from human plasma, the 
use of HSA was limited until the advent of recombinant HSA (rHSA).  
The introduction of rHSA, such as Recombumin® Alpha from Albumedix A/S, has resurrected the 
interest in HSA. Current focus in drug delivery utilizes the long half-life of albumin of 
approximately 20 days  (6, 18), while formulation scientist wish to harvest the high stability, anti-
oxidative behaviour and solubility of HSA to stabilize other proteins.  
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Figure 1-1Crystal structure of HSA in complex with Myristic acids (PDB 1E7G). Domain names are highlighted in bold 
with FA binding sites in italic. Fatty acids (FA) are presented as grey spheres with oxygens in red.  Domain colouring 
and naming of domains and FA binding sites, have been done in accordance with the nomenclature adopted by 
Bhattacharya et al.(14). References in the text to the FA binding sites are shorthanded to FA1-7. 
HSA HALF-LIFE EXTENSION  
The long half-life of albumin arises from binding to FcRn which results in a pH dependent 
recycling mechanism, rescuing HSA from degradation in the same manner as IgG (19, 20). Using 
albumin as a vehicle for drug delivery can take advantage of this prolonged half-life, increasing the 
half-life of otherwise fast degraded peptides and other small molecules. Different strategies for half-
life extension are being employed in several ways. One strategy is chemical conjugation to 
exogenous albumin via Cys34 or genetic fusion to the N - or C – terminal. Another strategy utilizes 
the natural affinity of HSA for FAs for in-vivo binding to endogenous albumin such as done for the 
acylated insulin and GLP-1 analogues, levemir and liraglutide (Novo Nordisk A/S). The increase in 
half-life of these peptides is mainly mediated by the oligomerization of the acylated peptides which 
stabilizes an oligomeric species and delays the protraction, while HSA binding is secondary (5, 21). 
Another interesting approach is the use of HSA/drug nanoparticles as used in Abraxane® (Celgene 
Corporation).  
Important to all strategies is the conservation of the three dimensional structure of both the drug and 
HSA and to avoid interfering with the FcRn binding site of HSA. Genetic fusion of a scFv fragment 
(antibody derived single-chain variable fragment) to the N- and C-terminal, showed that C-terminal 
genetic fusion has a slight negative binding to FcRn while N-terminal does not affect binding (22). 
Conjugation of different PEG sizes to Cys34 of HSA, has shown a negative influence on the 
binding of HSA to FcRn, while the same study show that by using a HSA variant with a higher 
FcRn binding affinity can circumvent this effect (23). 
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HSA STABILITY 
It is known that fatty acids and especially octanoate, stabilizes HSA while removing these makes 
HSA prone to dimerization and higher oligomerization (7). This behaviour stresses the importance 
of using a stabile HSA as an additive in formulation. In formulations HSA can aid in decreasing 
surface tension, which will decrease the interaction of the protein to be stabilized (Ps) with the 
air/water interface. Reducing the interaction with the liquid/container interface is equally important 
as both can induce non-specific aggregation.  Steric exclusion by HSA stabilizes Ps by increasing 
the preferential hydration and the antioxidant properties of HSA provided by the one free cysteine, 
Cys34, yields another protective layer from reactive oxygen species. 
1.2 Understanding the stability of a formulation 
Drugs can be administered in several ways such as subcutaneous, intravenous and orally. Different 
administration routes give rise to different challenges to a formulation scientist and the main focus 
here will be on liquid formulations. The formulation of a biologic is crucial to its stability both with 
respect to short – and long term stability. The properties of the liquid formulation or solution are 
determined by the chemical and physical properties of the protein and of the excipients in solution 
such as salts, sugars, surfactants and the pH of the system. These influence protein self-association 
and association with the air/surface interface and adsorption to the container.  
Proteins in solution are subject to a number of risk factors on their way to their destination. From 
expression and purification to end product and transport, and finally shelf-life until purchased 
several stress factors are present. Temperature differences, movement of containers and time are but 
a few factors that all poses different levels of stress which can lead to degradation. This shows the 
importance of the formulation and to what extend it needs to protect the protein. 
Increasing the concentration of a protein can lead to changes in solution properties from self-
association either native or non-native. Native self-association of proteins, such as oligomerization 
or clustering, is often reversible but can lead to instability in high concentrated formulations causing 
phase separation and high viscosity. Currently there is a focus on development of high concentrated 
biologics to ease patient comfort by switching from long term IV infusion and hospitalization to 
home injection via for example an injection pen as done today for biologics such as insulin and 
infertility drugs. In order for this to be realized these challenges need to be overcome. Non-native or 
irreversible aggregation is a complex process resulting from unspecific interaction of non-native 
conformations of the protein. These non-native proteins are a result of degradation and the result 
can be loss of activity or induced immunity in the patient. Degradation can be divided into chemical 
and physical processes. Modifications to covalent bonds such as deamidation of Asn and Gln 
residues, oxidation and disulfide-bond shuffling refers to chemical degradation, while the physical 
processes refers to unfolding and adsorption to a surface,  all potentially leading to aggregation of 
the non-native protein.  
To understand how proteins behave in solution and what forces contribute to stabilize the solution 
several techniques are available to either investigate chemical or physical stability (24). For high 
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concentration protein solution the choice of methods become limited though, as dilution often is 
needed for proper characterization. Extrapolation from dilute to concentrated solution is 
problematic due to the more complex behaviour of proteins at higher concentration (25). 
Characterization of the physical properties from dilute to higher concentrations is possible using 
solution methods such as static light scattering (SLS) and small angle-scattering (SAS).  These 
methods are highly complementary and provide information about the shape, size and molecular 
weight of the sample as well as information about the thermodynamic behaviour of the system 
through measurements on increasing protein concentrations. The thermodynamic behaviour is 
expressed via the second virial coefficient, B22, obtained directly from SLS and the structure factor 
(𝑆(𝑞)) derived from SAXS, which can be translated into an interaction potential describing the 
interaction between the molecules.  The structure factor reflects the distribution of the particles in 
the solution where the interaction potential describes repulsive or attractive interaction between 
molecules, but cannot give information about specific ion effects. 𝑆(0) is directly related to B22 but 
is an approximation as the beam stop makes it impossible to measure SAXS at 0 degrees. Due to 
several approximations needed in order to simulate macromolecular interaction the description is 
mainly qualitative. 
Different methods have been employed to extract information from SAXS and SANS studies. Early 
SAXS studies on α-crystallin proteins of the eye lens by A. Tardieu and co-workers (26, 27) used 
the renormalized mean spherical approximation (MSA), combined with a Verwey-Overbeek 
potential which is a pure repulsive coulombic potential. They show that the charge and diameter 
derived from 𝑆(𝑞) modelling are in close agreement with experimental derived parameters and 
relate the repulsive interaction to the spatial organization of α-crystallins inside the eye-lens leading 
to transparency. B. Sjöberg and K. Mortensen investigated HSA in D2O in a concentration range of 
4-260 mg/mL and at different NaCl concentration using small angle neutron scattering (SANS) (28, 
29). The structure factors were simulated using Monte Carlo simulation and they found that the 
interaction could be explained by a hard core combined with a symmetrical repulsive potential. 
They observed repulsion as low as ~4 mg/ml, even at a NaCl concentration of 1.08M. In another 
study bovine serum albumin (BSA) has been examined by SAXS in H2O and varying NaCl 
concentrations (30). The distinct feature in this study is the long range attraction needed to model 
the structure factors at NaCl concentration ≥  1 𝑀. Common to the studies is the use of the SANS 
and SAXS to investigate crowded solutions in very simple systems. In the work presented in 
chapter 3, we wish to apply SAXS to the investigation of the stability in more complex systems. 
 
1.3 Modelling of protein complexes with SAXS 
Small angle scattering (SAS) was pioneered by A. Guinier in the 1930ties (31) performing seminal 
work on metallic alloys and during the next 20 years SAS fundamentals were developed by among 
others P. Debye, G. Porod, and O. Kratky (32, 33).  Early SAXS studies on proteins were based on 
characterization of the radius of gyration (RG) using the Guinier approximation and evaluation of 
the shape using simple geometric models such as done by A. G. Malmon on Catalase in 1957 (34).  
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Synchrotron radiation made data collection easier accessible, granting SAXS focus again during the 
1970ties and forward. Data treatment was still hampered by lack of computer power though, why 
models continued to be based on geometric models (35). With the advent of easily accessible 
programs for data treatment and analysis and low resolution shape reconstruction programs during 
the 90ties, SAXS again has become increasingly popular. Today the ease of sample preparation, 
data collection and treatment makes SAXS not only popular but also an attractive technique for 
studying a wide variety of systems. 
In the field of biological macromolecules, SAXS has traditionally been used to characterize the 
overall structure and conformation of biological macromolecules and their complexes. From the 
SAXS profile of a monodisperse, non-interacting sample, RG, the oligomeric state as determined 
from molecular mass and the folded state shape are easily accessible. The resolution limit is in the 
area of 10 – 50 Å which corresponds to the overall shape of a protein but does not give detailed 
structural information (36). 
Structural information from SAXS data can be achieved in many ways, from ab-initio shape 
regeneration over simple rigid body approaches to high resolution docking methods. Important to 
all methods is the need of a monodisperse sample. Ab-initio methods provide the means to 
regenerate the three dimensional shape of a molecule or complex from the scattering curve or the 
pair distribution function utilizing programs such as DAMMIF (37)  and GASBOR (38). The 
resulting shape is of low resolution but can give a good impression of the shape of the protein or 
protein-protein complex. Rigid body programs utilize the information from high resolution 
structures to move the known structures of monomers into an overall oligomer/complex 
conformation which agrees with the data. This works well as an approximation but no specific 
interaction parameters between the amino acids are taken into account. To gain further insight into 
the specific interaction between proteins in a complex the use of in-silico modelling combined with 
SAXS is a promising field. The high resolution knowledge utilized in optimizing the interface 
between two docking partners combined with an overall shape constrain from SAXS has the 
potential to provide a more specific knowledge, keeping in mind that in-silico modelling has its own 
challenges. In chapter a benchmark of the docking program RosettaDock (39) in combination with 
SAXS is presented. 
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 Theory 2
2.1 Small angle X-ray scattering - SAXS 
When a sample is illuminated by an X-ray beam, the X-rays are scattered by the interaction with the 
electrons. Inhomogeneities in the sample, here the biological macromolecule, gives the 
characteristic isotropic scattering profile as a function of the momentum transfer vector, 𝑞, as 
illustrated in Figure 2-1. 𝑞 is the momentum transfer vector given by Equation 1, where 2𝜃 is the 
scattering angle and 𝜆 is the wavelength of the incident beam.  
Figure 2-1 The SAXS experiment. The X-ray beam is scattered by the particles in the sample and the intensity is 
recorded on a detector. Integration of the radially isotropic interference pattern as a function of 𝑞 gives the one-
dimensional scattering profile.  
Scattered beam k1=2π/λ 
  𝒒 = 𝐤𝟏 − 𝐤𝟐
Beam stop 
Incident beam k0=2π/λ 
Detector 
2θ 
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 𝑞 = (4𝜋 sin 𝜃)/𝜆 1)  
In dilute solutions particles are randomly orientated which gives rise to the low resolution from 
SAXS in the area of 10-50 Å. The intensity, 𝐼(𝑞), is the square of the scattering amplitude, 𝑨(𝒒), 
averaged over all orientations, where 𝑨(𝒒) is a Fourier transform of the excess scattering length 
distribution, 𝜌(𝒓). Integration in spherical coordinates gives the expression for (𝑞) , Equation 2, for 
a monodisperse solution without particle interference : 
 
𝐼(𝑞) = 4𝜋 ∫ 𝑝(𝑟) ∗
sin(𝑞𝑟)
𝑞𝑟
𝑑𝑟
𝐷𝑚𝑎𝑥
0
 2)  
where 𝐷𝑚𝑎𝑥 is the maximum particle diameter and 𝑝(𝑟) is the distance distribution function which 
can be determined from the inverse Fourier transformation of the intensity (Equation 3). The 𝑝(𝑟) 
function is a histogram of the distribution of intra-particle distances of the particle. An example of 
𝐼(𝑞) and 𝑝(𝑟) for a sphere are given in Figure 2-2. 
 
 
𝑝(𝑟) =
1
2𝜋2
∫ 𝐼(𝑞)𝑞𝑟 sin 𝑞𝑟
∞
0
𝑑𝑞 3)  
  
Figure 2-2 Example of the form factor, 𝑰(𝒒), (left) and 𝒑(𝒓) function for a sphere with 𝑫𝒎𝒂𝒙  of 10 nm (right). A 
subset of intra particle distances are illustrated by arrows in the inserted orange circle. 
The intensity of the protein is experimentally achieved by measurements on the sample and the 
buffer. Subtraction of the buffer from the sample signal results in the scattering intensity, 𝐼(𝑞), from 
the protein alone, Figure 2-3. 
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Figure 2-3 𝑰(𝒒) of the protein is achieved by subtracting the buffer from the protein/buffer mixture. 
Measurements on water can be used for calibration to get the scattering on an absolute scale in 
order to get the molecular weight (𝑀𝑊). Alternatively measurements on a reference protein can be 
used. The intensity at 𝑞 = 0, 𝐼(0) is proportional to the number of particles in the illuminated 
sample volume and is used to determine 𝑀𝑊, but is not directly accessible from SAXS due to the 
beamstop (see Figure 2-1). 
The Guinier approximation (1) which is valid at low angles (𝑞𝑅𝐺 < 1.3 for globular particles) can 
be used to extrapolate to  𝑞 = 0 and is given by Equation 4, which also provides the radius of 
gyration, 𝑅𝐺. Both parameters can be extracted from the 𝑝(𝑟) function (Equation 3) as well. 
 
𝐼(𝑞) ≅ 𝐼(0) exp [
−(𝑞2 ∗ 𝑅𝐺
2)
3
]  4)  
Once 𝐼(0) is determined from data on an absolute scale 𝑀𝑤 can be calculated from the water 
scattering using equation 5 (2): 
 
𝑀𝑤 =
(𝑁𝐴𝐼(0) 𝑐⁄ )
∆𝜌𝑀
2  5)  
Here Δ𝜌𝑀 = [𝜌𝑀,𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝜌𝑠𝑜𝑙𝑣?̅?]𝑟0, is the scattering contrast per mass, 𝜌𝑀,𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 3,22 ∗
1023𝑒 𝑔−1 is the number of electrons per mass of dry protein, 𝜌𝑠𝑜𝑙𝑣 = 3,34 ∗ 10
23𝑒 𝑐𝑚−3, the 
number of electrons per volume of aqueous solvent, ?̅?: The partial specific volume of the protein 
(estimated average: 0,74 𝑐𝑚3𝑔−1) and 𝑟0 = 2,8179 ∗ 10
−13 𝑐𝑚 is the scattering length of an 
electron. 𝑁𝐴 (Avogadro’s number). 
Additional information about particle shape can be achieved by ab-initio shape reconstruction using 
programs such as DAMMIF (3), where the approximate three dimensional shape of the protein is 
reconstructed from the 𝑝(𝑟) function. 
Prerequisites for particle shape determination are sample monodispersity, no particle correlation and 
that protein-protein interaction (PPI) is negligible. PPI can be either attractive or repulsive forces 
between the particles, which has an effect on the intensity at low q. The distribution of the particles 
is determined from the structure factor (𝑆(𝑞)) as illustrated in Figure 2-4.  
𝐼(𝑞)𝑠𝑎𝑚𝑝𝑙𝑒 𝐼(𝑞)𝑏𝑢𝑓𝑓𝑒𝑟 𝐼(𝑞)𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 
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Figure 2-4 The solution intensity can be described by the convolution product of the form factor (𝑷(𝒒)) and the 
structure factor (𝑺(𝒒)). 
𝑃(𝑞) is referred to as the form factor of the protein and is a result of all intra-particle distances 
reflecting the shape, while 𝑆(𝑞) is the structure factor which represents the inter-particle 
interactions or protein-protein interaction. The convolution product of these gives the measured 
intensity, 𝐼(𝑞).  From experiments, 𝑆(𝑞) can be extracted by dividing 𝐼(𝑞) by 𝑃(𝑞) which 
corresponds to 𝐼(𝑞) at low concentration. Mathematically this is described as: 
 
 
𝐼(𝑞) = 𝑛𝑃(𝑞)𝑆(𝑞)𝑒𝑓𝑓 6)  
where 𝑛 is the proportionality factor and 𝑆(𝑞)𝑒𝑓𝑓 is the structure factor derived from experimental 
data. 
2.2 Structure factors and interaction potentials 
The thermodynamic behavior of protein – protein interaction in solution can be described by 
Derjaguin-Landau-Verwey-Overbeek (DLVO) theory where the proteins interact through hard core 
(excluded volume), long-range repulsion and short range attraction potentials. Repulsive systems 
can often be explained from a hard core and coulombic repulsive potential while more complex 
systems need an attractive term (4–7).  
The structure factor describes a time averaged view of the behavior of the system and what forces 
contribute to the interaction potential. Calculation of 𝑆(𝑞) from interaction potentials and 
comparing to the experimental 𝑆(𝑞)𝑒𝑓𝑓 provide a means to understand what forces govern the 
behavior of the protein in the solution system and the strength of these.  
 To calculate the theoretical 𝑆(𝑞), we realize that for an isotropic system, 𝑆(𝑞) is the Fourier 
transform of the pair correlation function, 𝑔(𝑟), and the total pair correlation is ℎ(𝑟) ≡ 𝑔(𝑟) − 1. 
𝑔(𝑟) is the probability of finding a particle at a distance, r,  from the origin. 
In order to find for ℎ(𝑟) an analytical solution to the Ornstein-Zernike relationship (Equation 7) is 
needed. 
 
ℎ(𝑟) = 𝑐(𝑟) + 𝜌∫𝑐(|?⃗? − ?⃗? ′|)ℎ(𝑟′)𝑑𝒓′ 7)  
𝑆(𝑞) 𝑃(𝑞) 𝐼(𝑞) 
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where 𝑐(𝑟) is the direct correlation function. An initial problem arises as there are two unknowns 
(ℎ(𝑟) and 𝑐(𝑟)) but different closure relations are available to relate these two parameters. Blum 
and Hererra (8) developed a solution to solve this relation by using a two-Yukawa model while Liu 
et al. (5) later showed how this could be done practically with the mean spherical approximation 
(MSA). Here only the repulsive part of the Yukawa potential will be presented as this was used for 
the structure factor estimations in Chapter 3. 
The repulsive part of the Yukawa model is given by (Equation 8): 
 
𝛽𝑢(𝑟) = {
∞                                                                𝑟 < 𝜎
𝑍2𝜆𝐵
(1 + 𝜅𝜎/2)2
 
𝑒𝑥𝑝[−𝜅(𝑟 − 𝜎)]
𝑟            𝑟 > 𝜎
 8)  
 
Z corresponds to the protein valency,  is an effective hard sphere diameter, r is centre-to-centre 
separation, and  is the inverse temperature 1/kbT where kB is Boltzmann’s constant.   is the 
inverse Debye-Huckel screening length given by: 
 𝜅 = √2𝑒2𝑁𝐴𝐼/(𝛽𝜀𝜀0) 9)  
where I is the ionic strength of the solution, e is the electronic charge, 0 is the vaccum permittivity, 
 is the dielectric constant of water, and NA is Avogadro’s number.  B corresponds to the Bjerrum 
length, which is the separation between a pair of ions when the Coulomb energy is equal to thermal 
energy.   
The MSA contains a hard repulsive core which means 𝑔(𝑟) = 0 for 𝑟 ≤  𝜎 (5). This gives: 
 
𝛽𝑢(𝑟) = {
  ℎ(𝑟) = −1                                                        0 < 𝑟 < 𝜎
𝑐(𝑟) =
𝑍2𝜆𝐵
(1 + 𝜅𝜎/2)2
 
𝑒𝑥𝑝[−𝜅(𝑟 − 𝜎)]
𝑟            𝑟 > 𝜎
 10)  
 
The analytical solution has been solved by Y. Liu et al. (5) and applied here in a python script by 
Dr. Robin A. Curtis in Chapter 3. During the fitting to 𝑆(𝑞)𝑒𝑓𝑓, I, Z and 𝜌 where allowed to vary. 
Optimization of 𝜎 by variation of 𝜎 at different protein concentrations, gave an optimal diameter of 
63.6 Å which was set constant at all concentrations. 
2.3 Static Light Scattering 
Static light scattering (SLS) can be used for estimation of molecular weight and evaluation of the 
second virial coefficient (B22) to estimate protein solution properties. A monodisperse sample will 
yield the molecular weight (𝑀𝑊) and B22. Polydisperse systems poses issues in SLS as larger 
molecules will exhibit larger scattering as the scattering intensity, 𝐼𝜃 is proportional to the sixth 
power of the particle diameter. This also means that the sample has to be completely free of other 
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extraneous particles such as dust and all samples are filtered before measurements. SLS is, like 
SAXS, a contrast method where in order to get the protein signal, the buffer signal need to be 
subtracted.  
The light-scattering equation is given by (Equation 11): 
 𝐾𝑐(𝑑𝑛 𝑑𝑐⁄ )2
𝑅Θ
=  
1
𝑀𝑅𝑇
 (
𝑑Π
𝑑𝜌
) 
11)  
where c is protein concentration in units of g/mL, R is the gas constant, T is the temperature,  Π is 
the osmotic pressure, 𝜌 is the protein 𝑑𝑛 𝑑𝑐⁄  is the refractive index increment of the protein 
solution, 𝑅Θ is the Rayleigh scattering of the protein solution minus the scattering from the solvent, 
M is the protein molecular weight, and K is an optical constant equal to 2𝜋2𝑛0
2/(𝑁𝐴𝜆
4) where no is 
the refractive index of the solvent. The refractive index increment of the protein solution 
corresponds to a measurement taken at constant chemical potential of all solvent components. In 
solutions at low to moderate tonicities, the parameter has been measured extensively and is 
approximately equal to 0.185 mL/g.   
𝐵22 can be determined from static light scattering using low protein concentration data.  In this 
case, the osmotic compressibility is expanded in a virial expansion using Equation 11 to give:  
 𝐾𝑐(𝑑𝑛/𝑑𝑐)2
𝑅Θ
= 
1
𝑀𝑊
+ 2𝐵22𝑐 12)  
The virial coefficient is determined from a linear fit to Equation 12 from measurements with 
varying protein concentrations and the inverse of the y-intercept is equal to the protein average 
molecular weight. 𝐵22 provide information about the solution state and the stability as it is related 
to the sum of the potential of mean force (7). A positive value means a repulsive behaviour while a 
negative indicate attraction between the proteins. As attraction can lead to aggregation or 
crystallization, this gives an indication of how favourable the solution is for the given purpose. This 
has been used to identify a potential crystallization window, where the optimal conditions for 
crystal growth should appear (9). 
For concentration dependent oligomerization or hetero complex formation SLS offers another 
possibility, as measuring at different concentrations should give the oligomeric state, and help in 
determining the stoichiometry in a complex from the derived molecular weights. This has been used 
in Chapter 4 to investigate the complex between liraglutide and HSA. For this case, the main 
contribution to the solution non-ideality is due to the binding interaction.  As such, virial 
coefficients are not included in the light scattering equation, which reduces to Equation 13: 
 𝐾𝑐(𝑑𝑛/𝑑𝑐)2
𝑅Θ
= 
1
𝑀𝑊
 13)  
where 𝑀𝑊 is the weight average molecular weight, which is given by Equation 14: 
 T h e o r y  P a g e  | 27 
 
 𝑀𝑊 = ∑𝑐𝑖𝑀𝑖/∑𝑐𝑖
𝑖𝑖
 14)  
where the sum is over all species I, including monomers and the associated forms of the proteins. 
2.4 Rosetta  
The Rosetta modelling suite is a multipurpose software suite originally developed for de novo 
structure prediction (10). It contains a variety of applications for both designing and predicting 
protein structures (11), such as the protein docking tool for docking of non-identical proteins, 
RosettaDock (12, 13) used during this PhD study. RosettaDock is a multi-scale Monte Carlo (MC) 
based docking algorithm which combines a low resolution and a high resolution stage. The low 
resolution stage is a rigid body MC search in coarse-grain mode where the amino acids are 
represented as centroids, while in the high resolution stage the representation is full-atomic and both 
the rigid body orientation and the sidechain conformations are simultaneous optimized (12, 13).  
The energy function utilized by Rosetta is a knowledge based energy function which is mainly 
based on structural knowledge from the Protein Data Bank (PDB) (14). During docking, 
RosettaDock initially samples the conformational space, defined by rotation and translation of the 
smaller protein partner, by an MC search. During this stage, the residues are presented by the four 
backbone atoms, and the sidechain is represented as a centroid (12, 13). The resulting complex is 
evaluated based on the probability of the correctness of the decoy by evaluating the four low 
resolution energy terms listed in Table 2-1 (interchain_pair, interchain_vdw, interchain_env and 
interchain_contact). The environment term evaluates the immediate environment of a residue, and 
the pair-wise interaction evaluates the chemical environment. These are then compared to the 
probability of finding this conformation using statistical information derived from the PDB. The 
other two low resolution terms are setup to penalize overlaps and should roughly capture attractive 
and repulsive van der Waal interactions between the protein partners (12).  
The high resolution energy function is more complex as the centroid representation is extended to a 
full atomic presentation of the protein. The energy function has to be able to take into account 
electrostatic forces, hydrogen bonding, sidechain rotamers and so on. The details of the Rosetta 
high resolution energy terms are briefly described in Table 2-1 but will not be further elaborated 
upon here. The high resolution energy terms presented here are based on the Score12 energy 
weights (15) which have been used previously for interface recognition by Fleishman et al. (16). 
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Table 2-1 Energy function terms, short explanations and the weights used in the protocol presented in Chapter 6. 
Low resolution Explanation Weight 
fastsaxs  SAXS weight 0.5 
interchain_pair  Pair-wise interaction 1 
interchain_vdw  Bumps 1 
interchain_env  Environment 1 
interchain_contact  Contact 2 
High resolution Explanation Weight 
fa_atr Lennard-jones attractive 0.8 
fa_rep Lennard-jones repulsive 0.44 
fa_sol lazaridis-jarplus solvation energy 0.65 
fa_intra_rep  Lennard-jones repulsive between atoms in the same 
residue 
0.004 
fa_pair  Pair-wise interaction 0.49 
fa_plane  pi-pi interaction between aromatic groups, by default = 0 0 
fa_dun  internal energy of sidechain rotamers as derived from 
Dunbrack's statistics 
0.56 
hbond_lr_bb  
hbond_sr_bb  
hbond_bb_sc 
hbond_sc  
Backbone-backbone hydrogen bond, long range 
Backbone-backbone hydrogen bond, short range 
Sidechain-backbone hydrogen bond 
Sidechain-sidechain hydrogen bond 
1.17 
0.585 
1.17 
1.1 
p_aa_pp Probability of amino acid at Phi-psi 0.32 
 
dslf_ss_dst 
dslf_cs_ang  
dslf_ss_dih  
dslf_ca_dih  
Disulphide energies: Distance score 
C-S angles score 
Dihedral angles score 
Cα dihedral score 
0.5 
2 
5 
5 
pro_close Proline ring closure energy 1.0 
omega Omega dihedral in the backbone 0.5 
rama Ramachandran preferences 0.5 
Energy explanation from (13) and https://www.rosettacommons.org/manuals/rosetta3_user_guide/score_types.html 
(June 2016) 
 
An inherent problem with RosettaDock (13) is the difficulties in identifying the native-like structure 
which should be among the lowest energy scoring complexes identified. In order to better identify 
the native-like structure, one can apply different constrains and incorporation of SAXS data after 
the low resolution step where the initial complex is formed, should filter out overall shapes that are 
not consistent with the SAXS data. A benchmark of RosettaDock where SAXS data have been 
incorporated as constrain after the low resolution protocol is presented Chapter 6 using the 
presented score function. 
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 Albumin self-interaction 3
 
 
Human serum albumin (HSA) is a central theme throughout this thesis. Protein-protein interactions 
are investigated by focusing on the binding of lipidated peptides to HSA, conjugation to HSA and 
how different solution properties affect the concentration-dependent behaviour of albumin. In 
particular, we wish to examine the high concentration behaviour of HSA due to its potential as a 
pharmaceutical stabilizer. Biologics are often needed at high concentration in order to reach the 
desired effect, which poses a challenge to formulations, as proteins do not behave predictable at 
higher concentrations (> 1 mg/ml). One way to get around this is to use intravenous administration 
(IV) this way gaining the effective dose but over prolonged time. To increase patient compliance 
and comfort, there is focus on changing to subcutaneous injection (SC) in order to allow for at  
home administration, but this requires a higher protein concentration of up to 100 mg/dose (1). To 
this end, we wish to gain insight into how a higher concentration of HSA would affect the self-
interaction in different pharmaceutical formulation buffers. 
The different solution systems have been chosen to reflect different solution conditions. Two of the 
systems consist of buffer, stabilizers and HSA and the last one is defatted HSA in MilliQ water. The 
latter system is a situation where nothing is added to increase the solution stability of HSA and is 
expected to behave differently from the other systems. To further understand how these different 
systems affect the self-interaction of HSA at higher concentrations where repulsion is dominant, a 
constant concentration of HSA with increasing NaCl concentration was examined. 
Albumin in this study comes in the form of Recombumin® Alpha (Albumedix A/S). Here, albumin 
is formulated in 145 mM NaCl, 8mM octanoate, tween80 and water for injection. The properties of 
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these co-solutes are to increase stability of HSA. Octanoate is known to bind to HSA and is thought 
to bind mainly to Sudlow’s site II, Figure 3i-1, as observed by drug displacement experiments. It 
has further been shown that octanoate stabilizes HSA against heat induced denaturation and 
variation in pH (2) and has been used for many years to stabilize HSA (3).  
 
Figure 3i-1 The position of Sudlow’s site II in HSA (PDBID 1BJ5) . 
Even though HSA and its close relative bovine serum albumin (BSA) (76% sequence identity) have 
been thoroughly investigated (3, 4), modern studies mainly focus on the use of these proteins as 
model systems in method verification as they are considered as reference proteins. Additionally, a 
range of studies have been published since the elucidation of the crystal structure in 1999 by Sugio 
et al.(5) regarding the binding of a diverse set of ligands. To our knowledge, limited information is 
available in the literature regarding the use of HSA in formulation of other proteins at high 
concentration, and hopefully, this study can help increasing the knowledge about buffer effects on 
HSA self-interaction in order to understand these complex systems. 
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ABSTRACT 
Stability of proteins in solution can be affected by a number of factors such as temperature, pH, 
crowding and ionic strength/tonicity. In the present study, small-angle X-ray scattering (SAXS) and 
static light scattering (SLS) have been used to study the solution properties and self-interaction of 
rHSA molecules in two pharmaceutically relevant buffer systems. In one system, the tonicity is 
provided by NaCl and in the second system, the tonicity is primarily provided by a non-ionic sugar, 
trehalose. Additionally, the self-interaction of defatted rHSA was studied in pure Milli-Q water. In 
all three systems, studies are performed at a constant protein concentration with varying NaCl 
concentrations. 
The effective structure factors (𝑆(𝑞)eff) have been extracted from the scattering profiles and fit to 
the solution of the Ornstein–Zernicke (OZ) equation using a two-Yukawa interaction model. The 
two buffer systems could be modelled using a pure repulsive interaction potential. The tonicity 
corresponding to isotonicity is observed to coincide with the maximum screening observed in all 
systems, while this is not observed as a function of ionic strength, making tonicity an important 
parameter for protein interaction in the investigated systems. Trehalose is seen to provide a 
screening effect of added NaCl suggesting that trehalose may determine the range of interaction of 
the proteins in solution. Finally, it is proposed that the stabilizing effect of HSA could be mediated 
by a repulsive network of HSA molecules screening the interaction of other proteins, hereby 
decreasing the aggregation propensity. 
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INTRODUCTION 
In formulation of proteinaceous drugs, one of the main concerns is the stability of the drug 
molecule. Proteins at high concentrations tend to self-associate, potentially leading to high viscosity 
solutions or aggregation. Modifications such as oxidation or adsorption to the vial are additional 
concerns in formulation strategies. If the three dimensional structure of a protein is not conserved, 
this could lead to degradation and to the formation of new epitopes, which could induce an 
immunological response. Other important aspects such as activity could also be compromised. 
Finally, the formulation of course needs to be compatible with the route of administration. All these 
challenges generate issues during production, for ensuring prolonged shelf-life of a 
biopharmaceutical and in administration, which all set high demands on the formulation. 
Human serum albumin (HSA) is with a blood concentration of 35-50 mg/ml the most abundant 
plasma protein comprising more than half the amount of proteins in the blood plasma. HSA has 
many important physiological functions and for instance regulates the colloidal osmotic pressure 
and transports endogenous physiological metabolites and exogenous ligands such as fatty acids, 
hormones, bile acids and drugs (1–3). These properties have drawn much interest from the 
pharmaceutical industry and particular in clinical applications (4). It is used as a functional protein 
in many different applications where HSA's pharmacokinetic properties is utilized in drug delivery 
systems, and HSA's ability to increase the solution stability of other proteins is used in drug 
formulations.  
In drug delivery systems, HSA is used as a drug carrier where peptide-based drugs have been 
designed to interact specifically with endogenous albumin after injection. These include for instance 
the blog buster drugs Victoza
®
 (5) and insulin Levemir
®
 (6) for the treatment of diabetes. In 
Levemir
®
, a fatty acid is covalently linked to the gamma-NH2 of a lysine residue in the peptide-
based drug and the fatty acid will promote formation of a non-covalent complex with HSA 
facilitating that the drug is picked up after injection and delivered to the target by endogenous 
albumin (6). More recently, drugs have been developed where the drug has been covalently linked 
to albumin ex-vivo either through genetic fusion as for Eperzan
TM
 (7) and blood coagulation factors 
FVII, FVIII and FIX (8, 9) or through a covalent link obtained from a chemical conjugation (10). 
Entrapment of highly toxic small molecule based drugs for cancer treatment in HSA nanoparticles 
is another way of utilizing HSA as a drug delivery system (11).  
In formulations, HSA is used as a stabilizer preventing aggregation, as an anti-adsorption agent or 
as an antioxidant (12, 13) and was traditionally widely used in pharmaceutical products such as 
Avonex
TM
 and Epogen
TM
. However, due to severe safety issues associated with infection of patients 
with HIV virus from plasma-derived constituents in medicine in the 80ties and 90ties and later with 
the occurrence of mad cows disease transferred from infected cows, it became increasingly difficult 
to get regulatory approval of drugs containing constituents of mammalian origin, and the use of 
serum-derived HSA was therefore limited. With the development of recombinant HSA (rHSA) 
derived from yeast (Recombumin Prime
®
 and Alpha
®
, Albumedix A/S), the interest has resurfaced 
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in the last decade and an increasing number of modern pharmaceuticals containing rHSA like the 
trivalent subunit vaccine MMRII
®
 have been marketed (14).  
The use of albumin to stabilize protein-based drugs at low concentration was established decades 
ago and is expected to function via competitive inhibition of the protein-based drug adsorption to 
other materials (15). At protein-based drug concentrations less than 0.1 mg/mL, adsorption of 
protein-based drugs to the available air-liquid and solid-liquid surfaces in the primary packaging 
material will result in depletion and/or lead to surface-induced degradation of the active component. 
Hence, prevention of drug adsorption is thus essential and can be mitigated by addition of a non-
ionic detergent or by addition of HSA.    
In contrast to this, the mechanism of action for preventing aggregation is more speculative for 
formulations with protein-based drug concentrations above 1 mg/mL. Here, rHSA is used in 
concentrations ranging from a few mg/mL to all the way up to around 50 mg/mL (16, 17). At such 
high concentration (or similarly at “crowded conditions”), the aggregation of proteins is a complex 
process. One commonly recognized mechanism is the non-specific effects of steric exclusion (i.e. 
exclusion of volume) where the protein molecules in question (Ps) are excluded from the volume 
occupied by other inert protein species. With increasing concentration, the volume of the solution 
available to Ps is restricted to the part of space from which they are not excluded. In terms of 
thermodynamics, the entropy of a crowded solution is significantly reduced and hence the free 
energy of Ps increases. The system reacts to this by association of Ps to reduce the exclusion of 
volume (18, 19). However steric exclusion is not entirely non-specific, and in many cases, the 
aggregation propensity of proteins depends on their specific structures and local environments (20, 
21). It has been shown for monoclonal antibodies (MAbs) solutions at relatively high 
concentrations, that HSA prevents liquid-liquid phase separation of MAbs which is often preempted 
by aggregation or crystallization (22). HSA molecules weakly interact with MAb molecules leading 
to a reduction in the effective inter-protein interactions (22).  
To shed light on the observed stabilizing effect, we have used small-angle X-ray and static light 
Scattering (SAXS and SLS) to study the solution properties and self-interaction of rHSA molecules 
in two pharmaceutically relevant buffer systems and one system of defatted HSA in MilliQ where 
nothing is added for stabilization. For non-ideal systems displaying repulsive or attractive 
behaviour, the SAXS curve is the product of the form factor, 𝑃(𝑞), and the structure factor, 𝑆(𝑞), 
the latter providing information about the interaction potential.   
Early studies by A. Tardieu and co-workers (23–27)  on α-crystallin found in the eye lens, showed 
how SAXS could be used for examination of the interaction of proteins in high concentrated 
solutions. α-crystallin interaction was modelled using the renormalized mean spherical 
approximation (RMSA) with a Verwey-Overbeek potential which adequately described this system 
interacting through electrostatic repulsive interactions and a hard core potential (the excluded 
volume effect) (24).   
SANS studies of non-defatted HSA interacting in D2O with and without NaCl (1.08M) were 
modelled using Monte Carlo simulations by B. Sjöberg and K. Mortensen (28, 29). They found 
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increasing repulsive interaction with increasing HSA concentration and at the highest 
concentrations (~260 mg/ml), there were indications that the molecules tend to order themselves 
very close to each other. The advantage of using Monte Carlo simulations is that any particle shape 
and inter-particle potential may be modelled, though at high computational price.  
Finally, BSA has been used as a model protein to study high protein concentrations (up to 500 
mg/mL) in buffer free solution with and without NaCl using SAXS by Zhang et al.(30). The system 
is modelled by several potentials as the protein – protein interaction can be described by the form 
factor alone, Coulombic forces or a square well attractive potential.  
In the present study, we have applied the solution to the two-Yukawa potential developed by Liu 
and co-workers (31) to improve the understanding of HSA in three different systems. Yeast derived 
recombinant HSA (rHSA) in the form of Recombumin® Alpha produced by Albumedix A/S is 
used, and the self-interaction of rHSA is studied in two pharmaceutically relevant solvent systems. 
In one solvent system, the tonicity is primarily provided by a salt (hereafter called the OCT-buffer) 
In another solvent, the tonicity is provided by a non-ionic sugar, trehalose (hereafter called TRE-
buffer). Additionally, the self-interaction of defatted rHSA was studied in pure Milli-Q water (MQ). 
Tonicity is an important aspect in formulation of administered products, as the product needs to be 
isotonic with the patient´s blood in order not to damage tissue and/or produce pain. Tonicity can be 
calculated as the amount of solutes present in a solution, i.e. a solution of 1 mM NaCl corresponds 
to 2 mOsm/L. A solution of 280-305 mOsm/L is iso-osmotic with blood. Hence, the tonicity in 
formulations is typically between 280 and 305 mOsm/L. Isotonic solutions have the same amount 
of particles and thus the same osmotic pressure. 
We wanted to investigate the three different systems as function of ionic strength and change in 
tonicity, where the latter is chosen due to its pharmaceutical relevance. Ionic strength defines the 
ability of the solution to screen electrostatic interactions between proteins, while tonicity is related 
to the osmotic pressure arising from the additives in the formulation (eg, salt ions, buffers, sugar 
molecules). Tonicity is important for patient compatibility and could very well be important for 
protein interactions. Several SAXS studies have been performed to evaluate the effect of different 
salts on protein behaviour (30, 32–37). It is clear from these studies that monovalent salts such as 
NaCl in general have a screening effect. In previous studies (23–30), the focus was on the phase 
behaviour and model prediction of structure factors, while we in the current study focus on the 
evaluation of the effect of different buffers and salt concentration on the protein interactions. 
MATERIAL AND METHODS 
Recombinant Human serum albumin (rHSA) (100 mg/ml, Recombumin
®
 Alpha, Albumedix A/S) 
was supplied by Albumedix A/S. Defatted rHSA in a concentration of 100 mg/mL in Milli-Q water 
was prepared from Recombumin
@
 Alpha by removing bound fatty acids (octanoate) as described by 
Sogami & Foster (38). 
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Solvent systems 
Two distinct pharmaceutically relevant solvent systems were used (overview see Table 3-1). In the 
NaCl–buffer which is similar to the Recombumin® Alpha buffer, the tonicity is provided by a salt. 
In the trehalose-buffer which is similar to the buffer of bevacizumab in Avastin
®
, the tonicity is 
provided by the non-ionic sugar trehalose.  The third system chosen was pure Milli-Q water 
(MilliQ). Additionally, the effect of varying ionic strength was studied in all systems with the ionic 
strength change provided by NaCl.  
Table 3-1 Solvent systems.  
Solvent  Constituents pH 
OCT-buffer  145 mM NaCl, 8 mM octanoate, 0.05 g/L Tween 80 7.0 
TRE -buffer  42mM NaH2PO4•2H2O, 8mM Na2HPO4, 159mM α,α-trehalose•2H2O, 0.4 g/L 
Tween 20 
6.2 
MQ MilliQ water (18.2 MΩ·cm, MilliQ, Millipore) N/A 
N/A: not applicable 
Preparation of protein samples and buffers 
Recombumin
®
 Alpha in its own formulation was supplied freeze dried, and samples were prepared 
by dissolving the protein in NaCl-buffer at high concentration and subsequent dilution. The samples 
were not dialysed due to the high concentration needed. 
The trehalose buffer was exchanged by dialysis in three shifts over three days at 4°C applying soft 
stirring. The dialysis was performed with Slide-a-lyzer Dialysis G2 cassettes from Thermo 
Scientific with the appropriate molecular mass cut-off value. The individual samples were prepared 
by dilution or concentration of the dialyzed sample. Samples of defatted rHSA were prepared by 
dilution of a stock solution with Milli-Q water. Samples with varying salt concentration were 
prepared from buffer stock solutions with a high NaCl content by adding the appropriate amount of 
buffer to the individual samples. Importantly, buffers for buffer subtraction were also prepared to 
match the difference in NaCl content. All samples that needed further concentration were 
concentrated after dialysis using Pall Nanosep
® 
centrifugal device with Omega membrane 10K cut-
off. Concentration determinations were performed with the NanoDrop® 1000 Spectrophotometer 
from Thermo Scientific at 280 nm. The extinction coefficient was calculated to be 34445 
𝑐𝑚−1𝑀−1, with the ProtParam (39) tool from ExPASy.org (40) using the primary sequences of the 
HSA.  
SAXS  
Data Collection 
SAXS data collection was performed at the MAX IV laboratories at beamline I911-SAXS, Sweden 
(41). The sample detector distance and the direct beam position were calibrated using silver 
behenate (AgBe). Measurements on pure water were used to get the data on an absolute scale. 
Buffers were measured both before and after each sample and averaged before subtraction. The 
sample size was approximately 50 µl injected manually in a flow cell. 
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Measurements were performed on a series of rHSA samples at various concentrations prepared as 
described above. The protein concentration ranges in the individual buffers are listed in Table 3-3 
and Table 3-3, with respect to respectively rHSA concentrations and NaCl concentrations at fixed 
albumin concentration.  Data collection parameters are listed in Table 3-4. 
Table 3-2  SAXS measurements were performed at varying protein concentrations.  
Protein sample Protein concentration (mg/mL) Solvent 
Recombumin®Alpha 1 - 150 OCT -buffer 
Recombumin®Alpha 1- 180 TRE-buffer 
Defatted rHSA 1- 90 MQ 
 
Table 3-3 Varying NaCl concentrations at fixed rHSA concentration in various buffers. The salt concentration in 
the original buffer has been exchanged with the indicated salt concentrations. 
rHSA concentration (mg/mL) NaCl concentration (mM) Solvent  
~50 10, 20, 50, 100, 150, 200, 500, 1000, 2000 OCT -buffer (without 145 mM NaCl) 
~50 10, 20, 50, 100, 150, 200, 500, 1000, 2000 TRE-buffer 
~50 10, 20, 50, 100, 150, 200, 500, 1000, 2000 MQ 
 
Table 3-4 SAXS data collection parameters. 
Instrument MaxIV beamline I911-SAXS 
Detector Pilatus 1M 
Wavelength (Å) 0.9100 
q range (nm)  0.0825-5.0 
Exposure time (s) 3×60 
Temperature (K) 285 
Sample – detector distance (mm) 1972.485 
 
Data analysis 
All calibrations and corrections of the SAXS data were done using the in-house software Bli911-4 
(41). Buffer averaging and subsequent subtraction prior to data analyses were done in Primus (42). 
The ATSAS program package version 2.4 (43) was used for further data analysis. From SAXS, we 
can extract the radius of gyration, RG, molecular weight (𝑀𝑊) and the maximum particle diameter, 
𝐷𝑚𝑎𝑥 via the pair-distance distribution function, p(r). This analysis works well for monodisperse, 
ideal solutions and can be used to estimate an average solution shape, using programs such as 
DAMMIF (44) from the Atsas program package (43). Evaluation of the Guinier region was 
performed within Primus. The pair distribution function, p(r), were evaluated using the interactive 
program Gnom (45).  
The intensity, I(q),  in SAXS is measured as a function of the momentum transfer vector 𝑞:      
 
𝑞 =
4𝜋 sin 𝜃
𝜆
 1)  
 
λ is the wavelength, and 2θ the scattering angle. The intensity can be written as (46): 
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 𝐼(𝑞) ∝ 𝑃(𝑞)𝑆(𝑞) 2)  
The form factor, 𝑃(𝑞), is averaged over all sizes and orientations of the scattering particle, 〈𝑃(𝑞)〉, 
and describes the intra-particle effects of the particle, while the effective structure factor, 𝑆(𝑞), is a 
measure of the  inter-particle interaction, such as attraction and repulsion. The total scattering 
intensity, 𝐼(𝑞), thereby results from 〈𝑃(𝑞)〉 and the contribution from 𝑆(𝑞) (47).  At infinite 
dilution, 𝑆(𝑞) = 1 and no inter-particle interaction is present. 
The 𝑝(𝑟) function, is a histogram over all intra-particle distances and can be described by (48, 46):  
 
𝐼(𝑞) = 4𝜋 ∫ 𝑝(𝑟) ∗
sin(𝑞𝑟)
𝑞𝑟
𝑑𝑟
𝐷𝑚𝑎𝑥
0
 3)  
𝑃(𝑞, was derived from merging data at low and high concentration. The form factors were derived 
for each buffer system. This was done in order to obtain the effective structure factor, 𝑆(𝑞)eff, with 
varying concentrations which was found by dividing 𝐼(𝑞) by 𝑃(𝑞). A drawback of this method is 
that possible changes in the protein shape and size due to increasing protein concentration and 
repulsion are ignored. 
Static Light Scattering 
A Wyatt miniDAWN TREOS 3 angle detector was used for the static light scattering experiments.  
The instrument uses a 60 mW GaAs diode laser with vertically polarized light at a wavelength of 
658 nm.  Samples were injected using a syringe pump through an in-line 0.1 mm filter followed by 
the SLS flow cell connected in series to a UV Water 2487 absorbance detector.  We used a variable 
path length UV flowcell for accurate determination of protein concentration. The path length was 
set to 0.05 cm such that the absorbance of all protein solutions falls within the range where the 
Beer-Lambert law is valid. 
The static light scattering equation is given by (Equation 4): 
 𝐾𝑐(𝑑𝑛 𝑑𝑐⁄ )2
𝑅Θ
= 
1
𝑀𝑊𝑆(0)
=  
1
𝑀𝑊𝑅𝑇
 (
𝑑Π
𝑑𝜌
) 
4)  
where 𝑐 is protein concentration in units of g/mL, R is the gas constant, T is the temperature,  Π is 
the osmotic pressure, 𝜌 is the protein 𝑑𝑛 𝑑𝑐⁄  is the refractive index increment of the protein 
solution, 𝑅Θ is the Rayleigh scattering of the protein solution minus the scattering from the solvent, 
M is the protein molecular weight, and K is an optical constant equal to 2𝜋2𝑛0
2/(𝑁𝐴𝜆
4) where no is 
the refractive index of the solvent. The refractive index increment of the protein solution 
corresponds to a measurement taken at constant chemical potential of all solvent components. In 
solutions at low to moderate tonicities, the parameter has been measured extensively and is 
approximately equal to 0.185 mL/g.   
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The osmotic second virial coefficient, 𝐵22, is determined from static light scattering using only low 
protein concentration data.  In this case, the osmotic compressibility is expanded in a virial 
expansion using Equation 4 yielding:  
 𝐾𝑐(𝑑𝑛/𝑑𝑐)2
𝑅Θ
= 
1
𝑀
+ 2𝐵22𝑐 5)  
The virial coefficient is determined from a linear fit to Equation 5 from 10 measurements with 
varying protein concentration between 2 and 20 g/L. The regressed slope is equal to 2B22 and the 
inverse of the y-intercept is equal to the average protein molecular weight.  Reported error bars 
correspond to the standard error in the slope estimation. 
The thermodynamic solution behaviour is directly obtainable from the osmotic compressibility, 
which in turn, is proportional to the inverse of the static structure factor in the limit of q equal to 0 
(e.g. 𝑆(0)). Obtaining 𝑆(0) from SAXS requires using accurate models to divide out the 
contribution of the form factor to the scattering profile.    A more direct approach is to use static 
light scattering (SLS) where the wavelength of scattered light is much larger than the size of a 
protein molecule.  SLS has been used extensively to measure the osmotic second virial coefficient 
which reflects the orientation and separation averaged interaction between a pair of proteins.  SLS 
has an additional advantage over SAXS that measurements can be carried out in a higher 
throughput.  As such, the pH and ionic strength dependence of the virial coefficient is often fit to a 
potential of mean force model to separate out the contributions from excluded volume forces, 
electrostatic interactions, and other short-ranged forces between proteins (49–51). SLS has also 
been used for characterizing concentrated protein solution behaviour, but care must be taken to 
account for any angle dependence of scattered light. 
While the fit to SLS can provide information about the forces between proteins, the modelling of 
structure factors from SAXS or SANS can potentially give a more detailed picture of the interaction 
potential. The challenge is to achieve a proper analytical description and most methods use several 
approximations to be able to come to a solution. A common problem is to get an analytical 
expression for the shape of the protein, the form factor, as it rarely fit perfectly to a geometric 
description. Charge anisotropy is often assumed to be isotropic, i.e. the charge is uniformly 
distributed around the protein, and the possible rotational/translational orientation dependence is 
considered uncoupled, simplifying the expressions. 
Structure factor modelling 
𝑆(𝑞)eff have been extracted from the scattering profiles and fit to an analytical solution of the 
Ornstein–Zernicke (OZ) equation for the Yukawa interaction model within the mean spherical 
approximation (31). The repulsive part of the Yukawa potential is modelled using the electric 
double layer potential derived within Deryaguin-Landau-Verwey-Overbeek (DLVO) theory, which 
treats the protein as a uniformly charged sphere immersed in a dielectric continuum containing 
point charges (e.g. salt ions).  We do not consider any attractive attractive interactions.  As such, the 
two body interaction energy is given by (Equation 6): 
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𝛽𝑢(𝑟) = {
∞                                                                𝑟 < 𝜎
𝑍2𝜆𝐵
(1 + 𝜅𝜎/2)2
 
𝑒𝑥𝑝[−𝜅(𝑟 − 𝜎)]
𝑟            𝑟 > 𝜎
 6)  
 
where Z corresponds to the protein valency,  is an effective hard sphere radius, r is centre-to-
centre separation, and  is the dimensionless inverse temperature 1/kbT where kb is Boltzmann’s 
constant.   is the inverse Debye-Huckel screening length  
 𝜅 = √2𝑒2𝑁𝐴𝐼/(𝛽𝜀𝜀0) 7)  
where I is the ionic strength of the solution, e is the electronic charge, 0 is the vaccum permittivity, 
 is the dielectric constant of water, and NA is Avogadro’s number.  B corresponds to the Bjerrum 
length  0
2 4 eB  , which is the separation between a pair of ions when the Coulomb energy 
is equal to thermal energy.   
In this work, we set the effective diameter  of HSA to a value of 63.6 Å.  This value was shown to 
provide accurate fits to structure factor data obtained in solutions at pH 7 for BSA with different 
NaCl concentrations (32).  Previous studies on BSA (Bovine serum albumin) have used a value of 
66.8 Å (30) which was determined by equating the excluded volume of the sphere to the excluded 
volume of an oblate ellipsoid shape which accurately reproduced the form factor for BSA. In 
addition, we treat the protein charge, the screening length and the protein concentration as 
adjustable parameters in the fitting process, following the approach of Zhang et al.(30). 
Applying the same diameter of BSA to the modelling of HSA is reasonable as HSA and BSA has a 
~76% sequence alignment (aligned using BLAST, (52)) and an almost identical tertiary structure. 
A. Bujacz (53) solved the structures of bovine, equine and leporine serum albumins and find an 
overall r.m.s.d. between HSA (PDB: 1AO6 (54)) and BSA (PDB: 4F5T) of 1.53Å.  
RESULTS 
The results from SAXS, SLS and structure factor modelling are presented first for the OCT-system, 
the TRE-system and finally the MQ-system. The concentration series will be abbreviated OCTCONC, 
TRECONC, MQCONC and ionic strength samples as OCTNaCl, TRENaCl and MQNaCl for clarity. SAXS 
scattering data is provided in Supplementary Material, Figures S1-S3 and data treatment parameters 
in Table S2 for concentrations up to 10 mg/ml. Above this concentration all data reflect the 
presence of net repulsive interactions between proteins. 
The effective structure factors, 𝑆(𝑞)eff, were derived by dividing the scattering intensity by the 
experimentally derived form factor from the same buffer. This applies to the TRE system as well, 
whereas for the MQ system the TRE form factor was used due to apparent aggregation in the MQ 
system at low concentration.  For the ionic strength series the form factor from the concentration 
series was applied.   
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OCT system 
SAXS 
The OCT-system includes the concentration series (1-150 mg/mL) and the ionic strength data as 
described in Table 3-2 and Table 3-3. A decrease in structure factor at low q with increasing protein 
concentration reflects the effects of repulsive protein-protein interactions. The protein-protein 
repulsion is apparent from considering the data at concentrations as low as 5 mg/ml, Figure 3-1a. 
Conversely increasing NaCl concentration causes an increase in structure factor at low q reflecting a 
reduced protein-protein repulsion as seen in Figure 3-1b from an increase in 𝑆(𝑞 → 0).  The salt-
induced reduction reflects an electrostatic screening mechanism, which arises due to the high net 
charge on HSA at pH 7. 
Fitting of the structure factors for OCT-systems were performed using only the repulsive part of the 
Yukawa interaction potential and the resulting fits are shown in Figure 3-1 in black with the 
experimental and fitted parameters listed in Table 3-5 and Table 3-6 
  
                        a)                                                                                            b) 
Figure 3-1 Fitted structure factors in grays compared with experimental structure factors in orange. a) OCTCONC, 
b) OCTNaCl. 𝑺(𝒒) is only shown for samples at concentrations from 10 mg/ml as limited interaction is observable below 
this concentration. 
The parameters from fitting the 𝑆(𝑞) with increasing protein concentration are seen in Table 3-5 and 
show an almost constant charge and ionic strength. Overall the parameters show a good fit to the 
experimental data as seen in Figure 3-1a. The fitted value of Z is slightly less than the expected 
values measured experimentally (55–57), HSA is a negatively charged protein at pH above 5.1 (pI) 
with a net charge of around 14-17 at physiological pH (1, 56). The OCT-buffer has an ionic strength 
of 0.153 M, which is expected to decrease the charge. The lower fitted IS reflects that the repulsion 
between the particles is longer ranged, but has a smaller magnitude than expected from DLVO 
theory using the theoretical charge of the protein. Fixing IS to the experimental value results in the 
fit charge that is higher than expected for both buffers. 
 
Increasing protein concentration 
Increasing NaCl concentration 
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At 50 mg/ml and varying ionic strength (OCTNaCl) the fitted 𝑆(𝑞)eff  (Figure 3-1b) also reproduces 
the experimental trend adequately. The fitted parameters listed in Table 3-6 show that the change in 
ionic strength is accompanied by an apparent increase in charge of HSA for the high salt 
concentration dataset. Fitted concentrations are observed to be similar to the experimental values as 
also observed by Zhang et al. (30). At an ionic strength above 0.5 M, Zhang introduces an attractive 
square well potential in order to model the observed attractive interaction of BSA. This is not 
observed here for HSA. 
Table 3-5 Fit parameters from S(q) modelling for 
OCTCONC  of 15-150 mg/ml . IS: Ionic strength, Z : 
effective charge of particle. σ: diameter = 63.6 Å. 
 
Table 3-6 Fit parameters from S(q) modelling for 
OCTNaCl. IS: Ionic strength, Z : effective charge of 
particle. σ: diameter = 63.6 Å. 
Protein 
conc. 
(mg/mL) 
Fitted 
conc. 
(mg/mL) 
IS (M) Fitted IS 
(M) 
Z 
15.2 14.0 0.153 0.05 10.1 
22.6 21.4 0.153 0.05 9.5 
41.8 38.6 0.153 0.05 10.5 
83.0 74.0 0.153 0.06 11.5 
143.8 128.0 0.153 0.04 10.1 
 
Protein 
conc. 
(mg/mL) 
Fitted 
conc. 
(mg/mL) 
IS (M) Fitted IS 
(M) 
Z 
45.8 36.4 0.018 0.010 9.43 
44.7 38.2 0.028 0.014 9.68 
45.6 40.5 0.058 0.025 9.98 
44.5 39.1 0.108 0.046 10.98 
41.8 38.6 0.153 0.054 10.52 
42.3 39.2 0.208 0.069 11.66 
38.4 35.9 0.508 0.211 20.79 
 
 
Static light scattering 
The slope of the plots of 𝐾𝑐/𝑅𝜃 is used to determine the osmotic second virial coefficient, B22, and 
the inverse of the y-intercept is the infinite dilution value of the molecular weight. All 
measurements of molecular weight are on the order of 70.0 ± 3.5 kDa, indicating the samples are 
monodisperse. 
B22 was determined from SLS and estimated from SAXS. SLS can also be used to determine 𝑆(0) 
using equation 8. The 𝑆(0) estimated from SLS is plotted alongside 𝑆(0) from SAXS in Figure 
3-2a. A good correspondence between the two methods is observed. 
 1
𝑀𝑤𝑆(0)
=
1
𝑀𝑤
+ 𝐵22𝑐 8)  
 
B22 as a function of ionic strength is depicted in Figure 3-2b. A curve of best fit is shown for B22, 
which has been estimated using DLVO theory including only the hard sphere and repulsive terms as 
described by Roberts et al. (50). The fit value of net charge equal to - 15e is in good agreement with 
the net charge observed at the same pH for HSA of -14e by Fogh-Andersen et al.(56). This 
approximation captures the behaviour of both SLS and SAXS.  
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a)                  b) 
Figure 3-2 a) 𝑺(𝟎) as a function of concentration for OCT (OCTCONC). Blue calculated from light scattering and red 
from SAXS. b) For OCTNaCl the value of B22 has been determined from SAXS (red) and SLS (blue). Inserted is 
simulated data (black line) determined from DLVO theory with a charge of 15 (see text for details). 
TRE system 
 
SAXS 
 
SAXS was measured in a concentration range from 1-180 mg/mL with varying ionic strength as 
described in Table 3-2 and Table 3-3. The decrease in 𝑆(0) with increasing protein concentration 
reflects the presence of repulsive protein-protein interactions, while a change in salt concentration 
from 0 - 1M NaCl show limited screening effect in this system as seen in Fihure 3-3a and b. 
 
𝑆(𝑞)eff for TRECONC and TRENaCl are compared to the simulated 𝑆(𝑞) in Figure 3-3a and b. Overall 
the trends are reproduced except at the highest protein concentration where the peaks in the 
simulated 𝑆(𝑞) are more pronounced. In the decoupling approximation used to approximate the 
structure factor, the molecules are considered orientationally and translationally uncoupled giving 
the more pronounced oscillations, whereas experimentally shape anisotropy could affect 𝑆(𝑞)eff, 
resulting in a damping of the oscillations as observed. 
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a)            b) 
Figure 3-3 S(q) fits TRECONC a), and TRENaCl b). The fitted 𝑺(𝒒) for 160.8 and 181.8 mg/mL are almost identical and 
cannot be discerned in the figure. Experimental 𝑺(𝒒)eff are depicted in green colours and fit in greys. Concentration as 
seen in Table 3-7 and Table 3-8. 
The experimental and fitted parameters for the structure factors of the TRECONC and TRENaCl series 
are listed in Table 3-7 and Table 3-8, respectively. The effect of increasing the protein 
concentration is reflected in an apparent decrease in ionic strength and charge. This could imply 
longer range repulsion between the particles not caught by the DLVO potential. In between these 
concentrations the behaviour is similar to that observed for OCTCONC, but the charge is noticeably 
smaller than for the OCT-system and is probably reflecting the decrease in pH to 6.4.  
Table 3-7 Fit parameters from S(q) modelling  
of  TRECONC. IS: Ionic strength, Z :  
effective charge of particle. σ: diameter= 63.6 Å. 
Table 3-8 Fit parameters from S(q) modelling of 
TRENaCl. IS: Ionic strength, Z : effective charge of 
particle. σ: diameter = 63.6 Å. 
Protein 
conc. 
(mg/mL) 
Fitted 
conc. 
(mg/mL) 
IS (M) Fitted IS 
(M) 
Z 
15.4 5.1 0.066 0.036 17.1 
23.8 14.1 0.066 0.015 6.7 
32.7 26.4 0.066 0.023 7.7 
41.1 36.1 0.066 0.022 7.4 
63.2 60.5 0.066 0.022 7.1 
107.4 105.3 0.066 0.018 6.4 
168.0 160.1 0.066 0.008 4.6 
181.8 182.1 0.066 0.008 4.5 
 
Protein 
conc. 
(mg/mL) 
Fitted 
conc. 
(mg/mL) 
IS (M) Fitted IS 
(M) 
Z 
41.1 36.1 0.066 0.022 7.41 
39.9 35.1 0.076 0.026 7.39 
38.9 33.2 0.086 0.029 7.95 
39.3 29.4 0.116 0.037 8.78 
38.2 31.8 0.166 0.045 8.78 
34.2 27.7 0.216 0.041 8.06 
35.1 28.5 0.266 0.052 9.14 
30.7 26.1 0.566 0.075 11.38 
41.2 50.8 1.066 0.114 12 
 
 
Increasing the ionic strength for samples at 50 mg/ml gave rise to a smaller change in salt induced 
shielding as compared to OCTNACL as seen in the small increase in 𝑆(𝑞 → 0) in Figure 3-3b.  The 
fitting parameters in Table 3-8 show an apparent increase in charge and ionic strength similar to 
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OCTNaCl, but like TRECONC, a lower charge of HSA is observed. At high ionic strength a limited 
change in shielding should be reflected by a higher ionic strength and constant charge (58). The 
small change in 𝑆(0) probably results from the fact that the TRE-buffer has an ionic strength of 66 
mM before adding salt compared to 18 mM for the OCT buffer, meaning that the electrostatic 
interaction is already shielded to some degree before adding salt. 
Light scattering 
 
Figure 3-4 depicts 𝑆(0) calculated from SLS and 𝑆(0) derived from SAXS, and show how the 
interaction in the form of 𝑆(0) agree over the measured protein concentration. The TRECONC show 
very similar behaviour as OCTCONC, with varying protein concentration, as seen in the Figure 3-4.   
 
Figure 3-4 𝑺(𝟎) as a function of concentration for TRECONC. Blue are determined from SLS data and red from 
SAXS 𝑺(𝒒)eff data. Black data points presents the SLS results from OCTCONC. 
MilliQ 
 
SAXS 
 
The concentration range of defatted HSA in MQ was 1-100 mg/mL and the ionic strength 
measurements were like the other systems and described in Table 3-2 and Table 3-3. Defatted HSA 
in MQ has no stabilizing agents, which is reflected in attractive behaviour at low concentration as 
observed in the structure factor inset in Figure 3-5a. At concentrations above 10 mg/mL protein-
protein electrostatic interaction is present. The structure factors do however not show an oscillating 
behaviour, which could be a result of polydispersity, shape anisotropy or both. The low fitted 
concentration shown in Table 3-9, points towards higher molecular weight species being present. 
The fact that aggregation seem to decrease at a moderate protein concentration indicates that rHSA 
is self-stabilizing – as soon as the concentration of rHSA exceeds 10 mg/mL, the solution appears 
to become stable.  
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The tendencies of 𝑆(𝑞) of the two highest protein concentrations (Table 3-9) were possible to 
capture using the pure repulsive potential with parameters in the range of the OCTCONC. At lower 
concentration an attractive term is required to model the system. The lowest concentrations seem to 
have a low q-peak in the structure factor which could be a result of repulsion between larger protein 
assemblies (31), though no cluster peak is observed, ruling out the presence of defined clusters.  
    
                                                  a)                      b) 
Figure 3-5 a) Structure factor fits of 50 and 100 mg/ml samples. Small insert of all 𝑆(𝑞) from 1mg/ml to 100 mg/ml 
depicts the attractive interaction dominant at low concentration. b) MQNaCl ( varying IS at 50 mg/ml). 
For MQNaCl at 50 mg/mL, the behaviour of the 𝑆(𝑞) reflects the lack of buffer. The structure factors 
and fitting results are shown in Figure 3-5 with experimental and fitted parameters listed in Table 3-
10. An increase in fitted IS with increasing NaCl concentration is observed, while the protein 
charge only slightly increases. The fitted concentrations for MQNaCl is somewhat lower than the 
general trend and could be a consequence of dimers or larger multimeric species being present in 
solution. 
Table 3-9 Fit parameters from S(q) modelling of 
MQCONC. IS: Ionic strength, Z : effective charge of 
particle. σ: diameter= 63.6 Å. 
Table 3-10 Fit parameters from S(q) modelling of  
MQNaCl at 50 mg/ml and increasing ionic strength. 
IS: Ionic strength, Z : effective charge of particle. σ: 
diameter= 63.6 Å. 
Protein 
conc. 
(mg/mL) 
Fitted 
conc. 
(mg/mL) 
IS (M) Fitted IS 
(M) 
Z 
43.6 25.3 0 0.01 9.9 
88.3 72.2 0 0.02 9.59 
 
Protein 
conc. 
(mg/mL) 
Fitted 
conc. 
(mg/mL) 
IS (M) Fitted IS 
(M) 
Z 
43.6 25.3 0 0.009 9.9 
43.2 29.4 0.01 0.013 9.71 
45.1 32.5 0.02 0.016 9.65 
39.1 27.5 0.05 0.026 9.89 
41.5 28.7 0.1 0.038 11.03 
42.6 31.2 0.15 0.043 10.35 
45.9 35.5 0.2 0.046 9.45 
40.4 33.2 0.5 0.072 10.48 
36.1 34.5 1 0.081 10.51 
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DISCUSSION 
Three different systems have been investigated. Two pharmaceutical buffers were chosen: OCT-
buffer and TRE-buffer providing tonicity in two different ways. OCT-buffer consists of NaCl, 
Tween 80 and octanoate (Tabl3 3-1). The main tonicity providers in this solution are NaCl and 
octanoate, the latter binds to the fatty acid binding pockets of HSA, hereby stabilizing the protein. 
TRE-buffer consists of sodium phosphate and a high sugar content (trehalose) (Table 3-1); both of 
which provide for the tonicity of the formulation. Additionally, trehalose stabilizes protein 
conformation and thereby increases protein stability as preferentially excluded sugar molecules 
promote localization of water molecules around the protein (59, 60). 
SAXS measurements were performed on all systems while SLS was done for OCTCONC, OCTNaCl 
and TRECONC with good correspondence between the two experimental techniques. The B22 values 
could be modelled using hard sphere and screened columbic DLVO potential with a charge of 15, 
showing good correspondence with experimental values. To verify that the parameters derived from 
structure factor modelling were physical sound, the same DLVO model was used to estimate the B22 
values and compared to experimental  B22 (Not shown). 
CONCENTRATION SERIES 
For all three buffer systems, there is an increasing repulsive behaviour with increasing protein 
concentration. For OCTCONC and TRECONC (Figure 3-1a and Figure 3-3a), monodispersity was 
verified by SLS, and the protein interaction ((𝑆(0)) as a function of concentration and ionic strength 
(B22) was shown to correspond between the two methods. The decrease in 𝑆(0) with increasing 
protein concentration, Figure 3-2 and Figure 3-4, is due to the change in the isothermal osmotic 
compressibility (47). With an increase in concentration of the charged protein molecules, the 
compressibility increases due to packing of the molecules. The structure factors were possible to 
model at a constant protein diameter, using a pure repulsive potential except for MQCONC at low 
concentration where an additional attractive potential is needed.  
For all systems, the fit ionic strength is always less than the experimental ionic strength, when ionic 
strength is treated as a fitting parameter, indicating the range of the interaction is longer than we 
would expect based on DLVO theory.  When varying the ionic strength, the fit charge is remarkably 
constant for both types of buffers.  
A picture of the different behaviours in the three systems is illustrated in Figure 3-6, where the 
structure factor peak position 2π/q is plotted vs. protein concentration for the three different buffer 
systems. We observe a decrease in shielding with decreasing ionic strength and tonicity of the 
buffer (OCT ≥  TRE > MQ). This effect is somewhat more pronounced at low protein 
concentrations, and it seems that the difference between OCTCONC and TRECONC disappears around 
30 mg/ml. SLS and SAXS measurements showed that OCTCONC and TRECONC display the same 
𝑆(0) behaviour over the same concentration range (Figure 3-4) despite the apparent different charge 
of HSA in these systems. 
 A l b u m i n  s e l f - i n t e r a c t i o n  P a g e  | 49 
 
 
Figure 3-6 Structure factor peak position vs. protein concentration, colour code see insert. 
A useful quantity is 2𝜋/𝑞𝑝𝑒𝑎𝑘, since it reflects the effective particle diameter – the distance where 
the repulsive potential reaches a maximum. Plots of 2𝜋/𝑞𝑝𝑒𝑎𝑘 versus protein concentration in 
Figure 3-6, show a decrease in protein diameter with increasing concentration. At low 
concentration, the molecules will be further apart and no intermolecular interactions are observed. 
Hence, the individual proteins interact more strongly with the solvent and are able to freely rotate in 
the solution, resulting in a larger effective size of the protein. At higher concentration, protein 
molecules repulse each other, resulting in a decrease in free movement due to partially ordering, 
while the hydration layer becomes more compact. This will give an effective diameter smaller than 
that of a protein at lower concentration. This is in accordance with the results by Vérétout et al.(26) 
for α-crystallins, where the authors describe the decrease in size due to a more compact packing of 
the non-spherical molecules. Even though HSA is often described as a compact spherical molecule, 
it is a rather flexible protein as two of the three main domains show domain movement upon 
binding to fatty acids or the neonatal Fc receptor (61, 62). The shape is more like an ellipsoid (54) 
and could very well be forced to a partial ordering caused by its asymmetric shape and charge. 
Another explanation can be made from the fact that there is electrostatic repulsion, which leads to 
an average inter-particle spacing which is reduced with increasing concentration due to excluded 
volume or packing effects which correlates with the structure factor fitting data being able to 
capture the behaviour over all concentrations at constant diameter. The smallest distance observed 
in Figure 3-6, ~65 Å is close to the diameter of HSA and reflects that the molecules cannot get any 
closer. 
IONIC STRENGTH SERIES 
For the samples at 50 mg/ml and varying NaCl concentration, the three buffer systems show a 
decrease in repulsion with increasing salt concentration, reflected in an increase in 𝑆(0). The 
TRENaCl series is the least affected by the change in ionic strength.  
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Structure factor modelling reveal an increase in protein charge with increasing NaCl concentration 
for OCTNaCl, which is consistent with Zhang et al (30) and could possibly be explained by the 
binding of chloride ions to the surface (63, 64).  At salt concentrations greater than 1M, the relative 
large fit value of Z indicates the presence of a short-ranged repulsive force. Zhang et al. found 
attractive forces for BSA at high ionic strength which is not observed here. In The Zhang study, 
BSA self-interaction in water was investigated at different NaCl concentration, but it is not 
indicated if the BSA batch is defatted or not. The attraction they observe at high salt concentration 
could reflect the lack of buffer compared to the buffer systems investigated here where no 
oligomerization is observed except for defatted HSA in MQ.  The albumins in the pharmaceutical 
buffers investigated in this study show monodisperse, repulsive behaviour under all protein and salt 
concentrations, reflecting how albumin can be stable to use in formulations under these conditions. 
The MQNaCl only show a small increase in charge from 𝑆(𝑞) modelling compared to the other two 
systems. As no buffer is present, it is possible that defatted HSA can bind more ions, both cat- and 
anions, without changing much in apparent charge. This could still reflect the increase in fitted IS of 
the system, as ion binding could lead to an increase in hydration of the protein which in turn would 
increase repulsion. Even though we get a good fit to experimental 𝑆(𝑞), the concentrations are 
lower than expected, which could to be due to dimer or oligomer formation. 
Varying the ionic strength at a fixed protein concentration of 50 mg/ml has a limited effect for the 
TRENaCl system when compared to the OCTNaCl system, where the ionic strength change has a 
significant impact on the 𝑆(𝑞), reflecting the change in screening upon NaCl addition. The increase 
in the fitted HSA charge for TRENaCl despite the limited change in 𝑆(0), show that ion binding 
could be a possibility but that this must be screened by the buffer. Other additives in the buffer must 
be responsible for screening of the HSA molecules and somehow shield the effect of added NaCl. 
Despite the higher initial ionic strength of the TRE-buffer (66 mM) compared to OCT-buffer (18 
mM), this does not shield the individual HSA from each other in the TRECONC series, which show 
similar behaviour to OCTCONC, though with decreased charge as a consequence of decreased pH. 
The sodium phosphate buffer in TRE-buffer will screen the electrostatic interaction and limit the 
effect of further adding salt. Tweens are non-ionic detergents which are added to formulations as 
stabilizers to decrease protein interaction with for example the air/liquid interface, as this can 
potentially lead to protein aggregation. Tween20 (TRE-buffer) and 80 (OCT-buffer) have been 
shown to have a weak binding to HSA(65), but due to steric hindrance these do not form stable 
complexes and do not affect the scattering data. Trehalose in the TRE-buffer is a kosmotrope, i.e. 
protein stabilizing agent used to stabilize proteins. Trehalose is thought to exert its stabilizing effect 
by having an optimal configuration for hydrogen bonding with water and is thereby fully 
solubilized while it is preferentially excluded from the protein surface. This exclusion has been 
shown to decrease the diffusion of water around the surface of a protein thereby stabilizing the 
hydration (66). By excluding the protein from the solution and making a network with water and 
thereby disrupting the effect of NaCl, this could explain how a change in NaCl concentration has a 
minimum effect on the solution behaviour of HSA in TRENaCl at constant protein concentration, 
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whereas an increase in protein concentration will exhibit an identical change in charge of the system 
as this is dominated by the protein charge.  
B22 determinations using SLS were compared to values derived from SAXS for OCTNaCl as shown 
in Figure 3-2. It is observable that the screening effect of NaCl seems to reach a plateau around 150 
mM NaCl, where further addition of salt has little effect on the compressibility. This coincides with 
the isotonic concentration at 145 mM NaCl of the OCT-buffer. 
To evaluate this, we have plotted qpeak as a function of respectively the tonicity and the ionic 
strength and the results are shown in Figure 3-7. It is clear from the plots that when the qpeak value is 
plotted as a function of tonicity, the differences between the systems disappear, while this is not 
clear as a function of IS. There is a linear decrease in repulsion (increase in qpeak value) for low 
tonicity while the qpeak value is constant at a tonicity above 300 mOsm/L (black line inset) for all 
systems, interestingly corresponding to an isotonic solution. The largest difference is seen for the 
TRE buffer. Trehalose contributes to the tonicity but not to the ionic strength making these two 
parameters different. 
  
                                                a)                                                                                             b) 
Figure 3-7 The q-value of the maximum peak in the structure factor (qpeak) as a function of IS (a) and tonicity (b). 
The black line inset in a) it corresponds to an ionic strength of 0.145 M and in b) to 300 mOsm/L (see text). 
Below a NaCl concentration of 1M (IS =1.066), TRENaCl seems unaffected by the change in IS. This 
could mean that trehalose determines the range of the repulsive potential neglecting the effect of the 
addition of salt up to 1M NaCl. However, further studies are needed to investigate this. The current 
results indicate that isotonicity is an important parameter for protein interaction as a turning point 
for maximum screening.  
The stability of rHSA in the buffers does not decrease with increasing protein concentration or salt 
concentration. Actually, it seems from the MQ system that an increase in HSA concentration could 
have a self-stabilizing effect. The high surface charge of the protein promotes a repulsive behaviour 
which is seemingly constant above an “ideal” tonicity of 300 mOsm, for the salt and HSA 
concentration ranges investigated here. It has been suggested by Wang et al. (22) that HSA has a 
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weak attractive interaction with an IgG2 thereby decreasing phase separation by a partition of HSA 
into the antibody rich phase. The attraction between the IgG2 molecules was decreased by addition 
of HSA. This observation together with the repulsive behaviour of HSA in our systems makes us 
speculate if the stabilizing effect of HSA is the creation of a HSA repulsive network which shields 
the target proteins from each other, thereby preventing aggregation. 
CONCLUSION 
We have performed a study of the interaction of rHSA in three fundamentally different solution 
systems. The two pharmaceutical buffers show similarly behaviour as a function of concentration, 
observed by both SLS and SAXS, while structure factor modelling revealed that two different 
mechanisms could be responsible. Further investigation at 50 mg/ml and varying NaCl 
concentration showed that while OCTNaCl behaved as expected with increased shielding as a 
function of NaCl concentration, the increase in IS had a limited effect on TRENaCl.  Two possible 
reasons for this has been suggested; Trehalose in the TRE buffer could be responsible for 
determination of the range of the repulsive potential. Alternatively or in combination with, we 
observe that by using tonicity as a parameter instead of IS, we observe a plateau in the repulsive 
behaviour, with all measurements of TRENaCl lying above the isotonic limit of 300 mOsm, simply 
reflecting that limited screening is possible above this concentration. 
It is clear that at high concentrations, rHSA shows large repulsion with increasing order which has 
also been observed for -crystallin(26). We speculate that this could be the physical reason for the 
stabilizing effect of rHSA on other proteins. rHSA is screening itself and thereby creating a network 
making it possible for other proteins to distribute themselves amongst the rHSA molecules, 
preventing aggregation. This is also seen in the MilliQ system, where we have investigated defatted 
rHSA in water, and at a concentration of rHSA of 10 mg/mL seem to self-stabilize rHSA.  
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SUPPLEMENTARY MATERIAL 
 
a)                                       b) 
Figure S1 Scattering curves rHSA in NaCl-buffer. Data are shown for different rHSA concentration where 
increasing concentration is indicated by decreasing color intensity, see Table 2. (b) rHSA at 50 mg/ml with varying 
NaCl concentration. Increasing NaCl with decreasing color intensity. All curves have been normalized to 1 mg/ml. 
  
a)                    b) 
Figure S2 (a) Scattering curves rHSA in Trehalose-buffer. Data are shown for different rHSA concentration where 
increasing concentration is indicated by decreasing colour intensity, see Table 3-2. (b) rHSA at 50 mg/mL with varying 
NaCl concentration. Increasing NaCl with decreasing colour intensity. All curves have been normalized to 1 mg/mL. 
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a)                                                                                                 b) 
Figure S3  SAXS scattering curves for MilliQ at varying concentration a) and data with increasing NaCl (light 
blue) concentration b). 
Overview over all sample parameters for samples 1-10 mg/ml. All other samples show large 
deviations from ideality due to repulsion. For consistency the low concentration data for MilliQ is 
included despite the attraction influences the data at low concentration. 
Table S2 
Concentration (mg/ml) 
NaCl 
RG 
(Guinier) 
(nm) 
StDev Porod Vol RG (Gnom) 
(nm) 
Dmax (nm) I(0) (Gnom) Mw 
(g/mol) 
 
1 3.05 0.12 113.01 3.06 10.45 0.0411 56.9 
2 2.98 0.11 113.05 3.01 10.22 0.0786 54.4 
5 2.95 0.09 108.72 2.94 10.32 0.178 49.3 
10 2.82 0.05 103.12 2.83 8.61 0.32 44.3 
 
Concentration (mg/ml) 
Trehalose 
RG 
(Guinier) 
(nm) 
StDev Porod 
Vol 
RG (Gnom) 
(nm) 
Dmax (nm) I(0) (Gnom) Mw 
(g/mol) 
 
1 2.86 0.19 97.49 2.81 8.93 0.0385 53.3 
2 2.77 0.08 93.40 2.79 8.85 0.0697 48.3 
5 2.76 0.10 96.68 2.71 8.72 0.197 54.6 
10 2.63 0.20 95.44 2.7 8.01 0.359 49.7 
 
Concentration (mg/ml) 
MilliQ 
RG 
(Guinier) 
(nm) 
StDev Porod 
Vol 
RG (Gnom) 
(nm) 
Dmax (nm) I(0) (Gnom) Mw 
(g/mol) 
 
1 6.74 0.54 308.74 6.73 23.57 0.126 187.9 
2 4.71 0.22 227.93 4.9 16.48 0.187 140.5 
5 3.14 0.47 115.63 3.21 10.98 0.215 66.3 
10 2.75 0.18 101.65 2.88 9.63 0.443 68.5 
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 Liraglutide and its interaction with HSA 4
 
 
Protein complexes, such as ligand – receptor binding and homo/hetero-oligomerization, are results 
of attractive protein-protein interaction in the form of hydrophobic interactions, electrostatic forces 
and hydrogen bonding. These more or less specific interactions result in the complementarity 
between two or more molecules. Self-association resulting in oligomers can be a way for nature to 
store proteins, such as the hexameric insulin in the beta-cells, but also a trick to extend half-life by 
protecting from renal clearance.  
GLP-1 (7-36-amide ) has a limited in-vivo half-life (t½ < 3 min) because of the combined effect of  
rapid clearance by the kidneys as a result of its small size and degradation by the dipeptidyl-
peptidase IV (DPP-IV) protease to the inactive 9-26-amide(1, 2). As GLP-1 is a promising agent for 
the treatment of type 2 diabetes mellitus, several strategies have been employed in order to 
circumvent both proteolytic cleavage and fast renal clearance. One such strategy is the increase in 
size to decrease renal clearance. Liraglutide is an acylated GLP-1 analogue, which has a half-life of 
11-15 hours (3), which is around 300 times increase in half-life compared GLP-1. This is thought to 
be mediated by self-association, hereby increasing the size and reducing degradation by DPP-IV, 
and association with endogenous HSA.  
The association with HSA has been shown to be 99.4% by in-vitro binding studies in human plasma 
(4) but the specific binding has to our knowledge not been elucidated. It is thought to bind via the 
fatty acid pockets of HSA(5) but whether this is as a multimer or monomer is unknown. The self-
association of liraglutide results in an oligomer, which has been found to be a concentration 
independent heptamer by Steensgaard et al.(6) (Poster) by analytical ultracentrifugation (10 mM 
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Tris/CLO4, pH 8) while Wang et al.(7) found it to be an octamer using static light scattering (20 
mM phosphate buffer, 0.1 M NaCl, pH 7.4). 
The structures of monomeric GLP-1 and liraglutide have both been determined by NMR. Below in 
Figure 4i-1 the difference between the two peptides is depicted. GLP-1 (8) is  a pure α-helical 
peptide whereas the fatty acid moiety conjugated to Lys26 of liraglutide (PDBID 4APD, no 
reference) introduces a kink in the structure (Figure 4i-1b). The surface representation highlights 
how the fatty acid (FA) wraps around the surface of peptide. The FA is believed to stabilize the 
oligomerization of liraglutide as this behaviour is not observed for GLP-1 (6). 
 
a)                                                                                        b) 
Figure 4i-1 The structures of  a) GLP-1 (PDBID 1D0R) and b) liraglutide (PDBID 4APD). Lys26 is highlighted in 
dark blue and the FA in orange stick presentation. The surface of the peptides is shown in gray. 
To elucidate the overall structure of the oligomeric species present under formulation conditions we 
have used SAXS, SLS combined with in-silico modelling. Further, we wished to investigate the 
potential complex of liraglutide with HSA, which has been examined with SAXS and SLS.  
In the following will be given a small overview of the SAXS and SLS studies performed. The SLS 
measurements were performed under the guidance of Dr. Robin D. Curtis. This is followed by a 
publication in Biophysical journal (Biophysical Journal, Volume 109, September 2015 1-12) 
published by our group last year, involving the pursuit of the liraglutide oligomer structure. 
MATERIAL AND METHODS 
Liraglutide oligomerization and its interaction with HSA have been investigated by SAXS and SLS. 
SAXS data were collected at MAXIV laboratories, beamline I911-SAXS, in Lund, Sweden, and 
SLS was measured at University of Manchester, School of Chemical Engineering and Analytical 
Science, Manchester, U.K. 
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SAXS 
Sample preparation 
Three data collections on liraglutide were perfomed and referred to as Lir
A
, Lir
B
 and Lir
C
. Lir
A
 and 
Lir
B
 include measurements of mixtures with HSA; Lir
A
 with defatted HSA (dHSA) and Lir
B
 with 
dHSA and recombinant albumin (rHSA) in the form of Recombumin® Alpha. An overview is 
presented in Table 4i-1. 
Buffer A (Lir
A
) consists of 00.376mM Na2HPO4•2H2O, pH 8.1 (adjusted with HCL/NaCl), 
Victoza® and HSA (dHSA
a
) were dialyzed into the buffer over three days as described in the 
following paper.  
Buffer B (Lir
B
 and Lir
C
) consists of 0.8 mM Na2HPO4•2H2O, 4.7 g/L propylene glycol, 1.83 g/L 
phenol, pH 8.1 (as formulated, Victoza®), The buffer was separated from liraglutide by up-
concentration of Victoza® in Pall Microsep
TM
 Advance Centrifugal Devices 3.5K,  5ml. The final 
concentration was estimated from initial volume minus end volume. 
Table 4i-1 Overview of SAXS samples 
Sample Buffer Sample concentrations  
(mg/mL) 
HSA/Lir mixtures  
HSA (mg/mL) 
Molar ratios (HSA:Lir) 
LirA Buffer A 1, 2 and 4.5 dHSA , 1, 2, 5 , 10  1:6 
LirB Buffer B 0.4, 0.7, 1.7, 4.3 and 9.6 dHSA and rHSA, 1, 2, 5 , 10 1:~5 
LirC Buffer B 0.6, 1.2, 3.1, 4.3, 6.1 and 7.3 n/a n/a 
 
rHSA were formulated as 145 mM NaCl, 8 mM octanoate and 50 mg/L Tween 80 (as the 
formulation of Recombumin® alpha) and dHSA in MilliQ. Data was collected together with Lir
B
. 
Concentration determination in non-phenol buffer (Lir
A
, rHSA and dHSA) was performed with the 
NanoDrop® 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) at 280 nm. The 
extinction coefficient was calculated to be 6990 cm
-1
M
-1
 with the PROTPARAM (9) tool from 
ExPASy.org (10) using the primary sequence of the protein.  
Mixtures HSA/Lir: 
Lir
A
: mixtures were prepared by adding dHSA to Lir
A
 and diluting with Buffer A. 
Lir
B 
: mixtures were prepared by adding dHSA or rHSA to liraglutide and dilution with Buffer B. 
dHSA and rHSA were filtered through a 100K filter (Pall Microsep
TM
 Advance Centrifugal 
Devices) to limit higher order species, prior to mixing. Buffer B was diluted with the corresponding 
amount of rHSA buffer or MilliQ for buffer measurements. Well aware that this is an 
approximation for the buffer subtraction, the purpose was to examine liraglutide in its formulated 
buffer (Buffer B). 
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Data collection 
SAXS data on liraglutide were collected three times at MAXIV laboratories, I-9-11-2. Data 
collection parameters are shown in Table 4i-2. The sample detector distance and the direct beam 
position was calibrated using silver behenate (AgBe). Measurements on pure water were used to get 
the data on an absolute scale. Buffers were measured both before and after each sample and 
averaged before subtraction. The sample size was approximately 50 µl injected manually in a flow 
cell. 
Table 4i-2 Data collection parameters from MAXIV laboratories. A new detector was installed between the 1st and 
2nd measurements, from MARCCD to PILATUS 1M. 
                             Lir
A
 
Instrument MAXIV lab. beamline I911-SAXS 
Detector MARCCD 
Wavelength (Å) 0.9100 
Q range (nm) (Momentum transfer) 0.08-4.0 
Exposure time (sec) 3*120 
Temperature (K) 298 
Sample – detector distance (mm) 1971.977 
 
 
                             Lir
B
 and Lir
C
 
Instrument MAXIV lab. beamline I911-SAXS 
Detector Pilatus 1M 
Wavelength (Å) 0.9100 
Q range (nm) (Momentum transfer) 0.08-4.85 
Exposure time (sec) 6*30 
Temperature (K) 298 
Sample – detector distance (mm) 2001.074 
 
 
All calibrations and corrections of the SAXS data were done using the in-house software Bli911-4 
(11). Buffer averaging and subsequent subtraction prior to data analysis was done in Primus (12). 
The ATSAS program package version 2.4 (13) was used for further data analysis. Evaluation of the 
Guinier region was performed within Primus and the pair distribution function, p(r), were 
determined using the interactive program GNOM (14).  
SLS 
Sample preparation 
Liraglutide and rHSA were dialyzed into Buffer B without phenol in order to be able to determine 
the concentration as phenol interferes with UV absorption with a max at 270 nm. Dialysis was 
performed into 3*900 mL over three days with three shift of buffer at 4 °C. Concentration was 
determined by UV absorbance at 280 nm in a 1 mm cuvette in a traditional VWR 
spectrophotometer. The measurements on liraglutide were performed twice, with and without 
phenol (LirS1 and LirS2). 
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Data collection 
Static light scattering measurements was performed at the University of Manchester using a 
computer programmable syringe pump (highlighted in green in the Figure 4i-2) combined with a 
miniDAWN TREOS detector (Wyatt Technology) as depicted in Figure 4i-2. The protein samples 
were injected in-line through a 0.1 m filter. A Waters 2487 absorbance detector was connected to 
the outlet for on-line concentration detection using absorbance at 280 nm. 
Two different concentration ranges were probed, for LirS1: 0.2 - 1.6 mg/mL and LirS2: 0.32 - 3.1 
mg/mL. Due to the interference of phenol it was not possible to determine the concentration in-line 
for the first experiment. The second experiment was performed without phenol. 
 
 
Figure 4i-2 The in-house setup. The Treos is seen on bottom right. The syringe pump used for sample injection is seen 
in the green rectangle. Two pumps were used for determination of HSA-Lir complex formation. 
The complex was investigated by an initial high concentration of rHSA without liraglutide present 
and increasing liraglutide concentration by 10 % per step, while decreasing the rHSA concentration 
correspondingly. If complex formation is present a plot of 𝑀𝑊 versus liraglutide ratio should 
deviate from linearity. 
RESULTS 
SAXS 
The results from SAXS measurements of liraglutide are shown in Figure 4i-3 and data treatment 
parameters are listed in Table 4i-3. Liraglutide show repulsion down to 1mg/mL. This makes data 
analysis challenging as it affects the lower q region (Figure 4i-3), which obscures the Guinier region 
and induces ripples in the 𝑝(𝑟) function making both RG and Dmax difficult to estimate.  
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Table 4i-3 Parameters from SAXS data analysis. RG: radius of gyration, Dmax: maximum particle diameter, 𝑴𝑾: 
molecular weight.  
 
Lir 
(mg/mL) 
HSA  
(mg/mL) 
RG(Guinier) 
(Å) 
RG (Gnom) 
(Å) 
Dmax 
(Å) 
𝑴𝑾 
(kDa) 
       
LirA 1  23.1 23.8 82.0 26 
 2  21.7 22.3 75.9 25 
 4.7  22.2 22.2 74.2 25 
LirB 0.7  20.1 21.5 64.2 29.3 
 1.7  20.9 21.7 73.3 28.7 
 4.3  20.3 22.6 72.0 30.5 
LirC 0.6  20.2 21.5 69.2 25.6 
 1.2  17.6 218 71.5 28.3 
 3.1  19.1 22.1 67.0 28.2 
Expected  Lir 𝑀𝑊 Monomer/Hexamer/Heptamer/Octamer                                            3.75/22.5/26.3/30.0 
rHSA  0.86 30.5 30.6 105.0 66.2 
       
dHSA/LirB 0.24 1 26.8 29.0 89.8 60.0 
 
0.48 2 26.2 29.1 89.9 65.0 
 
1.21 5 25.3 29.2 88.5 66.0 
 
2.42 10 23.1 28.6 83.0 69.0 
rHSA/LirB 0.24 1 28.1 28.7 87.7 60.0 
 0.48 2 26.4 28.2 84.5 60.0 
 1.21 5 24.3 28.2 82.0 58.0 
 2.42 10 23.0 27.7 82.0 53.0 
       
                                                                                                                                                            
                             a)                                                              b)                                                                c) 
Figure 4i-3 SAXS log/log plots of liraglutide samples. a) Lir
A
, b) Lir
B
  , c) Lir
C
 
The interaction between dHSA and Liraglutide was first investigated in Buffer A. dHSA was 
chosen to avoid competition between the C16 FA of liraglutide with FA’s pre-bound to HSA. Four 
different concentrations were collected (dHSA 1-10 mg/mL with liraglutide in a 1:6 molar ratio). 
dHSA in the phosphate buffer turned out to have a high dimer content and analysis by singular 
value decomposition (SVD) by the program POLYSAS, ATSAS 2.4 (13, 19) for determination of 
the amount of species present, turned out inconclusive and the data is not presented here due to 
polydispersity. 
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For Lir
B
 the interaction was probed using both dHSA in MilliQ and rHSA, in order to detect a 
possible difference induced by octanoate bound to rHSA. If liraglutide would be a heptamer in 
solution as indicated by the first SAXS measurements, it could be possible that liraglutide would 
bind as a heptamer to HSA and the molar ratios were designed to be (HSA:Lir) 1:7. The 
concentration of Lir
B
 was overestimated as seen from comparing the scattering curves to the 
samples without phenol (Lir
A
), and the actual molar ratio was approximately 1:5.  
Molecular weight estimates of the mixtures compared to rHSA and liraglutide (Table 4i-3) show 
a 𝑀𝑊 close to that of rHSA. Calculating an expected 𝑀𝑊 from the initial concentrations and 
assuming no binding, one gets a 𝑀𝑊 of 54.3 kDa which is slightly lower than the experimental, 
which could be an indication that a larger species is present. Dmax and RG values lie in-between 
those of rHSA and liraglutide. As repulsion is observed over the entire concentration range, Dmax is 
probably underestimated. 
The scattering curves from dHSA/Lir
B
 and rHSA/Lir
B
 are presented in Figure 4i-4. All the 
scattering curves overlap over the entire q-range indicating the same species are present in the 
samples. Comparing dHSA with rHSA we observe that the dHSA mixtures show a slightly more 
repulsive behavior than the rHSA mixtures. Analysis of both type of mixtures by POLYSAS gives a 
number of components equal to three, indicating that, besides HSA and liraglutide, a third specie is 
present in the mixtures which could be a complex between HSA and liraglutide.  
 
a)                                                                      b)                                                   
Figure 4i-4 SAXS log/log plots of a)  dHSA/ Lir
B
 and b) rHSA/ Lir
B
 
SLS 
𝐾𝑐/𝑅Θ versus concentration is shown in Figure 4i-5 for the two concentration ranges and 𝑀𝑊 and 
B22 estimates are given in Table 4i-4. Limited interaction is observed up to 1.5 mg/mL, while 
repulsion becomes apparent above this concentration. The B22 is determined from the slope above 
1.27 mg/mL. 
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Figure 4i-5 SLS data as a function of concentration. Lir1 is with phenol and Lir2 is without. 
SLS results on liraglutide show that a pure oligomeric species are present in Buffer B over the 
measured concentration range, in agreement with the SAXS results. The resulting 𝑀𝑊 lies in-
between that of a hexamer and a heptamer (see 𝑀𝑊 reference values in Table 4i-3). 
Table 4i-4 Experimental SLS parameters for Liraglutide in Buffer to with and without phenol. 
Sample Concentration (mg/mL) 𝑴𝑾 (g/mol) B22 (mL mol g
-2
) 
LirS1 0.2 - 1.6 23616.3 -9.58E-05 
LirS2 (no phenol) 0.32 - 3.1 25686.8 1.80E-03 
rHSA (no phenol) 2 – 16 71655.2 4.26E-4 
 
rHSA in Buffer 2 without phenol gave an 𝑀𝑊 of 77.7 kDa (Table 4i-4) close to the theoretical of 
66.47 kDa, indicating monodispersity, and a B22 in good correspondence with the values observed 
in Chapter 3, Figure 3.2b, of this thesis, Table 4i-4. 
Interaction between rHSA and liraglutide was investigated with SLS as well. The experiment was 
setup to start with 100 % rHSA and decrease with 10 % per step while liraglutide would start at 0% 
and increase to 100 %. If a complex is formed, a plot of 𝑀𝑊  versus the liraglutide concentration 
ratio will deviate from a straight line according to Equation 1: 
 
𝑀𝑊
𝐴𝑉 =
(𝜌𝐿𝑖𝑟 − 𝑥) ∗ 𝑀𝐿𝑖𝑟
2 + (𝜌𝐴𝐿𝐵 − 𝑥) ∗ 𝑀𝐴𝐿𝐵
2 + 𝑐𝑐𝑜𝑚𝑝𝑙𝑒𝑥 ∗ (𝑀𝐿𝐼𝑅 + 𝑀𝐴𝐿𝐵)
2
𝑐𝑡𝑜𝑡𝑎𝑙
 
1)  
 𝐿𝑖𝑟𝑂 + 𝐴𝑙𝑏 
𝐾𝐴
⇔ 𝐴𝐿𝐵 − 𝐿𝑖𝑟𝑂 
2)  
 
𝐾𝐴 =
[𝐴𝑙𝑏 − 𝐿𝑖𝑟𝑂]
[𝐴𝑙𝑏][𝐿𝑖𝑟𝑂]
 
3)  
𝑐 is the protein mass concentration and x equals the concentration of the complex (𝑐𝑐𝑜𝑚𝑝𝑙𝑒𝑥).  M is 
the molecular weight (here determined from experiment) and 𝜌𝑖 is the initial protein density in g/L. 
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𝐿𝑖𝑟𝑂 is the liraglutide oligomer, 𝐾𝐴 is equal to 1/𝐾𝐷 and is the association constant for the complex 
formation. By using the initial concentrations of liraglutide it is implicitly assumed that liraglutide 
binds as the oligomeric species to HSA and that, the presence of HSA does not interfere with the 
oligomerization of liraglutide. It is further assumed that no aggregation is present in the samples. 
The concentration of the complex is determined from the dissociation (KD) or association constant 
from Equation 3. Using this approach, we get the curves in Figure 4i-6 which depicts the 
experimental 𝑀𝑊 from SLS and 𝑀𝑊 calculated using Equation 1 for different scenarios; No 
binding, high binding and an estimate where KD is optimized for a 𝑀𝑊 profile similar to the 
experimental. 
 
Figure 4i-6 Determination of binding. Experimental Mw has been plotted alongside a predicted Mw from no 
interaction (marine) and high binding (turquoise) and weak binding (KD 𝟏𝟓𝟎 µ𝑴) predicted from theoretical Mw 
calculations using the start and end concentrations from SLS results. 
DISCUSSION 
The liraglutide oligomer is observed to be concentration independent in both SLS and SAXS 
measurements in a concentration range stretching from 0.2 to 9.6 mg/mL and shows repulsive 
behaviour above 1.5 mg/mL. The 𝑀𝑊  determinations range from 23.6 kDa (SLS) to 27.4 ± 2.0 
kDa (SAXS) which is probably caused by poor concentration determinations, partly caused by 
phenol interference. Steensgaard et al. (6), observed  a heptamer (Theoretical 𝑀𝑊: 26.3 kDa)  by 
AUC which is in close accordance with our results, though the final oligomeric specie cannot be 
definitively determined from these experiments. There is a high probability of the heptameric specie 
from the SAXS results though a hexamer or octamer cannot be ruled out. The robustness of the 
oligomer over the concentration ranges is probably due to the interaction of the FA chains with each 
other or the surface of the protein stabilizing the oligomer (see the monomeric structure in Figure ), 
as also discussed by Steensgaard et al.(6). 
In human plasma 99% of liraglutide has been found to bind HSA (4) but no information about the 
HSA-liraglutide complex has been published. It is assumed that binding is mediated by the C16 FA 
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conjugated to Lys26 via a γ-glutamic acid spacer, which can interact with HSA by binding to the 
FA binding pockets.   
The presented results from SAXS and SLS indicate that a complex is present in solution, but under 
the given solution condition, the binding is weak. Extraction of the complex from SAXS is not 
possible within the experiments performed here and no solution structure can be presented. Figure  
summarizes the results from SLS using a limited model, assuming binding of the oligomeric 
liraglutide to HSA. Fitting of this model to the experimental determined 𝑀𝑊, show that a complex 
must be present albeit with a high KD (~150 µM). The experimental result deviates from the model 
at a liraglutide ratio of 0.1. As it cannot be ruled out that liraglutide can bind as a monomer, the 
model can be extended to include larger aggregates of the protein such as the oligomer. This only 
accounts for the larger species and not for higher polydispersity. Using the monomer binding model 
the initial experimental rise in 𝑀𝑊 can be accounted for, though with worse fit over the rest of the 
𝑀𝑊 range as seen in Figure 4i-7, where the “no binding” plot is included for reference. The 
aggregate dominates the  𝑀𝑊,  calculation and no further rise in 𝑀𝑊,  is observed with decreasing 
KD. 
 
Figure 4i-7 Binding of monomeric liraglutide to HSA and accounting for the presence of large oligomers in 
solution. The red curve represent the theoretical 𝑴𝑾 
Which model that is best suited to represent the data is presently not possible to determine. The 
liraglutide oligomer seems very robust, but it is possible that by mixing with albumin the oligomer 
will dissociate resulting in a highly polydisperse solution. Further studies preferably at different 
ionic strengths to reduce the electrostatic repulsion, should provide further information about the 
complex. Once the optimal solution conditions and concentrations of HSA and liraglutide are 
determined a solution structure could be obtained by SAXS. 
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CONCLUSION 
Liraglutide has been shown to be robust oligomer of probable heptameric nature at pH 8.1 using 
both SLS and SAXS. The nature of the interaction and the role of the FA chains have not been 
addressed here. In the following manuscript MD simulations compared with SAXS results has been 
performed in order to get further insight to the interaction. Experimentally the oligomer could be a 
target for small angle neutron scattering (SANS) studies using contrast variation which might be 
able to provide information of the role of the FA’s. 
The putative HSA-liraglutide complex has been detected by SLS and SAXS but with a low binding 
affinity. Free palmitate or FA C16 has an approximate 𝐾𝐴 of 14.5 ∗ 10
−7𝑀 (20), which is a lot 
lower than estimated for liraglutide in experiments. The binding affinity could be reduced by the 
“large” GLP-1 hanging onto it or the solution conditions should be optimized. 
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ABSTRACT  
The glucagon-like peptide 1 (GLP-1) analogue, liraglutide, is a GLP-1 agonist and is used in the 
treatment of type 2 diabetes mellitus and obesity. From a pharmaceutical perspective, it is important 
to know the oligomerization state of liraglutide with respect to stability. Compared to GLP-1, 
liraglutide has an added fatty acid (FA) moiety that causes oligomerization of liraglutide as 
suggested by small-angle X-ray scattering (SAXS) and multi angle static light scattering (MALS) 
results. SAXS data suggested a global shape of a hollow elliptical cylinder of size hexa-, hepta or 
octamer, whereas MALS data indicate a hexamer. To elaborate and further the explanation of the 
stability of these oligomers and the role of the FA chains, a series of molecular dynamics 
simulations were carried out on 11 different hexa-, hepta- and octameric systems. Our results 
indicate that interactions of the fatty acid chains contribute noticeably to the stabilization. The 
simulation results indicate that the heptamer with paired FA chains is the most stable oligomer 
when compared to the 10 other investigated structures. In agreement with the SAXS data, the 
heptamer forms a water-filled oligomer of elliptical cylindrical shape. Theoretical SAXS curves 
extracted from the simulations qualitatively agree with the experimentally determined SAXS curves 
supporting the view that liraglutide forms heptamers in solution. 
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INTRODUCTION 
The glucagon-like peptide 1 (GLP-1) receptor is a well-established therapeutic target for the 
treatment of type 2 diabetes mellitus (T2DM) (1–3), and extensive research has established the 
physiologic roles of GLP-1 and its endogenous receptor in regulating glucose homeostasis and 
energy metabolism (4, 5). GLP-1-(7-37) is a 31 amino acid incretin hormone secreted by the 
endocrine L cells in the gut wall upon glucose intake (6), and is secreted in response to the nutrient 
content of the gastrointestinal tract and thus potentiate insulin exocytosis from pancreatic -cells in 
a glucose-dependent manner (6, 7). Additionally, GLP-1 suppresses appetite, glucagon secretion, 
and gastric emptying, all of which contribute to inhibition of the postprandial rise in plasma glucose 
concentrations (8). GLP-1 is responsible for up to 60 % of the postprandial insulin response (9). 
Recent studies show that GLP-1 is not only a key factor in T2DM treatment, but also has potential 
in the treatment of obesity (1, 10) and has shown positive effects on neuroprotection in animal 
models (11), which can potentially be used for the treatment of Parkinson’s and Alzheimer’s 
disease (12–15). 
 
While GLP-1 is interesting for a pharmaceutical application, it cannot be used for routine treatment, 
since its biological half-life is only a few minutes (16, 17). The short insulinotropic action of GLP-1 
results from the degradation of the peptide by dipeptidyl-peptidase IV (DPP-IV) and rapid renal 
clearance due to its relatively small size (18–20). DPP-IV degrades GLP-1 at the N-terminus by 
cleaving off the first two amino acids, generating the biologically inactive fragment, GLP-1-(9-37) 
(9, 21). To overcome this shortcoming, different strategies have been used. Those include: 1) 
incorporation of the peptides in injectable microspheres; 2) fusion with larger carrier molecules like 
albumin or fragment crystallizable region of immunoglobulin G or polyethylene glycol; and 3) 
attachment of a fatty acid (FA) directing oligomerization and promoting reversible binding to 
endogenous human serum albumin (HSA) (20). All three approaches result in an increased half-life 
partly due to the increased size of the drug minimizing the renal clearance mechanism. The latter 
approach, for instance, has been utilized in designing the GLP-1 analogue: liraglutide (Victoza®, 
Novo Nordisk A/S, Bagsværd, Denmark) (22, 23). An in depth understanding of the 
oligomerization state of liraglutide is not only instrumental in the understanding of the increased 
half-life observed for this molecule but also to ensure a stable oligomeric state, since uncontrolled 
and extensive oligomerization can drive fibrillation (24). As shown in Figure 4-1, liraglutide, a C-
16 acyl chain (palmitoyl) is linked to Lys26 via a γ-glutamic acid spacer, and the lysine in position 
34 of the native GLP-1 sequence is exchanged with arginine to ensure homogenous palmitoylation 
at position 26 (25, 26). The general understanding is that the acyl chain allows a non-covalent 
binding to albumin, which delays both proteolytic inactivation by DPP-IV and renal clearance, 
resulting in a biological half-life of about 13-14 hours and allowing once-daily administration (2, 
23). A further prolongation may also be caused by the fatty acid chain that may sterically hinder 
DPP-IV from degrading liraglutide (5). Furthermore, studies have shown that one way to stabilize 
GLP-1 is to add a clustering agent that causes the peptide to oligomerize (2), thus, the FA chain in 
liraglutide could act as a clustering agent. 
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Figure 4-1 Amino acid sequence of liraglutide. 
Although the pharmacological efficiency of liraglutide has been established (23, 27), there is a lack 
of a molecular understanding of the solution structure of liraglutide. Using analytical  
ultracentrifugation, Steensgaard and co-workers could show that liraglutide oligomerizes in a 
concentration independent manner forming predominately heptamers in the concentration range of 
0.004–4.501 mg/mL (28). Recently, Wang and co-workers studied the pH dependence of the size 
and secondary structure of liraglutide oligomers using light-scattering and circular dichroism, 
respectively (29). The authors report a transformation from an octamer to a dodecamer at pH 6.4 
and 6.9 with subsequent partial loss of the -helical structure of liraglutide. Furthermore, it has 
been shown that the oligomerization of GLP-1 and similar peptide analogues is dependent on the 
pH and ionic strength (30), and thus different solution structures may exist (3, 31). 
 
To get further insight in the solution structure of liraglutide, we have performed a series of 
molecular-dynamics (MD) simulations, and simulation results are compared with results from small 
angle X-ray scattering (SAXS) and multi angle static light scattering (MALS) experiments. 
MATERIAL AND METHODS 
SAXS 
A quantity of 3 ml commercial Victoza® (contains 18 mg liraglutide ((free-base, anhydrous); Novo 
Nordisk A/S) and the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; 
propylene glycol, 14 mg; and phenol, 5.5 mg in aqueous solution (32)) was dialyzed against 3×1 L 
buffer containing approximately 0.47 mg/mL (0.376 mM) Na2HPO4•2H2O, pH 8.1, over 3 days. 
Concentration determinations were performed with the NanoDrop® 1000 Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA) at 280 nm. The extinction coefficient was calculated to 
be 6990 cm
-1
M
-1
 with the PROTPARAM (33) tool from ExPASy.org (34) using the primary 
sequence of the protein.  
SAXS measurements were performed at the MAX IV laboratories at beamline I911-SAXS, MAX 
IV Laboratories, Lund, Sweden (35). The sample detector distance and the direct beam position 
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were calibrated using AgBe (silver behenate). Parameters are shown in Table S2 in the Supporting 
Material. Measurements on pure water were used to get the data on an absolute scale. Buffers were 
measured both before and after each sample and averaged before subtraction. The sample size was 
~50 µL injected manually in a flow cell. Measurements were performed on a series of liraglutide 
samples at approximate concentrations: 1 mg/mL, 2 mg/mL, and 4.7 mg/mL.  
All calibrations and corrections of the SAXS data were done using the in-house software Bli911-4 
(35). Buffer averaging and subsequent subtraction prior to data analysis was done in Primus (36). 
The software package ATSAS ver. 2.4 (37) was used for further data analysis. Evaluation of the 
Guinier region was performed within Primus. The pair distribution function, p(r), was evaluated 
using the interactive program Gnom (38). 
Asymmetric flow field flow fractionation-UV-MALS  
Asymmetric flow field flow fractionation (AF4) separation was performed using a Dionex UltiMate 
3000 autosampler and pump (Thermo Fisher Scientific Inc., Waltham, MA, USA) connected to a 
Wyatt Eclipse AF4 separation system (Wyatt Technology Europe Gmbh, Dernbach, Germany) 
followed by a Dionex UltiMate 3000 RS variable wavelength UV detector (Thermo Fisher 
Scientific) set at 280 nm and a Dawn Heleos-II 18-angle MALS detector (Wyatt Technology 
Europe). Separations were performed using a 10 kDa molecular weight cutoff PES 
(polyethersulfone) membrane in a 17.5 cm separation channel with an S-350 µm spacer. Samples 
were introduced to the channel at 0.2 mL/min and subsequently focused at the head of the channel 
at a focus flow rate of 1.5 mL/min. Samples were eluted over 15 min with a channel flow rate of 1 
mL/min and a cross flow gradient of 4.0 to 2.5 mL/min. Undiluted Victoza® (6 mg/mL liraglutide) 
and 10x diluted Victoza® (diluted with eluent) was injected and eluted with 20 mM phosphate, 100 
mM NaCl, and 0.05 % NaN3, pH 8.1, filtrated through a 0.1 µm filter. Different injection volumes 
of undiluted and diluted Victoza® were used, and the resulting mass loads were 6, 12 and 18 µg 
liraglutide. The molecular weight of liraglutide was calculated using the software ASTRA Ver. 
6.1.2 (Wyatt Technology Europe) with dn/dc  = 0.185 mL/g and UV extinction coefficient (280nm) 
= 6990 cm
-1
M
-1
. 
MD simulations 
Several orientations and oligomers of liraglutide have been investigated. All are based on the 
solution NMR structure of liraglutide (PDB: 4APD) obtained from the Protein Data Bank (39). The 
coordinates from the PDB file were copied, translated and rotated in a circle with a radius of 20 Å, 
corresponding to the results from SAXS experiments. This resulted in several oligomers containing 
six, seven, or eight monomers, respectively. A set of oligomers was created where the monomers 
were oriented so that two FA chains were paired in the direction of the elliptical cylinder 
arrangement, which hereafter will be referred to hexa-, hepta-, and octamer systems (Figure 4-2). In 
the heptamer, one monomer was oriented with the FA chain pointing outward of the elliptical 
arrangement. 
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Furthermore, another set of oligomers were created where some of the monomers were flipped 
upside down to see if interactions between the C- and N-terminal charges would stabilize the 
structures. For this set of oligomers, the hexa- and one octamer were made with every second 
monomer flipped upside down. In the case of the heptamer, only the monomer with the FA chain 
pointing outward was flipped upside down. Also, another octameric structure was prepared where 
every second monomer pair was flipped upside down. These configurations are hereafter referred to 
as AA6_3ud, AA7_1ud, AA8_4udp, and AA8_4uds systems where ‘ud’, ‘p’, and ‘s’are short for 
upside down, pair, and single, respectively (Figure 4-2). To clarify the extent of the stabilizing 
effect of the FA chain on the structures, another set of oligomers were created. One oligomer is 
constructed according to the rotation and translation of the first heptamer, but it does not contain 
any FA chains (hereafter referred to as AA7_glp1 and represented in Figure 4-2). Three other 
oligomers were also created; a hexa-, hepta-, and octamer where all the monomers are rotated so 
that the FA chains are pointing outward of the elliptical arrangement. These will hereafter be 
referred to as the AA6_FAout, AA7_FAout, and AA8_FAout systems (Figure 4-2). This gives a 
total of 11 oligomeric structures. 
The structures were solvated using the program Solvate from the H. Grubmüller and Groll (40). 
Water molecules were described by the TIP3 water model (41). Next, the systems were neutralized 
by adding 3 Na
+
 ions per monomer. Simulations were performed at an ionic strength of 0.1 M NaCl 
(see details in Table 4-1). All simulations were performed using the computer program NAMD (42) 
with the CHARMM36 force field (43). The same simulation parameters were used as described by 
Madsen et al. 2011 (44). (See Supporting Material for detailed description). Analyses of the 
trajectories were carried out in VMD (45). 
Theoretical SAXS curves:  
The program CRYSOL (46), which is part of the program package ATSAS Ver. 2.6 (37), was used 
to compare the SAXS curves of the structures extracted from the MD simulations with the 
experimental measured SAXS curve of the oligomer. CRYSOL calculates the scattering intensity 
based on the atomic coordinates of the protein and adds a hydration layer simplified as a continuous 
outer envelope (37). 
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Figure 4-2: Representation of the start structures for the 11 oligomeric structures. All structures are shown from a 
top view. The red line represents the orientation of the FA chain on each monomer, and the ellipses reflect the size and 
shape of the oligomers. 
Table 4-1 System and simulation details of the 11 oligomeric systems. 
Structure 
No. of 
atoms 
No. of 
waters 
No. of 
NaCl 
Initial box size 
(Å) 
Simulation time 
(ns) 
Hexamer 140203 45615 86 113×118×115 69 
Heptamer 53774 16665 31 83×88×89 129 
Octamer 136414 44000 83 113×115×115 71 
AA6_3ud 57419 18055 34 91×88×85 34 
AA7_1ud 57090 17769 33 91×87×87 39 
AA8_4udp 54814 16834 32 91×85×85 41 
AA8_4uds 54928 16872 32 91×85×85 43 
AA6_FAout 52289 16247 31 83×90×85 21 
AA7_FAout 53114 16445 31 83×88×89 51 
AA8_FAout 54937 16875 32 83×90×90 21 
AA7_glp1 51729 16131 30 83×87×87 69 
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RESULTS 
In this section experimental results from SAXS and A4F-UV-MALS are presented, followed by the 
computational results. 
SAXS 
SAXS intensity curves of liraglutide measured at different concentrations are shown in Figure 4-3. 
Repulsion is observed already at 1 mg/mL while the shape of the curve is consistent over the 
concentration range reflecting a similar shape of molecule. This is also reflected in the Kratky plots 
shown in Figure S1. Corresponding pair distribution functions are provided in Figure S2.
 
Figure 4-3: Scattering curves normalized for concentration. Plots at concentrations 1, 2, and 4.7 mg/mL. Inset 
shows scattering over entire measured scattering  range. Lir = liraglutide. 
Table 4-2 summarizes the extracted data analysis parameters. The radius of gyration (Rg), maximum 
particle diameter (Dmax) and I(0)/c show a slight decrease with concentration as expected from the 
repulsive behaviour, 
Table 4-2: Parameter overview extracted from SAXS measurements. 
Concentration 
mg/mL 
RG      Guinier 
(Å) 
RG      p(r) 
(Å) 
Dmax 
(Å) 
I(0) 
Guinier 
I(0)   p(r) I(0)/c Molecular Weight 
(kDa) 
1 23.1 23.8 82.0 0.021 0.021 0.021 26 
2 21.7 22.3 75.9 0.040 0.041 0.020 25 
4.7 22.2 22.2 74.2 0.096 0.096 0.020 25 
 
The partial specific volume, ν, used for calculating the molecular weight is chosen to match pure 
protein and is set to the average value of 0.73 cm
3
/g. To compare the experimental results with the 
model structures extracted from the simulations, the experimental data were extrapolated to q = 0 to 
avoid inter-particle repulsion. 
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AF4-UV-MALS  
Analysis of liraglutide showed a single peak and a uniform molecular weight across the peak in all 
analyses (Figure 4-4, left) indicating that repulsive behavior is negligible at the concentration range 
found in the detector. The average molecular weight across the peak was 22 kDa, which 
corresponds to a hexamer assuming a monomer molecular weight of 3.7 kDa. Undiluted Victoza (6 
mg/mL liraglutide) and 10× diluted Victoza were analyzed and different injection volumes were 
used, which resulted in mass loads of 6, 12 and 18 µg liraglutide. Liraglutide is diluted during 
analysis by the eluate, and the resulting liraglutide concentration was quantified in the eluate 
passing the UV detector (Figure 4-4, right). Peak liraglutide concentrations of 0.012, 0.024 and 
0.036 mg/mL were observed.   
 
Figure 4-4: AF4-UV-MALS analysis of undiluted Victoza® (6 mg/mL liraglutide) and 10× diluted Victoza® 
(F10). Different injection volumes were tested. All analyses showed a single peak in the UV chromatogram and a 
uniform molar mass of around 22 kDa across the peak (left). No other peaks were observed in the chromatogram. The 
liraglutide concentration in the eluate passing the UV detector is shown in the right graph. 
MD simulations:  
Simulations were performed on several sets consisting of hexa-, hepta-, and octamer oligomers to 
study the structural arrangement and stability of the oligomers including the role of the FA in 
promoting the stability of the oligomers. The last structures taken from the simulations are shown in 
Figure S3, S4, and S5. 
 
Figure S3, S4, and S5 show that although the internal structures for all 11 oligomers are highly 
distorted compared to the start structures (Figure 4-2), all of them but AA6_3ud (Figure S4 a)) 
maintain a tunnel-like structure which is, however, more or less flattened and resembling an 
elliptical shape.  
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Figure 4-5: SASA as a function of time for the hexamer, heptamer, and octamer. The area has been normalized 
according to the number of monomers. SASA was calculated every 50 ps along the trajectory using a van der Waals 
radius of 1.4 Å. 
The solvent accessible surface area of the oligomers seen in Figure 4-5, S6, and S7 relates to the 
packing of the monomers. 
Overall, the packing of the heptamers appears to be more prominent than the octamers throughout 
the simulations indicated by the lower SASA. The AA6_3ud structure has a significant lower 
packing than the AA7_1ud, AA8_4udp, and AA8_4uds structures, which most likely is a result of a 
complete opening of the elliptical structure as seen in Figure S4 a). The relatively high SASA for 
the AA6_FAout oligomer could be due to the elongation of some of the monomers which appear to 
unfold from the helix structure (Figure S5 a). 
The time evolution of the root mean square deviation (RMSD) is shown for the 11 structures in 
Figure 4-6, S8, and S9. 
 
Figure 4-6: RMSD of the entire oligomeric structure for the hexa-, hepta-, and octamer. Structures were aligned to 
the first frame (t = 0) and deviations are determined for the backbone chains. 
From the initial steep increase in RMSD, it is evident that the oligomers rearrange to some extend 
within the first 6 ns. Furthermore, Figure 4-6, S8, and S9 show that the RMSD converges for the 
hexamer, AA6_3ud, heptamer, AA7_1ud, AA8_4udp, AA8_4uds, AA8_FAout, and AA7_glp1 
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conformations. These structures appear to be stable when it comes to the overall movement of the 
systems. The octamer, AA6_FAout, and AA7_FAout, however, do not converge. Furthermore, the 
three hexameric systems and AA7_FAout present a significantly higher RMSD value compared to 
the other systems. 
 
To further monitor the movement of the monomers, the 2D positions of the α-carbon in the FA-Lys 
linker (Figure S11) for all 11 oligomer conformations, projected onto the yz plane (the monomers 
are translated and rotated around the x-axis), are shown as a function of simulation time in Figure 
4-7-Figure 4-9. 
 
From Figure 4-7, we can conclude that the spread of the hexamer is larger than for the heptamer and 
the octamer throughout the simulation. Furthermore, the hexamer is squeezed to give a more 
flattened shape. Whereas, for the octamer it appears that the elliptical structure is unstable since one 
monomer appears to migrate from the oligomeric structure. In the case of the heptamer, Figure 4-7 
b), it is evident that the position of the α-carbon is rather dense throughout the simulation and that 
the structure resembles an ellipse. 
 
 
Figure 4-7: Position of α-carbon in the FA-Lys linker of the hexamer, a), heptamer, b), and octamer, c), as a 
function of simulation time. One monomer is highlighted by a circle in the octamer, c), to indicate the possible 
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disintegration of this structure. Coordinates taken from the first 15 ns, 5 ns in the middle of the simulation, and the last 
~5 ns are shown. The circles and dashed lines indicate the average structure within the 5 ns intervals shown by the dots. 
The yz α-carbon atom coordinates for the FA-Lys linker were plotted in intervals of 50 ps. 
Figure 4-8 a  shows that the AA6_3ud structure flattens drastically, which corresponds to the more 
open structure seen in Figure S4 a. The AA8_4udp structure maintains a more elliptical 
arrangement, even though one monomer seems to be leaving the structure (indicated by the 
circumference). The AA8_4uds structure presents a lot of movement and gains a squared shape. 
The AA7_1ud structure is, like the hexamer in Figure 4-7 a, squeezed so that the elliptical structure 
is destroyed. 
 
In AA7_glp1, Figure 4-9 d, monomers are more mobile than compared with the other structures 
resulting in a disordered (unstable) structure. In Figure 4-9 b, the AA7_FAout structure appears to 
maintain an elliptical structure, but the movement of the α-carbons is not very spread out. Figure 
4-9 c shows that the α-carbon movement of the AA8_FAout system is rather centered on the 
starting position throughout the simulation, which indicates a stable system. However, as seen for 
the octamer and AA8_4udp systems, one monomer escapes from the elliptical arrangement. The 
AA6_FAout system (Figure 4-9 a) moves significantly throughout the simulation and this 
movement results in a flattened structure.  
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Figure 4-8: Position of α-carbon in the FA-Lys linker of the AA6_3ud, a), AA7_1ud, b), AA8_4udp, c), and 
AA8_4uds d), as a function of simulation time. One monomer is highlighted in a circumference in AA8_4udp, c), to 
indicate the possible disintegration of the AA8_4udp system. See figure caption Figure 4-7 for details. 
Mean energy calculations based on the structures taken at every 50 ps throughout the simulations 
are given in Table 4-3. The energies calculated for the oligomeric system (peptide-peptide, P-P) and 
the oligomer-water interactions (P-W) are normalized to the number of monomers in each oligomer 
to make comparison of the different systems possible. From these, it can be seen that the total P-P 
van der Waals (vdW) energy for the heptamer is lower than for any of the other oligomers. 
Considering the P-W interactions, the energy for the heptamer system is less negative than found 
for the other systems. In general, all the hexameric systems of liraglutide (hexamer, AA6_3ud, 
AA6_FAout) are higher in P-P vdW energy which might indicate that these structures are less 
stable than the hepta-, and octameric liraglutide oligomers. The energies show relatively large 
fluctuations (data not shown) which is also reflected by the relatively large standard deviations. 
This indicates that internally the 11 oligomeric systems are flexible structures. 
 
Table 4-3: Mean energies and corresponding standard error of the mean (for P-P and P-W) and standard 
deviation (for S-S) for the 11 systems are calculated for the simulations. Van der Waals (vdW) energies for the 
peptide-peptide (P-P), peptide-water (P-W), segment-segment (seg-seg) with FA pairs (S-S FA), seg-seg without FA 
pairs interacting (S-S), and - for the heptamer – seg-seg interactions for the monomer pairs including the monomer with 
the FA pointing outward (S-S FA out) are calculated. Energies are also calculated for the systems where all FA chains 
are pointing outward (S-S all FA out). The energies for the P-P and P-W interactions are normalized according to the 
number of monomers in the structure. MDEnergy from NAMD was used to calculate the energies in intervals of 50 ps 
for the simulations. 
Structure 
P-P vdW 
(kcal/mol) 
P-W vdW 
(kcal/mol) 
S-S vdW 
(kcal/mol) 
S-S FA vdW 
(kcal/mol) 
S-S FA out 
vdW 
(kcal/mol) 
Hexamer -188 ± 18.9 -84.7 ± 21.1 -20 ± 4.5 -44 ± 6.1 - 
Heptamer - 200 ± 14.8 -68.1 ± 19.3 -37 ± 5.6 -56 ± 4.7 -23 ± 3.8 
Octamer -187 ± 13.7 -84.4 ± 18.0 -21 ± 3.8 -62 ± 4.1 - 
AA6_3ud -185 ± 16.4 -88.1 ± 22.1 -4.6 ± 2.2 -52 ± 7.1 - 
AA7_1ud -191 ± 19.8 -83.0 ± 22.4 -12 ± 4.6 -50 ± 4.7 -38 ± 4.8 
AA8_4udp -189 ± 15.1 -86.8 ± 18.9 -18 ± 3.1 -55 ± 3.5 - 
AA8_4uds -190 ± 16.5 -85.3 ± 21.1 -24 ± 3.6 -54 ± 4.4 - 
AA7_glp1 -160 ± 15.1 -84.9 ± 19.0 -23 ± 5.1 -26 ± 5.0 -29 ± 5.2 
Structure 
P-P vdW 
(kcal/mol) 
P-W vdW 
(kcal/mol) 
S-S all FA out vdW (kcal/mol)  
AA6_FAout -171 ± 13.4 -104 ± 21.5 -23 ± 3.0 
AA7_FAout -187 ± 18.9 -86.5 ± 25.3 -33 ± 3.0 
AA8_FAout -176 ± 13.1 -98.6 ± 22.8 -35 ± 3.0 
 
The analyses were done for segment-segment interactions where FA chains are facing each other 
(S-S FA), no FA chains are between them (S-S), one FA chain pointing outward (S-S FA out), and 
all FA chains pointing outward (S-S all FA out). See Figure 4-10 and Figure 4-2 for illustration of 
S-S, S-S FA, S-S FA out, and S-S all FA out (AA6/7/8_FAout structures), respectively. The two 
last analyses were only done for the heptamer, AA7_1ud, and for the AA6_FAout, AA7_FAout, 
and AA8_FAout oligomers since these were the only conformations relevant for such investigation. 
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Results for the AA7_glp1 structure are reported as those for the heptamer even though it does not 
have any FA chains attached, since the monomers in the AA7_glp1 structure are rotated the same 
way as those in the heptamer with paired FA chains. It can be seen that for the structures with FA 
pairs, the energies are significantly lower for the monomer pairs that have FA chains facing each 
other, than those where no FA chains are between them. This supports the view that interactions of 
the FA chains contribute to the stabilization of the oligomers of liraglutide (2, 5).  
 
DISCUSSION 
 
The experimental SAXS curves (Figure 4-3) show that even at the lowest measured concentration 
of 1 mg/mL, repulsive interactions between liraglutide oligomers are present which increases with 
increasing concentration. Repulsive interactions can lead to an underestimation of the molecular 
weight. The SAXS data suggest that the solution structure of liraglutide is a hexa-, hepta-, or 
octamer. The uncertainty arises from uncertainties related to the measured concentration and the 
estimated partial specific volume (v) (and hence the number of monomers in the oligomer). To our  
 
Figure 4-9: Position of α-carbon in the FA-Lys linker of the AA6_FAout, a), AA7_FAout, b), AA8_FAout, c), and 
AA7_glp1 d), as a function of simulation time. See figure caption Figure 4-7 for details. 
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knowledge, there is no value of ν for liraglutide available in literature. In this study, v = 0.73 cm3/g 
(corresponding to an average value for pure proteins) was used. The FA chain could contribute to 
an increase in the partial specific volume, but to which extent is difficult to estimate. Using v = 0.74 
cm
3
/g as also reported in literature (47), the molecular weight increases to that resembling an 
octamer. From the SAXS measurements, it can only be concluded that the solution structure of 
liraglutide is an oligomer of approximately heptameric molecular size, with a consistent shape of an 
elliptical cylinder, and that this oligomerization is concentration-independent within the measured 
range. 
 
The MALS results indicate a hexameric solution structure of liraglutide. In contrast to the SAXS 
data, no repulsion interactions between oligomers were observed in the concentration range of 
0.012-0.036 mg/mL. Note that the SAXS data were measured in the concentration range of 1.0-4.7 
mg/mL where 1 mg/mL corresponds to the lowest concentration that can be measured. 
 
 
Figure 4-10: A surface plot of the liraglutide monomer showing the seg-seg orientations. The hydrophobicity is 
given in green and grey (hydrophobic) and orange (hydrophilic). The FA chain is colored in gray. a) shows the different 
hydrophobicity on either side of the monomer. 
 
Simulation results suggest that the hexamer is an unfavorable arrangement for the monomers as 
seen from the structural deviation of the oligomers, given by the RMSD (Figure 4-6) and the two-
dimensional plot of the α-carbon in the FA-Lys linker (Figure 4-7). However, the packing of the 
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structure is relatively tight with a low SASA (Figure 4-5) which indicates that more interactions are 
obtainable. This is also supported by the relatively low P-P energy of the hexameric system 
compared to the others (Table 4-3). The heptamer seems to present a very favorable arrangement 
with a tight packing indicated by the low SASA (Figure 4-5), little displacement given by the low 
and converging RMSD (Figure 4-6), and the overall elliptical shape seen in the two-dimensional 
plot of the α-carbon in the FA-Lys linker (Figure 4-7). This is also the structure with the overall 
lowest P-P energy of ~ -200 kcal/mol. The octamer, like the hexamer, also appears to present an 
unfavorable arrangement with a slight opening and disintegration of the elliptical structure as seen 
in the end structure (Figure S3), the two-dimensional plot of the α-carbon (Figure 4-7), and the high 
SASA (Figure 4-5). The AA6_3ud presents the worst monomer arrangement out of the 11 
investigated structures based on the end structure (Figure S4) that opens completely resulting in an 
unstable conformation as also seen from the relatively large SASA (Figure S6), increasing RMSD 
(Figure S8), and the scattered α-carbon position (Figure 4-7). The AA7_1ud, AA8_4udp, and 
AA8_4uds systems all maintain a relatively well arranged end structure (Figure S4) even though 
one monomer appears to be leaving the general elliptical structure of AA8_4up. In contrast to this, 
the overall packing of the three systems is relatively tight (Figure S6), but the overall movement is 
scattered and very spread out as seen in the 2D plot of the α-carbon (Figure 4-8). Thus, it seems like 
interactions between the C- and N-termini are not contributing to the energy, hence, liraglutide is 
most likely not to arrange like the flipped structures (AA6_3ud, AA7_1ud, AA8_4udp, and 
AA8_4uds). The AA6/7/8_FAout structures also present unfavorable arrangements of the 
monomers as can be seen by the large scattering of the individual monomers in the 2D plot of the α-
carbon (Figure 4-9) and large overall displacement represented by the RMSD (Figure S9).  
 
The most important analysis result for these structures is, however, that the S-S all FAout energies 
for all three systems are less negative than those of the segment interactions in systems where the 
FA chains are pointing towards each other (Table 4-3). This amplifies the hypothesis of liraglutide 
oligomer structures that give rise to FA interactions. However, when the FA chains are pointing 
outward they could, in theory, wrap around the elliptical structure in such a manner that they 
interact, but this appears not to be the case based on the energy calculations (Table 4-3) and the fact 
that all the FA chains in all the three structures seem to be randomly laying on the surface of the 
oligomers (Figure S5) which could promote clustering of oligomers. However, this is not the case 
since SAXS and MALS data indicate the presence of one defined oligomeric species. The 
AA7_glp1 was made as a reference structure when considering the role of the FA chains. The 
results show that the movement of the individual monomers of this system (Figure 4-9) is rather 
large. This emphasizes the stabilization effect of the FA chains. The system seems to have a tight 
packing (Figure S7), however, this fact is more likely to be a result of the missing FA chains in the 
structure, and hence, less surface area. The S-S energies bear witness of a great lack in possible 
interactions since these energies are significantly less negative (~ -29 kcal/mol) than for those 
systems with FA chains present (S-S FA average energy ~ -54 kcal/mol). This corresponds well 
with the hydrophobic/hydrophilic areas of the monomer shown in Figure 4-10 where it is evident 
that there is a difference in the hydrophobicity around the monomeric structure. All in all, it shows 
that the FA chains are important in stabilizing the liraglutide oligomer. 
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It thus appears that the heptamer is the most favorable arrangement, which is further supported by 
the comparison between the experimentally determined SAXS (SAXS
exp
) curve and curves 
extracted from the simulations. The theoretical SAXS (SAXS
comp
) curves along with the 
experimentally determined curve are shown in Fig. S10. SAXS
comp
 curves were calculated from the 
last structure of the 11 simulations.  
The discrepancies (χ2 values) for the 11 curves compared to the experimentally obtained SAXS 
curve are, together with the radii of gyration, given in Table S1. Besides the radius of gyration for 
the octamer, the radii of the systems lie very close to those found from the experimental data seen in 
Table 4-2. Also, the discrepancies given in Table S1 does not present one specific candidate with 
the best fit, as several of the systems have low discrepancies between their end structures and the 
experimentally obtained data. 
 
To clarify the best fit further, we show the time evolution of the discrepancies between SAXS
comp
 
and SAXS
exp
 for the 11 oligomers in Fig. 4-11. 
 
Fig. 4-11: Discrepancies of the calculated SAXS
comp
 curves and that of liraglutide as a function of simulation 
time, calculated every 5 ns. The arrows indicate that the χ2 values continuously increase with simulation time. 
The discrepancy of the heptamer is rather stable and low throughout the simulation. So is χ2 of the 
hexamer, AA8_4udp, AA8_4uds, and the AA7_glp1 systems. On the contrary, the discrepancy of 
the octamer and AA6_3ud is very high, and increases with simulation time. That of the 
AA6_FAout, AA7_FAout, and AA8_FAout systems and AA7_1ud fluctuates significantly 
throughout the simulations. The results show that the global structure and size seems to be correct, 
especially for the heptamer and hexamer, but none of our simulated structures capture the precise 
shape of SAXS
exp
. 
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Table 4-4: Scoring chart of the 11 oligomeric systems. Each system is evaluated compared to each other in each of 
the 7 categories; lowest and most stable SASA, lowest and most stable RMSD, most stable 2D projection and elliptical 
shape, lowest P-P vdW energy, highest P-W vdW energy, lowest discrepancy from measured SAXS curve taken for the 
end structure, and lowest mean and standard deviation of the discrepancy throughout the simulation (data taken from 
Fig. 4-11). The SASA, RMSD, and 2D projection plots are inspected visually. 1 is the best score and 11 is the worst. 
The total score is normalized. 
Structure SASA RMSD 2D 
projection 
Energy SAXS Total 
score P-P 
vdW 
P-W 
vdW 
χ2 
value 
χ2 value 
fluctuation 
Hexamer 2 8 3 5 5 7 4 4.9 
Heptamer 1 4 1 1 1 3 2 1.9 
Octamer 7 10 6 6 3 11 10 7.6 
AA6_3ud 10 11 11 8 9 10 11 10 
AA7_1ud 4 5 10 2 2 6 7 5.1 
AA8_4udp 6 3 5 3 8 5 6 5.1 
AA8_4uds 5 2 8 4 7 4 3 4.7 
AA6_FAout 11 9 2 10 11 2 8 7.6 
AA7_FAout 8 7 9 7 4 9 9 7.6 
AA8_FAout 9 1 4 9 10 1 5 5.6 
AA7_glp1 3 6 7 11 6 8 1 6.0 
 
 
Summarizing and combining all the results (see Table 4-4 for a combined scoring chart), it appears 
that the most likely solution structure of liraglutide is a heptamer where the monomers are 
orientated in such a way so that the attached FA chains can interact in three pairs in the direction of 
the elliptical arrangement and with the remaining monomer oriented so that the FA chain is pointing 
out. 
The heptamer, with the above mentioned conformation, presents the best model with a total score of 
1.9 being the best scoring structure in 4 out of 7 categories and landing either a second, third or 
fourth place in the remaining categories. It presents the best energy interactions as well as the least 
structural deviation of the monomers and highest packing. The hexamer presents the second best 
solution, but does not score best in any category. The AA6_3ud structure presents the worst 
arrangement of the monomers with a total score of 10. 
CONCLUSION  
From a pharmaceutical perspective, it is important to know the oligomerization state of liraglutide 
with respect to stability, since uncontrolled and extensive oligomerization can drive fibrillation. 
Furthermore, oligomerization is important for stabilization of the formulation, which has a 2 year 
shelf-life in liquid form. Furthermore, MALS provides information about the mass, and SAXS 
provides information on mass, radius of gyration and shape. In order to get further insight in the 
solution structure of liraglutide, we have performed molecular dynamics simulations. The SAXS 
curves indicate that liraglutide undergoes concentration-independent oligomerization. Depending on 
the partial specific volume used for deducing the molecular weight and in turn the number of 
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monomers in an oligomer, liraglutide may form hexa-, hepta- or octamers in solution. In contrast, 
the MALS results suggest that liraglutide forms hexamers in solution. The experimental results are 
not conclusive with respect to the size of the oligomers. Furthermore, no information can be 
deduced from these measurements regarding the orientation and stabilizing role of the acyl chains in 
the oligomers. 
We, therefore, performed molecular dynamics simulations on several oligomeric sets consisting of 
hexa-, hepta-, and octamers. Our simulation results indicate that interactions between the FA chains 
contribute to the stabilization of the structure and that the heptamer presents the best representation 
of the investigated liraglutide oligomer. Furthermore, comparing the experimentally determined 
SAXS curve with the SAXS curves determined from the structures extracted from the simulations 
shows qualitative agreement for the overall size and shape. This indicates that liraglutide in solution 
is most likely to form heptamers in a hollow, water-filled, elliptical cylindrical shaped structure 
where the monomers are orientated in such a way so that FA chains can interact pairwise. However, 
from the simulations, we presently are not able to identify the absolute position of the FA chains in 
the heptamer, but it is clear that interactions between them are significant. 
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SUPPORTING MATERIAL 
2 tables, 11 figures and a detailed description of the molecular dynamics simulation parameters are 
available at 
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SUPPORTING FIGURES AND TABLES 
 
Fig. S4-12: Kratky plots at concentrations 1-4.7 mg/mL. Lir = liraglutide. 
 
Fig. S4-13: Pair distribution functions, p(r), at concentrations 1-4.7 mg/mL. Lir = liraglutide. 
The p(r) curves in Fig. S4-13 show a decrease in particle size with increasing concentration as the 
p(r) curve is affected by the repulsive behavior. 
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Fig. S4-14: Last structure taken from the hexa-, hepta-, and octamer simulations. One monomer in the octamer, c), 
is highlighted in a circumference as it seems to migrate out of the elliptical structure and position itself on the surface of 
the oligomer. The FA chains, C-terminus, and N-terminus are colored in yellow, green, and blue, respectively.  
 
Fig. S4-15: Last structures taken from AA6_3ud, AA7_1ud, AA8_4udp, and AA8_4uds. One monomer in 
AA8_4udp, c), is highlighted in a circumference as it seems to migrate out of the circular structure. The FA chains, C-
terminus, and N-terminus are coloured in yellow, green, and blue, respectively.  
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Fig. S4-16: Last structures taken from the oligomers with FA chains pointing outward, a)-c), and the system with 
no FA chains, d). The FA chains, C-terminus, and N-terminus are colored in yellow, green, and blue, respectively. 
 
Fig. S4-17: Solvent Accessible Surface Area (SASA) as a function of time for AA6_3ud, AA7_1ud, AA8_4udp, 
and AA8_4uds. The area has been normalized according to the number of monomers. SASA was calculated every 50 
ps along the trajectory using a van der Waals radius of 1.4 Å. 
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Fig. S4-18: Solvent Accessible Surface Area (SASA) as a function of time for AA6_FAout, AA7_FAout, 
AA8_FAout, and AA7_glp1. The area has been normalized according to the number of monomers. SASA was 
calculated every 50 ps along the trajectory using a van der Waals radius of 1.4 Å. 
 
Fig. S4-19: RMSD of the entire oligomeric structure for AA6_3ud, AA7_1ud, AA8_4udp, and AA8_4uds. 
Structures were aligned to the first frame (t = 0) and deviations are determined for the backbone chains. 
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Fig. S4-20: RMSD of the entire oligomeric structure for AA6_FAout, AA7_FAout, AA8_FAout, and AA7_glp1. 
Structures were aligned to the first frame (t = 0) and deviations are determined for the backbone chains. 
 
Fig. S4-21: Theoretical calculated SAXS curves for each of the simulated oligomers together with the 
experimentally obtained data for liraglutide extrapolated to give a slope of zero at the intercept with the y-axis. 
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Table S5: Discrepancies (χ2) calculated between SAXScomp curves and SAXSexp and radii of gyration (Rg). 
Structure χ2 value Rg SAXS
comp
 (Å) 
Hexamer 9.04 22.04 
Heptamer 4.84 21.45 
Octamer 120.03 26.21 
AA6_3ud 50.30 24.43 
AA7_1ud 7.40 21.93 
AA8_4udp 5.77 21.57 
AA8_4uds 6.76 21.24 
AA6_FAout 3.28 22.19 
AA7_FAout 12.08 22.00 
AA8_FAout 3.19 22.03 
AA7_glp1 10.13 22.37 
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SUPPORTING MATERIAL AND METHODS 
Table S6: Experimental set up of SAXS measurements. 
Instrument MaxIV beamline I911-SAXS 
Detector MARCCD 
Wavelength (Å) 0.9100 
q range (nm)  0.08-4.0 
Exposure time (s) 3×120 
Temperature (K) 298 
Sample–detector distance (mm) 1971.644 
 
Due to the attached FA chain, some changes were made to the topology and parameter files. Force 
field parameters describing the FA-Lys26 linker (Fig. S4-22) atoms were adapted from the Gln 
residue. The Lennard Jones potential was used for the short range interactions with a cut-off of 12 Å 
in combination with a switching function starting from 10 Å ensuring that the potential goes to zero 
at the cut-off distance. A neighbouring list with a pair list distance of 14 Å was applied and updated 
every 20 fs. The nonbonded interactions were updated every 1 fs. The long range interactions were 
described by the particle mesh Ewald (48, 49) approach with a full electrostatic evaluation every 2 
fs and with a grid size of ~1 Å. First, the systems were energy minimized for 1000 steps using a 
conjugate gradient energy minimization scheme. Then the systems were simulated at 303 K for 
~20-128 ns – see Table S6 in main text for details. The integration time step was set to 1 fs where 
every 500th frame was saved for analyses. All simulations were performed under constant NPT 
conditions, i.e. constant number of atoms (N), constant pressure (P), and constant temperature (T). 
The Langevin method (50) was used to control the target temperature of 303 K and a Langevin 
piston set to 1 atm with a damping coefficient of 5 ps
-1
 was applied to control the pressure. 
 
Fig. S4-22: Structural formula of the FA chain to Lys linker. 
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 GLP-1Conjugation 5
 
 
Utilization of the extraordinary half-life of HSA by conjugation, introduces challenges such as 
conserved tertiary structure of both HSA and conjugate. It is crucial that the conjugation does not 
disrupt interaction of the conjugate with its target while HSA conserves binding to FcRn.  
A study on mutations in the C-terminal region of HSA, which is mainly responsible for the 
interaction with FcRn, has identified HSA variants with increasing and decreasing binding affinities 
for FcRn (1). As a decrease in FcRn affinity has been observed for a HSA C-terminal genetic fusion 
protein (2), it is plausible that the use of a higher affinity variant could compensate for this loss. 
Following this study, S. Petersen et al.(3) examined the conjugation of different PEGS to Cys34 of 
wild type (WT) HSA and a high binding (HB) variant. A decrease in affinity was observed for all 
conjugates but the HB conjugates retained a higher binding affinity to FcRn than WT. 
In the present study we have examined the effect of conjugating GLP-1 to HSA via a PEG linker. 
GLP-1 - albumin conjugates have been characterized by their affinity towards FcRn and GLP-1R 
and compared to wild type HSA and GLP1. By combining pharmacokinetic (PK) data with the 
solution structure from SAXS we wished to be able to discuss the results from a structural point of 
view. 
While it was not been possible to elucidate the solution structure of the liraglutide-HSA complex, 
the structure of GLP-1 conjugated to HSA can be approximated by utilizing prior knowledge of the 
high resolution structures of the monomers. This concludes the HSA and HSA interaction chapters. 
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ABSTRACT 
Glucagon–like peptide 1 (GLP-1) is a small incretin hormone secreted as response to food intake, 
resulting in amplification in the insulin response. Though interesting as a drug candidate for the 
treatment of type 2 diabetes mellitus, its short plasma half-life of approximately 3 minutes limits its 
use. A strategy to extend the half-life of drugs is to utilize the long half-life of human serum 
albumin (HSA) by conjugation, complexation or fusion to HSA. HSA has a plasma half-life or 
around 21 days, mediated partly through the interaction with the neonatal Fc receptor (FcRn), 
rescuing HSA from lysosomal degradation. Conjugation of GLP-1 to Cys34 of HSA could possibly 
affect the binding of HSA to FcRn while also affect the potency of GLP-1. Conjugation of GLP-1 
to Cys34 of recombinant HSA (rHSA) and two variants with lower and higher binding affinity to 
FcRn (NB and HB albumin), show that conjugation has limited effect on the binding properties of 
the conjugates compared to the respective HSA variants. Increased in-vivo half-life of the 
conjugates is observed in NMRI WT mice compared to GLP-1, while the potency of the GLP-1 is 
decreased by 3-4 orders of magnitude. The solution structure of the rHSA variants and conjugates 
were determined by small angle X-ray scattering (SAXS) where the conjugates show a somewhat 
flexible nature with the GLP-1 pointing away from the surface of HSA. The low resolution structure 
from SAXS combined with high resolution structural information from X-ray crystallography 
explains the observed behaviour, as limited interference is seen between FcRn and the conjugate 
while albumin steric hindrance explains the decreased potency of the conjugates. 
Abbreviations: HSA: Human Serum Albumin; GLP: Glucagon-like-peptide-1; Wild-Type: WT; 
dipeptidyl-peptidase-IV: DPP-VI;NMR: Nuclear magnetic resonance ; FcRn: neonatal Fc receptor; 
SAXS: Small angle X-ray scattering. GLP-1-PEG- mal: HGEGTFTSDVSSYLEGQAAKEFIAWL 
VKGR-K-(8-amino-3,6,dioxaoctanoyl-maleimidopropionyl))  
Keywords: GLP-1, Glucagon like peptide 1, albumin, HSA, SAXS, Small angle X-ray scattering, 
pharmaco kinetics, pk, FcRn binding, albumin conjugation, half-life extension 
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INTRODUCTION 
According to Mathers et al 2006 (1–3), diabetes was the 11th most prevalent cause of death 
worldwide in 2002 with a projected average annual change in age-standardized death rate of 1.1 and 
1.3 % for males and females, respectively, rising to become the 7
th
 most prevalent cause of death in 
2030. In the year 2000, 171 million had diabetes and this number is thus estimated to increase to 
366 million people in 2030 (2). Since the approval of Bayetta by the FDA in 2005 as the first in 
class GLP-1 receptor agonist, GLP-1 has been successfully used for the treatment of diabetes 
providing effective control of blood glucose levels, lowering of systolic blood pressure and 
reduction of body weight (3).  
Glucagon–like peptide 1 (GLP-1) is a 30 amino acid (7-36-amide; UniProt: P01275) peptide 
incretine hormone secreted as response to food intake (4), resulting in amplification in insulin 
response (5, 6). The reported plasma half-life of GLP-1 is, however, less than 3 minutes (7–10) 
wherefore the native peptide is unsuitable as a drug candidate. There are two main reasons for this; 
due to its small size GLP-1 is cleared rapidly by renal filtration (9). Furthermore, a specific 
inactivation mechanism exists as GLP-1 is sensitive to dipeptidyl-peptidase-IV (DPP-IV) activity 
and therefore is rapidly inactivated in human plasma by truncation of the N-terminal His-Ala 
forming the inactive 9-36-amide degradation product (11).   Studies using continuous administration 
of GLP-1, indicates clinical relevance of GLP-1 as a drug candidate when the action of the peptide 
is sufficiently extended (12), and three different approaches have been pursued to extend the 
circulatory half-life of GLP-1;  reduction of the sensitivity towards DPP-IV degradation, decreasing 
the rate of passive renal clearance and third,  mobilization of active recycling mediated by the 
neonatal Fc receptor. Reduction of sensitivity towards proteolytic inactivation by DPP-IV 
significantly extends the half-life of GLP-1 from minutes to hours. Examples of this approach are 
the development of drug candidates such as Exenatide (13) and lixisenetide (14) available on the 
market as Bayetta and Luximia, where the half-life was successfully increased from a few minutes 
to 2.4 and 3-4 hours, respectively, allowing for twice and once daily administration. Although a 
lowering of the DPP-IV induced degradation results in a ~50 fold increase in the half-life, renal 
filtration is still very efficient in clearing the peptides. Increasing size to diminish renal clearance 
will additionally increase the half-life of GLP-1 and this approach has been utilized in the 
development of several drug candidates such as liraglutide available on the market as Victoza®. 
Liraglutide is a human GLP-1 analogue lipidated at position 16 allowing for complex formation 
between endogenous human serum albumin (HSA) and liraglutide. Formation of the HSA-
liraglutide complex increases the size from ~3 to approximately ~70 kDa. The lipidation is 
additionally inducing a concentration independent multimerization of the peptide resulting in a 6-8 
fold increased size to approximately 30 kDa (15). The lipidation results in a plasma half-life of 11-
13 hrs (16), however it is unclear which of the species, the HSA-liraglutide complex or the 
liraglutide multimer, that are pharmacologically relevant. Another approach to increase the size is 
used in LY2428757. Here, GLP-1 is pegylated resulting in a half-life of 2.5 days in cynomalgus 
monkey(17)). A similar half-life of 2.5 days in Cynomolgus monkey was achieved from fusion of 
an unstructured recombinant polypeptide of 864 amino acids (XTEN) to exenatide, (18).  
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Additional prolongation of half-life is achieved by covalent attachment of exenatide to the Fc 
domain of IgG (19) or to HSA (20).  Both IgG and HSA has an extra ordinary long half-life of 21 
days. The long half-life is a result of an active rescue mechanism where HSA  (21–23) and IgG  
(24–27) is captured by  the MHC-related neonatal Fc receptor (FcRn) and recycled. FcRn rescues 
the proteins in the endosomes after pinocytosis through a strong interaction triggered by the low pH 
(~pH 6-6.5) in this cellular compartment. Binding to FcRn prevents HSA and IgG from entering 
into the lysosomal pathway for destruction. Instead the proteins are released into the extracellular 
space triggered by an increase to physiological pH (~ pH 7.4). 
Mustering of the FcRn recycling mechanism by covalent attachment to the Fc domain of IgG or 
HSA further extends the half-life by a factor of ~2.5. Dulaglutide, an exenatide-Fc fusion protein, 
has thus been reported to have a circulatory half-life of 4 days. Albiglutide, a (GLP-1 analogue)2-
albumin fusion and CJC-3134, an exenatide-albumin conjugation have been reported to have a half-
life of 6  (28, 29) and 8 (30) days respectively. Semaglutide(31, 32) is a once-weekly GLP-1 
analogue with two amino acid substitutions and acylated at Lys 26, giving rise to decreased in-vivo 
degradation by DPP-IV and an increased half-life due to increased albumin binding (33). 
In Table 5-1 we show a selection of GLP-1 variants with their reported half-life.  It is evident from 
Table 5-1 that the effect of each half-life extension strategy is additive and combining the three 
gives the longest extension of half-life. Reducing the sensitivity to DPP-IV inactivation thus 
provides approximately ~50 fold increase in half-life. Decreasing passive renal clearance provides 
an additional ~25 fold increase in half-life depending on the hydrodynamic radius of the drug and 
an additional ~3 fold increase can be achieved by mobilisation of the FcRn mediated recycling 
mechanism. 
GLP-1 structure 
The solution structure of GLP-1 has been solved by NMR (pdbid: 1D0R) (34), and shows a helical 
peptide with flexible N-and C-terminals. The structure of the GLP-1 analogue liraglutide (pdbid: 
4APD (35))  is also helical, with a small kink in the middle of the helix at the Lys26 position where 
a glutamic acid spacer is positioned. Exendin-4 (pdbid: 1JRJ) (36) is also a helix structure.  
The first structure with ligand binding to the extracellular part of the GLP-1 receptor (GLP-1R) was 
with exendin-4 bound (pdb ids: 3C5T, 3C59) (37), showing that both hydrophobic and hydrophilic 
interactions are responsible for the binding and that the C-terminal part of the helix binds to the 
extracellular part of the receptor. A similar pattern is seen in the complex between GLP-1  and 
GLP-1R (pdbid: 3IOL) (38) and semaglutide and GLP-1R (pdbid: 4ZGM) (31). A two-step binding 
mechanism of GLP-1 to the receptor has been proposed involving initial binding of the C-terminal 
of the peptide to the N-terminal extracellular part of the GLP-1R. This then facilitates the 
interaction of the N-terminal of GLP-1 to the core part of the GLP-1R (reviewed by Hoare (2005) 
(39)). The receptor is a seven-transmembrane G protein-coupled receptor (GPCR) belonging to the 
class B GPCR(40). The structure of the transmembrane (TM) part of the homologue glucagon 
GPCR has been solved by X-ray crystallography (41, 42), but no structure of the entire ligand 
bound receptor is available and is believed to be somewhat flexible. 
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Table 5-1 Selected GLP-1 variants with reported half-life. 
Drug Molecule Half-life extension Half-
life 
human 
 
Fold 
increase 
in t1/2 
Dosing 
frequency 
References 
Decreased 
DPPIV 
sensitivity 
Decreased 
renal 
clearance 
FcRn 
recycling 
    
- Human 
GLP-1 
- - - < 3 
min* 
- Continues 
infusion  
(7–10) 
Bayetta  Exenatide Yes - - 2.4 
hrs* 
48 Twice 
daily 
(13) 
Lyxumia Lixisenetide Yes - - ~3.5 
hrs* 
70 Once daily (14, 43)  
Victoza® Liraglutide 
Lipidated 
GLP-1 
? Multimer 
formation 
Association 
with 
endogenous 
HSA 
? 
 
11-13 
hrs* 
260 Once daily (44) 
- Exenidin4-
XTEN 
Yes E-XTEN 
fusion 
- 2.5 
days** 
(1200) - (18) 
LY2428757 Exenidin4-
PEG 
Yes PEGylated 
Exenatide 
- 2.5 
days** 
(1200) - (17) 
Trulicity Dulaglutide  
Fc-
Exenatide  
Yes Fusion to 
Fc 
Yes ~4 
days* 
1920 Once 
weekly 
(45) 
Semaglutaide Semaglutide Yes Yes 
Association 
with 
endogenous 
HSA 
? ~7 
days* 
3840  (32) 
 
Albiglutide HSA-GLP1-
GLP1 
Yes WT-HSA 
fusion 
Yes 6-8 
days* 
3840 Once 
weekly 
(28, 29) 
 
CJC 1134 HSA-
Exenatide 
Yes Conjugation 
to WT-HSA 
Cys-34 
Yes ~8 
days* 
3840 Once 
weekly 
(30) 
*in human ** in Cynamolgous monkey 
Conjugation to albumin can both have an adverse effect on the binding of albumin to FcRn resulting 
in limited half-life extension, and result in decreased potency of the conjugate influenced by either 
structural changes from the conjugation strategy or simply sterically hindrance in binding to its 
target.  
The recombinant HSA (rHSA) variants described here have previously been identified as high – and 
low FcRn binding variants(46) and PEG conjugation to Cys34 has shown a decrease in FcRn 
binding(47). As conjugation to albumin is a viable strategy for half-life extension for small peptide 
molecules, we set out to estimate the effect of conjugation of GLP-1 to Cys34 and how this would 
affect the different rHSA variants and the potency of GLP-1. The conjugation made little difference 
in the binding kinetics of all conjugates compared to their respective rHSA variant, while GLP-1 
shows an almost four orders of magnitude decrease in potency upon conjugation. PK results found 
an almost 300 times increase in half-life of GLP-1-HB-albumin compared to GLP-1 increasing the 
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exposure of the peptide to the body. These results has been complimented with structural models of 
the conjugates derived from small angle X-ray scattering (SAXS). SAXS is an ideal tool for the 
characterization of less rigid structures where the application of crystallography is limited (48, 49) 
and the combination of high resolution X-ray structures and low resolution SAXS models explains 
the observed effects.  
METHODS  
Albumin variants 
Wild type albumin and albumin variants (see Table 5-2) were produced by secretion from yeast as 
described elsewhere (50), followed by a 2 step  purification using AlbuPure
®
 (ProMetic 
BioSciences Ltd UK) and diethylaminoethyl weak anion exchange Sepharose Fast Flow (GE 
Healthcare). 
Table 5-2 Albumin variants. 
Short name 
 
*
Compound  Sequence information 
WT-albumin Wild type albumin Native sequence (uniprot P01275) 
NB-albumin No binder albumin, an albumin variant, with 
low affinity to the neonatal Fc receptor (FcRn) 
K500A (46) 
HB-albumin High binder albumin, an albumin variant, with 
high affinity to FcRn 
K573P (46) 
GLP-1-PEG-WT-albumin GLP-1 conjugated to WT albumin Conjugation to Cys34 
GLP-1-PEG-NB-albumin GLP-1 conjugated to NB albumin Conjugation to Cys34 
GLP-1-PEG-HB-albumin GLP-1 conjugated to HB albumin Conjugation to Cys34 
* The sequence and identity of all compounds was confirmed by MS (data not shown) 
Albumin GLP-1 conjugation 
GLP-1 with a C-terminal maleimide group was purchased from PolyPeptideLaboratories France 
(Sequence of maleimide coupled GLP-1: HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR-K-(8-
amino-3,6,dioxaoctanoyl-maleimidopropionyl)) (GLP-1-PEG-mal). The maleimide group reacts 
with the free Cys34 of HSA hereby conjugating GLP-1 to HSA. The resulting linker segment which 
couples GLP-1 to HSA is shown in Figure 5-1. 
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Figure 5-1 The linker segment between HSA and GLP-1. The linker is shown with an unreacted maleimide 
group and the two proteins are compressed in size in order to highlight the linker. The arrow indicates the 
reaction of the maleimide with Cys34. 
Buffer components and salts for the purifications were purchased from Sigma Aldrich. All solutions 
were prepared using water for injection (WFI) (HyClone WFI, Thermo scientific). The conjugation 
reaction was performed in PBS (Medicago, Sweden) at pH 7.1 with 1.5 molar excess of albumin to 
GLP-1-PEG-mal. The reaction was performed over night at room temperature with gentle shaking 
and terminated by addition of 0.5 volume WFI followed by pH adjustment to 5.3 with acetic acid. 
Un-conjugated GLP-1-PEG-mal was removed by AlbuPure® matrix (ProMetic BioSciences) 
chromatography, unconjugated albumin and conjugates were eluted with 50 mM Ammonium-
acetate, 10 mM Octanoate pH 7.0 as described in (3). The affinity purified material was added 
ammonium sulphate to 0.5 M for separation of unconjugated and conjugated albumin on a HiTrap 
Butyl sepharose HP column (GE Healthcare) equilibrated in 0.5 M (NH4)2SO4, 20 mM Na-
phosphate, 5 mM Na-octanoate pH 7.0. GLP-1-PEG-albumin was eluted with a linear gradient from 
0.5 M (NH4)2SO4, 20 mM Na-phosphate, 5 mM Na-octanoate pH 7.0 to WFI. Mono-conjugates 
eluted at approx. 0.25 M (NH4)2SO4. The purified mono-conjugate was added 1/10 volume of 10x 
PBS to stabilize pH. The conjugation was stabilized by hydrolysis (ring-opening) of the maleimide 
ring (51) by addition of glycine to 25 mM and pH adjustment to 9.0. The hydrolysis was performed 
for 20 hrs at room temperature and terminated by neutralizing to pH 7.0. The HiTrap Butyl 
sepharose HP purification was repeated to obtain the stabilized mono-conjugate, and the samples 
changed into PBS using VivaSpin20 (Sartorius Stedim) with a 30K membrane for in vitro and in 
vivo studies.  
Octet/ FcRn binding kinetics 
Biolayer interferometry on an Octet Red96 system (PALL/ForteBio) was used to characterize the 
binding kinetics of the GLP-1-PEG-albumin conjugates. Biotinylated mouse- and human-FcRn 
were purchased from Immunitrack, Denmark, and immobilized on streptavidin coated biosensors 
(PALL/ForteBio) in PBS pH 7.4 supplemented with 0.01% Tween-20.  
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The sensors were pre-blocked to minimize non-specific binding by 5 min soaking in albumin 
diluted to 0.5 mg/mL in 25 mM Na-acetate, 25 mM NaH2PO4, 150 mM NaCl, 0.01% Tween-20 pH 
5.5, followed by 5 min. rinse in the same buffer without albumin, and subsequently in milliQ water. 
The sensors were prepared for storage by soaking in 15% sucrose and air drying. 
For kinetic characterization, a 7-step two fold dilution series was prepared in 25 mM Na-acetate, 25 
mM NaH2PO4, 150 mM NaCl, 0.01% Tween-20 at pH 5.5 starting at 100 µg/mL for pH 5.5 except 
for NB-albumin and GLP-1-PEG-NB-albumin starting at 400 µg/mL. The binding kinetics were 
performed at 30ºC with a 120 sec. association phase and 300 sec. dissociation phase. The sensors 
were regenerated with PBS pH 7.4 and equilibrated in 25 mM Na-acetate, 25 mM NaH2PO4, 150 
mM NaCl, 0.01% Tween-20 at the specified pH between the different samples. All data were 
referenced with FcRn-streptavidin sensors in buffer without albumin or conjugate. Data analysis 
was performed using the Octet data analysis software ver. 8.0 (PALL/ForteBio) using curve fitting 
to a 1-1 model for estimation of kinetic parameters. For the variants with a fast off-rate only the first 
30 sec of the dissociation phase was included for curve fitting to minimize the contribution of un-
specific binding to the sensors. 
 
SAXS solution structure determination 
Table 5-3: Experimental set up of SAXS measurements 
Instrument MaxIV beamline I911-SAXS 
Detector PILATUS 1M 
Wavelength (Å) 0.91 
q range (nm)  0.07-4.8 
Exposure time (s) 360 
Temperature (K) 298 
Sample–detector distance (mm) 2404 
 
SAXS measurements were performed at the MAX IV laboratories at beamline I911-SAXS, Lund, 
Sweden (52). The sample detector distance and the direct beam position was calibrated using silver 
behenate. Parameters are listed in Table S6. Measurements on pure water were used to get the data 
on an absolute scale. Buffers were measured before and after each sample and averaged before 
subtraction. The sample size was approximately 50 µL using an automated flow cell. Measurements 
were performed on a series of samples of the different albumin variants and of the GLP-1-PEG-mal 
conjugated to the same variants as outlined in Table 5-4 
Table 5-4 Samples for small angle X-ray scattering experiments 
Compound Sample concentration  
(mg/mL) 
WT-albumin 1, 2, 5, 10, 20  
NB-albumin 1, 2, 5, 10, 20  
HB-albumin 1, 2, 5, 10, 20  
GLP-1-PEG-WT-albumin 1, 2, 5, 10  
GLP-1-PEG-NB-albumin 1, 2, 5, 10  
GLP-1-PEG-HB-albumin 1, 2, 5, 10  
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All calibrations and corrections of the SAXS data were done using the in-house software Bli911-4 
(52). Buffer averaging and subsequent subtraction prior to data analysis was done in Primus (53).  
The difference between the scattering curves of conjugates and albumin variants was qualitatively 
compared by comparing the curves individually by 2. We have done this using the online similarity 
tool created by the Sibyls group (54). 
The ATSAS program package version 2.4 (55) was used for further data treatment and analysis. 
Evaluation of the Guinier region was performed within Primus. The pair distribution function, p(r), 
was evaluated using the interactive program GNOM (56). The flexibility was analysed using the 
dimensionless Kratky plot (57) where (𝑞𝑅𝑔)2𝐼(𝑞)/𝐼(0) is displayed as a function of 𝑞𝑅𝑔, making 
the plot independent of the protein size and the intensity scale.  
Modelling of both conjugates and albumin variants was performed in two steps. Rigid body 
modelling of the GLP-1-PEG-albumin conjugates with a 7 residue linker between the albumin 
(pdbid: 1AO6 (58)) and GLP-1 (pdbid: 1D0R (34)) were done in BUNCH (59). Due to variations in 
the models produced by Bunch, the flexibility of the conjugates were evaluated using the ensemble 
optimization method (EOM) (48, 60).  
GLP-1 activity assay 
In vitro biological activities of GLP-1, GLP-1-PEG-mal and GLP-1-PEG-WT-albumin conjugates 
were determined by an agonist-binding assay using TC6 pancreatic tumour cells. Cells were 
incubated with titrations of test compounds or 10 nM control GLP-1 (7-37) for 10 minutes at room 
temperature and cAMP was measured by homogeneous time resolved fluorescence (HTRF) as 
described (12). Results were normalized to control GLP-1 and EC50 values were calculated from fits 
of dose-response curves (four parameters variable slope). 
Pharmacokinetics in NMRI WT mice  
The pharmacokinetic study was approved by the ethical committees at both BioAdvice (Ølstykke, 
Denmark) and Novozymes A/S. The study was performed at BioAdvice. 5 mg/kg of GLP1-PEG-
WT-albumin, GLP1-PEG-HB-albumin or WT-albumin were administered intravenously to NMRI 
mice (female, aged 8-10 weeks, weight between 20 and 22 g, 10 mice/compound, 5 mice/time 
point). Blood samples were collected from the tail vessel in time intervals of predose ½, 1, 2, 4, 8, 
12, 24, 48, 72, 96, 120, 144, 168 and 192 hours. Upon collection, the blood samples were kept at 
cool temperature for a maximal duration of 3 hours followed by centrifugation at 14000G for 15 
min at 20C and stored at -80C prior to bioanalysis. Serum concentrations were determined using 
an AlphaLISA method employing a commercial albumin kit (AL296C, Perkin Elmer, MA, USA) 
combined with a monoclonal anti-GLP-1 biotinylated monoclonal antibody (Ab121072, Abcam) to 
detect both albumin and GLP-1 moieties simultaneously; for albumin alone the albumin kit was 
used.  The standard curve on each plate was fitted to a four-parameter nonlinear regression model 
and the serum concentrations were calculated at each time point using the dilutions that fell within 
the linear range of the standard curve. Due to a sparse sampling group, mean serum concentration 
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profiles were subjected to non-compartmental pharmacokinetic analysis using WinNonLin 6.3. 
Nominal time points and doses were used, and all data points were equally weighted in the analysis.  
RESULTS 
The kinetic parameters of the non-conjugates and the GLP-1-PEG-albumin as determined by 
Biolayer interferometry are summarized in Table 5-5. The data show that conjugation of GLP-1 to 
Cys-34 has no apparent negative impact on the in-vitro interaction with neither human-FcRn nor 
mouse-FcRn. The albumin variants (WT, NB, HB) and the conjugates hereof exhibit comparable 
improvements as compared to the WT-albumin. The KD’s summarized in Table 5-5 are in the same 
range as earlier reported when measured using the Biolayer interferometry method as reported for 
(in nM) WT-albumin (human-FcRn: 797.9155.0, mouse-FcRn: 5391.0367.7), HB-albumin 
(human-FcRn: 31.59.8, mouse-FcRn: 764.317.5) and mouse-albumin (human-FcRn: 74.613.4, 
mouse-FcRn: 314.912.1) in Viuff et. al. (61). As reported previously, mouse-albumin binds to the 
mouse-FcRn with a significant higher affinity than the human-albumin variants (61).  
Table 5-5 Octet Binding kinetics – affinity towards the human-  and mouse-FcRn receptor 
 Human-FcRn Mouse-FcRn 
 KDSD 
(nM) 
konSD 
(10
-3
/Ms) 
koffSD 
(10
3
/s) 
KDSD 
(nM) 
konSD 
(10
-3
/Ms) 
koffSD 
(10
3
/s) 
WT-albumin 548.7 90.2 31.52.8 17.11.4 4702.01096.5 11.73.9 52.09.5 
GLP-1-PEG-WT-albumin 856.594.9 25.52.8 21.71.4 3506.7910.2 11.72.6 39.65.5 
NB-albumin Low binding Very low binding 
GLP-1- PEG-NB-albumin Low binding Very low binding 
HB-albumin 25.24.3 35.43.9 0.90.1 1774.0299.7 20.13.0 34.91.0 
GLP-1- PEG-HB-albumin 26.12.7 40.32.1 1.00.1 1324.7418.7 21.54.9 27.11.5 
mouse-albumin 191.631.4 22.61.6 4.30.4 486.2125.2 21.34.0 10.10.7 
 
GLP-1-albumin conjugates potency and pharmacokinetics 
GLP-1-PEG-WT-albumin potency was investigated and compared to that of unconjugated GLP-1. 
When conjugated to PEG-albumin the potency of GLP-1 is reduced by 3-4 orders of magnitude, 
seen by a shift in EC50 from 5.257×10
-11
 to 1.730×10
-7
.(See Table insertion in Figure 5-2). A similar 
decrease in pegylated GLP-1 potency has been reported before (62). Steric hindrance from the 
albumin likely cause this drop in potency as conjugation of GLP-1 to PEG-mal (GLP-1-PEG-mal) 
alone result in a similar though smaller reduction (data not shown). 
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Figure 5-2 In vitro biological activity of GLP-1 and GLP-1-PEG-albumin in βTC6 cells. cAMP response is shown 
and data represent the means ±SD of replicates. 
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Figure 5-3 Pharmacokinetic profiles of WT-albumin, GLP-1-PEG-WT-albumin and GLP-1-PEG-HB-albumin in 
NMRI mice administered 5mg/Kg, i.v. Data represent ten mice and are presented as mean SDs. 
 
The pharmacokinetics (PK) in mice after single IV administration is shown in Table 5-6. For GLP-1 
the half-life in mice is approx. 2 min, while for WT-albumin it is approximately 22 hours. 
Conjugating GLP-1 to WT-albumin extends the half-life of GLP-1 by a factor of 255 to 8.5 hours. 
When using the albumin variant HB the half-life of GLP-1 was prolonged up to 300 times (Figure 
5-3 and Table 5-6). Due to the relatively poor engagement of albumin with the mouse FcRn 
receptor (Table 5-5) the performance of the HB-albumin conjugates in mice is only slightly 
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improved compared to what is achieved with WT-albumin. However, based on the PK performance 
of these variants in cynomolgus macaques (61) and humanized FcRn and albumin double transgenic 
mice (61) models compared to WT albumin, we expect the albumin variants to provide a significant 
improvement in PK for GLP-1 in humans.  
Table 5-6 Pharmacokinetics in Mice after Single IV Administration. Tmax:time to reach maximum serum 
concentration,  Cmax:  maximum concentration after administration, AUC0-: area under the curve, t1/2 : elimination 
half-life, VZ: the volume of distribution, Cl: Clearance;  the volume of plasma from which a drug is eliminated per unit 
time. 
Compound Tmax 
(h) 
Cmax 
(µg/mL) 
AUC0- 
(h.µg/mL) 
t1/2 
(h) 
VZ 
(mL/Kg) 
Cl 
(mL▪Kg/h) 
GLP-1     2 min   
WT-albumin 0.5 66  1481 21.5 104 3.4 
GLP-1-PEG-WT-albumin 0.5 27 276 8.5 223 18.1 
GLP-1-PEG-HB-albumin 0.5 48 494 9.9 143 10.1 
 
SAXS RESULTS 
All scattering profiles are shown in supplementary figure S1 and the data analysis parameters are 
shown in supplementary Table S1. The albumin variants have similar scattering curves as has the 
conjugates. This is further verified by the qualitative comparison shown in supplementary figure S2, 
which also establishes limited similarity between the albumins and the conjugates. 
All GLP-1-PEG-albumin conjugates have larger radius of gyration (Rg) than the albumin variants as 
shown in Table 5-7. This indicates that the conjugated GLP-1 somewhat protrudes away from the 
albumin instead of interacting with the surface. This is further verified by the results from the 
dimensionless Kratky plots shown in supplementary figure S3. Again the conjugates are seen to 
have an overall larger radius of gyration. 
Table 5-7 Rg determined from Guinier analysis using Primus (53). 
Compound 
(1 mg/ml) 
RG (nm) Standard  
deviation 
Compound 
(1 mg/ml) 
RG (nm) Standard 
deviation 
WT-Albumin 2.96 0.19 GLP-1-WT-Albumin 3.16 0.18 
NB-Albumin 3.00 0.29 GLP-1-NB-Albumin 3.19 0.18 
HB-Albumin 2.98 0.18 GLP-1-HB-Albumin 3.18 0.26 
 
Albumin exists in crystal structures with and without fatty acids (FA) bound. We compared the 
SAXS measurements of the albumin variants to the defatted structure (pdbid: 1AO6 (58)) and a 
fatty acid bound structure without the FAs (pdbid: 1BJ5 (63)) using Crysol (64). The best match 
was the defatted structure, which was used for further modelling.  
The structure of GLP-1 was taken as an ensemble representative from the pdb entry 1D0R. This 
structure of human GLP-1 is an NMR structure determined at pH 2.5, while a crystal structure in 
complex with GLP-1 (PDBID 3IOL) is at 6.9. These two structures show very similar secondary 
structure, though the NMR structure is more flexible. There is from these experiments no reason to 
believe that GLP-1 should change structure in the pH range examined here. The linker between 
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albumin and GLP-1 was modelled by 7 glycine residues, approximating the chemical nature of the 
linker (PEG-mal – for description see Albumin GLP-1 conjugation, Figure 5-1). Bunch (59) gave 
models with χ2 values in the range from 3.48 -3.88 for the GLP-1-PEG-HB-albumin vmodels, 
showing diversity between the position of the GLP-1 compared to albumin. χ2 is the discrepancy 
between the estimated and measured scattering curves. Results from the 10 independent Bunch 
simulations from the GLP-1-PEG-HB-albumin are shown in Figure 5-4. The NB and the WT 
variants gave similar results.  
 
Figure 5-4 GLP-1-HB-Albumin Albumin is shown in gray and the conjugated GLP-1s are shown as 10 
representative structures. 
Due to the semi-flexible nature of the conjugates observed from Bunch and the dimensionless 
Kratky plot, modelling was performed again but this time with the Ensemble Optimization Method 
(EOM)(48, 60). EOM was run in two different ways: One with the structure of GLP-1 set as a helix, 
i.e. the same PDB structure as above, and a flexible linker of 7 residues and one where the entire 
GLP-1 plus linker are flexible, though with native like backbone angles. The results are shown in 
figure S4 which show that the helical structure of GLP-1 is a good approximation, as the 𝑅𝐺 and 
𝐷𝑚𝑎𝑥 distributions are very similar between the two methods and the χ
2 
values were 1.15 and 1.145 
respectively for the GLP-1-PEG-HB-albumin conjugates, confirming the flexibility of the GLP-1 
position. The slightly less compact distribution of the GLP-1-NB-albumin is due to a larger noise in 
this data set. 
DISCUSSION 
The albumin variants were designed to have different affinities for the FcRn receptor as confirmed 
by the KD data in Table 5-5 showing increased binding for HB-Albumin compared to WT, but low 
binding for the NB-Albumin. Two crystal structures exist of the FcRn:HSA complex. A complex of 
a quadruple HSA variant V418M/T420A/E505G/V547A in complex with human FcRn (hFcRn) 
(pdbid 4K71(65)) and a complex between WT HSA and hFcRn (pdbid 4N0F (66)). The pH 
dependent binding of HSA to the FcRn receptor facilitates the recycling of albumin. HSA 
undergoes a conformational change upon binding, which is a major movement of domain III and a 
smaller movement of domain I with respect to domain II. The domain positions of HSA are 
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illustrated in Figure 5-7. It is suggested that the pH dependent binding is governed primarily by 
FcRn His161, which is the only histidine residue observed in the interface between HSA and FcRn 
(66). Furthermore, it is observed that two conserved tryptophan residues, Trp53 and Trp59 in the 
FcRn α-chain, are deeply docked into the fatty acid binding sites in HSA suggesting that binding of 
fatty acids to HSA hampers recycling (65) and that the interface between HSA and FcRn is mainly 
governed by hydrophobic interactions.  
The SAXS experiments performed at pH 7.4 confirm that the solution structure of the two albumin 
variants (NB and HB) and the wildtype protein are indistinguishable from each other as the 
scattering curves are identical (as shown in figures S1 and S2). All SAXS curves could be fitted 
with the defatted structure (pdb 1A06). 
The GLP-1-PEG-albumin conjugates also had similar scattering curves and could all be modelled 
using GLP-1 protruding from the surface of a HSA molecule with the HSA conformation found in 
the defatted structure. Flexibility of the linker was confirmed by comparing Bunch and EOM 
results, though limited to a cone area of an approximate diameter of 40 Å, Figure 5-4.  
The NB variant K500A is changed on the surface of domain III, involved in the FcRn binding. The 
lysine in the native structure of the HSA-FcRn complex, is making a salt bridge to HSA Glu531. 
This salt bridge is not present in the two albumin structures (pdbids: 1A06 or 1BJ5) and may take 
part in the domain movement, facilitating FcRn binding. Furthermore, it is in proximity of the 
pocket where the FcRn Trp53 is binding. It is plausible that breaking this salt bridge will make it 
less favourable for Trp53 to bind, affecting complex formation (see Figure 5-5). As seen in Figure 
5.5, HSA Lys500 can make a salt bridge to Glu46 in the FcRn α chain stabilizing the complex. This 
provides further explanation as to why the K500A mutant has a weak binding to FcRn. 
 
Figure 5-5 HSA Lys500, HSA Glu531 (black) and FcRn α Glu46 (dark blue) showing electrostatic interaction in 
the HSA-FcRn structure (PDBID 4N0F) on the left The  HSA Glu531 and HSA Lys500 do not interact in fatty 
acid bound HSA (PDBID 1BJ5), right. The gray spheres are myristic acids bound to HSA. Color code: Gray: HSA, 
Blue: FcRn α chain. 
When speculating about binding to the FcRn receptor there is no reason to believe that the 
mechanism for the HB variant differs from that found for the wildtype protein. The pH dependent 
K500 
E53
W53 
K500 
E53
E46 
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binding is believed to be trickered by protonisation of the FcRn His161, facilitating a hydrogen 
bond to HSA Glu82 (66). This should still be possible in the investigated K573P HB variant. The 
observed difference in binding is a slightly improved association rate and a slower dissociation rate 
as seen in Table 5-5, with retained pH dependent binding as observed by  Petersen et al. (47). The 
HB variant has been changed on the surface of domain III where it interacts with the FcRn β2m 
chain. The human protein is unique in having a lysine at position 573 – the most common amino 
acid at this position (and also in mouse) is a proline (65). Consulting the two available crystal 
structures of HSA complexed with FcRn: pdbid:4K71 and pdbid:4N0F, shows that Lys573, is 
interacting with the Ser20 and Glu69 in pdb structure 4K71 but not in 4N0F where it is bend away 
from FcRn Phe22 in the β2m chain, as seen in Figure 5-6. The global binding mechanism behind 
the effect of changing Lys573 is therefore less clear. If steric hindrance with Phe22 is minimized it 
may be rationalized that by changing it to a smaller side chain, binding would be improved. It is 
also plausible that the proline substitution promotes formation of the hydrophobic interface between 
HSA and FcRn. 
 
  
 
 
 
 
 
 
 
Figure 5-6 Interaction of Lys573 (black) with Ser20, Phe22 and Glu69 from the β2m chain of FcRn. PDBID:4N0F 
to the left and 4k71 to the right. Color code: Gray: HSA, Green: FcRn β2m chain and Blue: FcRn α chain. Distances are 
shown in italic and measured in Pymol, given in Å. 
Petersen et al. (47) examined the effect of conjugation of different sizes of PEG to Cys34 of rHSA 
on the binding affinity to FcRn, and proposed that steric hindrance could be the reason for the 
observed decreased affinity of the conjugates compared to HSA. Following the discussion from 
above, Cys34 is situated in domain I of HSA and though Cys34 is not observed to be important for 
FcRn binding, however, one could imagine steric hindrance from the GLP-1 conjugate that sticks 
out from the albumin surface as seen in Figure 5-4. From Table 5-5 it is seen that the affinity for 
binding to the FcRn receptor is basically unaltered by conjugation of the GLP-1 molecule in 
contrast to the PEG results. This indicates that the albumin variants may bind unhindered to the 
FcRn receptor in-vitro even with GLP-1 conjugated to Cys34.  The large and more flexible PEG 
could interact with HSA inferring steric hindrance through interaction with the surface, while the 
smaller and more rigid secondary structure of GLP1 is pointing away from rHSA thereby limiting 
interference.  
4.1 5.3 
5.4 
K573 
F22 S20 
E69 
4.1 4.8 
3.0 
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While KD seems unaffected by conjugation, PK data show a decrease in half-life for the conjugates 
compared to WT-albumin. This could point towards other factors than FcRn binding affecting the 
circulating half-life such as the clearance rate discussed below, though interference of the GLP-1 
conjugate could be possible in-vivo. The reduced half-life of the conjugate compared to the 
unconjugated albumin is likely due to the increased clearance of the conjugate from the mouse by 
the GLP-1 part binding to the GLP-1R and the conjugate being cleared by receptor mediated 
clearance. PK was performed in mice and the affinity of the mouse-albumin against the mouse-
FcRn is significantly higher than any of the human albumin variants tested. Even for the high binder 
albumin variant (HB-albumin), KD is still approximately 4-fold higher than the mouse albumin KD 
against the mouse receptor (Table 5). Cross-species differences constitute a major limitation in pre-
clinical development particularly upon distinct receptor binding kinetics. It has been recognized that 
rodent models are very limited to study the pharmacokinetics of albumin-linked drugs (67). To this 
end, a number of transgenic mice have been developed over the years to tackle these issues and 
enable meaningful assessment of these compounds to adequately guide drug developers and 
decision-making processes (61, 68).  
The poor affinity of the human variants against the mouse receptor results in relatively fast 
clearance in the mouse model (Figure 5-3 and Table 5-6). The WT-albumin half-life is comparable 
to the half-life of a mouse FcRn knock out variant, i.e. 22 hours, and therefore nearly half the half-
life of the WT mouse albumin which is approximately 50 hours (ref or data not shown). Moreover, 
the binding improvement achieved for the engineered HB-albumin over the mouse receptor is 
minor, only 2-3 fold when compared to the 25 fold improvement seen against the human receptor. 
Despite the marginal improvements in FcRn receptor binding affinity seen for the GLP1-PEG-HB-
albumin variant, this variant still outperforms its WT counterpart, Table 5-6. The HB conjugate has 
a slower clearance from plasma leading to 80% larger exposure and approximately 1.2-fold longer 
half-life. It is expected that this improvement will translate into a much more significant 
pharmacokinetic improvement in non-human primates. Andersen et al. (46) observed an increase in 
half-life of HB-albumin from WT NMRI mice (30.6 h) to Rhesus monkeys (210.7 h) of 7.5 days 
and providing the significant pharmacological improvements achieved for the recently developed 
GLP1 albumin fusion, albiglutide, currently prescribed for one-weekly administration, it is expected 
that a HB albumin will bring additional benefit by extending the half-life of the drug and hence 
reduce the frequency of administration.  
As shown, the combination of peptides or small molecules using linkers can have an unfavourable 
effect on the activity of the active ingredient. Structural data can guide us in engineering the drug, 
focusing on its optimal presentation and availability, while maintaining the integrity of the albumin 
and its interaction with FcRn. 
In Figure 5-7 the structure of HSA in complex with the extracellular domain of the FcRn receptor 
(pdbid 4N0F) has been superimposed on a representative model of the GLP-1-PEG-HB-albumin 
derived from SAXS data using BUNCH (see Figure 5-4b). The conjugation of GLP-1 to Cys34 is 
seen to be in close proximity to the interface area between albumin and FcRn.  Apparently, it – even 
if it is close to the FcRn receptor – does not sterically hinder the binding of HSA to the FcRn 
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receptor confirming the octet data. Here it is observed that the affinity and thus the ability to bind to 
the FcRn receptor seem unchanged upon conjugation.    
 
Figure 5-7 The structure of HSA in complex with the FcRn receptor (pdbid 4N0F) superimposed on a BUNCH 
model of GLP-1- HB-albumin. Albumin is displayed in gray, FcRn α receptor in blue, β-2m in green and the GLP-1 
conjugated to albumin in pink. The domains are illustrated by medium gray for domain I, dark for domain II and light 
gray for domain III. 
While the interaction of FcRn with albumin is important for half-life extension of GLP-1, the 
efficacy is highly dependent on GLP-1 interaction with GLP-1R. From the biological activity assay 
it was observed that PEG-mal-conjugation to GLP-1 alone lowered the potency for the GLP-1R, 
and that additional conjugating HSA decreased the potency by four orders of magnitude. This 
probably means that binding to the GLP-1R is sterically hindered. In Figure 5-8 the structure of 
GLP-1 in complex with the extracellular part of the GLP-1R (pdbid 3IOL) has been superimposed 
with the same representative model of the GLP-1-HB-albumin as in Figure 5-7. Here it is seen that 
the conjugate may bind to the extracellular part of GLP-1R. A suggested two-part binding model 
involves secondary binding to the core domain of GLP-1R, and despite the assumed flexibility of 
the extracellular domains position of GLP-1R, a model has been proposed by Siu et. al.(41). This 
model has been used to approximate the position of HSA compared to the membrane in Figure 5-8 
(right).  Realizing the limitations of this model, it is apparent that albumin within the  GLP-1-PEG-
albumin conjugate does impact the activity of the GLP-1 moiety, possibly by colliding with the 
membrane, resulting in the lower potency observed for conjugated GLP-1. It is important to note 
that interaction with the GLP-1R is still possible and the significantly longer half-life of the albumin 
conjugates should more than compensate for the reduced potency.  
Domain III 
Domain I 
Domain II 
Domain I 
Domain III 
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Figure 5-8 The structure of GLP-1 in complex with the GLP-1 receptor (pdbid 3IOL) superimposed on a Bunch 
model of GLP-1- HB-albumin. The GLP-1 receptor is dark blue and GLP-1 is turquoise. The superimposed GLP-1 
conjugated to albumin is in pink and albumin is displayed in gray. In the right hand figure the position of the membrane 
with the TM (PDBID: 5EE7 (42)) in green has been approximately positioned inspired by the model by Siu et al. (41). 
A flexible domain between the extra cellular domain and the TM is missing and is probably flexible as indicated by the 
black arrow. IC: intracellular, EC: extracellular. 
CONCLUSION  
GLP-1 has proven a suitable candidate for the treatment of type 2 diabetes mellitus but has limited 
use due to its short half-life. Half-life extension strategies utilizing the long plasma half-life of HSA 
is a clever way of using nature’s own resources. Conjugation of GLP-1 to Cys34 of albumin could 
have an adverse effect on both binding of albumin to the FcRn receptor and GLP-1 affinity to GLP-
1R. Here the potency and pharmacokinetics of GLP-1 and GLP-1 conjugated to albumins with 
varying affinity to the FcRn receptor have been determined and combined with structural 
characterization of the conjugates using SAXS. 
Conjugation to Cys34 of albumin has earlier been shown to decrease the affinity towards FcRn by 
using different sizes of PEG linked to Cys34. We have shown that conjugation of GLP-1 to Cys34 
does not affect the in-vitro binding kinetics to FcRn, but conjugates have decreased affinity for 
GLP-1R. GLP-1 is a smaller and more rigid molecule than PEG, with a defined secondary structure 
and could very well have a different effect on the albumin - FcRn affinity than PEG. PK show a 
decrease in half-life of the conjugates compared to WT in NMRI WT mice. This is probably due to 
an increase in clearance in mice resulting from decreased FcRn affinity, though in-vivo steric 
hindrance of the conjugate cannot be ruled out. 
EC IC 
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SAXS derived structural models show that the GLP-1 protrudes out from the albumin molecules 
with a small degree of flexibility inferred by the linker. Combining the SAXS results with 
modelling using crystal structures confirms the findings that conjugation has limited effect on the 
interaction with FcRn in-vitro, hereby keeping the affinity of the HB albumin, while describing how 
albumin interference decreases the affinity for GLP-1R. The decrease in GLP-1R affinity should be 
more than compensated for by the increased half-life, hereby increasing the availability of the 
peptide drug and confirms the importance of utilizing higher affinity albumin variants when 
conjugating to albumin. 
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SUPPLEMENTARY 
S1 
All scattering profiles are shown in supplementary figure S1 and the data analysis parameters are 
shown in supplementary Table S1. NB-, HB- and WT-albumin show the same behaviour in 
solution, with only limited repulsion observable at 10 mg/mL. The conjugates have a slightly 
different scattering profile from the albumin variants but are quite similar to each other. 
 
Figure S1 SAXS scattering curves of (left) albumin variants and (right) conjugates.  
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Table S1 Overview SAXS parameters 
RG: Radius of gyration, Dmax: maximum particle diameter and Mw: molecular weight determination. A slight repulsion 
is observed with increasing concentration, which reflects in decreasing Rg and Mw. Due to slight flexible nature of the 
conjugates and the conjugate itself, the p(r) functions displayed a tail making it difficult to estimate Dmax. 
Concentration 
mg/ml 
Porod Volume RG (nm)  
(Guinier) 
RG (nm) 
p(r) 
Dmax (nm) I(0)  
p(r) 
I(0)/c Mw 
WT-Albumin        
1 101.7 2.9 3.0 10.4 0.045 0.045 62.2 
2 103.2 2.9 2.9 9.3 0.081 0.041 56.1 
5 100.0 2.9 2.8 9.2 0.202 0.040 56.0 
10 94.1 2.7 2.8 8.3 0.409 0.041 56.6 
NB-Albumin        
1 106.3 3.0 3.0 10.5 0.042 0.042 58.7 
2 103.2 3.0 2.9 9.9 0.088 0.044 60.8 
5 100.5 2.9 2.9 9.9 0.208 0.042 57.6 
10 97.9 2.8 2.8 8.2 0.404 0.040 56.0 
HB-Albumin        
1 103.2 3.0 3.0 10.2 0.046 0.046 63.6 
2 105.9 3.0 3.0 10.4 0.092 0.046 63.4 
5 101.6 2.9 2.9 9.5 0.208 0.042 57.6 
10 96.0 2.7 2.8 8.6 0.401 0.040 55.5 
        
GLP-WT-Albumin       
1 117.6 3.2 3.2 10.6 0.044 0.044 60.25 
2 115.1 3.1 3.1 11.0 0.086 0.043 59.42 
5 113.9 3.1 3.0 10.7 0.203 0.041 56.23 
10 110.6 3.0 3.0 10.4 0.325 0.033 45.01 
GLP-NB-Albumin       
1 116.8 3.2 3.2 11.2 0.045 0.045 62.46 
2 116.5 3.2 3.1 9.7 0.083 0.042 57.48 
5 114.3 3.1 3.1 10.9 0.205 0.041 56.78 
10 107.9 2.9 3.0 10.3 0.373 0.037 51.66 
GLP-HB-Albumin       
1 116.1 3.2 3.2 11.1 0.048 0.0476 65.92 
2 113.1 3.1 3.1 10.2 0.083 0.0413 57.13 
5 112.9 3.0 3.0 10.5 0.212 0.0424 58.72 
10 107.8 3.0 2.9 8.8 0.388 0.0388 53.74 
 
S2 
To verify the small differences between the scattering curves we have used the online similarity test 
created by the Sibyls group (54). We used Chi
2
 to get the below result, showing a high degree of 
similarity between albumin variants and in-between conjugates, while a smaller to low similarity is 
observed from albumins to conjugates 
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Figure S5-9 Similarity test based on Greg L. Hura et al. (54). The higher similarity is observed from red colours 
while yellow represent less similarity (see inset in figure). The albumins are seen to be similar as are the conjugates 
while conjugates and albumins all show differences.  
S3  
The results from the dimensionless Kratky plots are shown and in supplementary figure S3.where 
each conjugate is compared to the corresponding albumin variant. All plots show how the 
conjugates are larger in dimension with some flexibility as the maximum of the curve is shifted to 
higher qRG values.   
 
Figure S3 Dimensionless Kratky plot of GLP-HB-albumin compared to HB-albumin (see text for interpretation) 
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S4 
In figure S4 the average RG values of the selected representative structures are inserted in the 
legend, as to better compare the different plots. The pool distribution in black gives the distribution 
from the 10000 structures produced by EOM before optimization. The distributions of Rg and Dmax 
for the constructs are very similar using either of the two above mentioned approaches indicating 
that GLP1 is still in its helical conformation as observed in the NMR structure, validating the results 
using the structure. Focusing on the top plot in figure S4, GLP1-NB-albumin is seen to have the 
highest Rg distribution, which correlates with Bunch modelling and relates to higher noise in this 
data.  From this we are able to conclude that GLP1 is reasonably rigid, while the linker provides for 
limited flexibility. Limited flexibility can be conferred from the narrow Rg distribution as compared 
to the pool distribution. Another noticeable thing is the extended conformation of these constructs, 
which can be observed from the peaks position in the plots which is moves to higher RG than the 
pool peak, but also from analysis done by the software (49), where the entropy of the system is 
investigated. For all four systems the conclusion is extended with limited flexibility. 
 
 
 
Figure S4 EOM results. Rg distributions. Top diagram is from evaluation of the linker flexibility only, while in 
the bottom diagrams no structure was provided for GLP1, thereby assuming full flexibility.  
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 Docking of protein complexes by 6
combining RosettaDock and SAXS 
 
 
 
SAXS provides us with the information about particle shape and the nature of interaction. In the 
study of the oligomeric nature of liraglutide, molecular dynamics (MD) simulations were applied to 
gain insight to the possible 3D structure. Other studies during this work have only employed low-
resolution methods, either by combining knowledge from high resolution structures and docking 
them into the shape derived from SAXS, such as BUNCH in the modelling of HSA-GLP-1 
conjugation or simply shape reconstruction using programs such as DAMMIF. While these methods 
works well as approximations, no knowledge about specific interactions between the proteins such 
as van der Waal or electrostatic interaction is taken into account. 
Combining SAXS with in-silico modelling could provide a way to utilize the power of SAXS, 
extending the resolution by including the high resolution knowledge incorporated into the energy 
functions of such modelling tools. 
The Rosetta software suite was originally developed for de-novo protein folding (1) and is today 
extended to a variety of protein modelling protocols, including the protein-protein docking protocol, 
RosettaDock (2–4). The setup of Rosetta provides a flexible approach to modelling as the different 
protocols can be combined, by for example including small molecules or the incorporation of 
spatial constrains (5, 6). Combining RosettaDock with experimental SAXS results was originally 
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supposed to be applied to complexes identified during this thesis work, but as limited information 
was available on the success of combining RosettaDock with SAXS, we set out to identify the 
success of the approach and potential pitfalls. In the following we will present a benchmark of 
RosettaDock using SAXS constrains, showing how the combined approach can improve the 
docking energy landscape and increase the chance of identifying a near native structure. 
1.  Simons, K.T., C. Kooperberg, E. Huang, and D. Baker. 1997. Assembly of protein tertiary structures from 
fragments with similar local sequences using simulated annealing and Bayesian scoring functions. J. Mol. Biol. 
268: 209–225. 
2.  Gray, J.J., S. Moughon, C. Wang, O. Schueler-Furman, B. Kuhlman, C. a. Rohl, and D. Baker. 2003. Protein–
Protein Docking with Simultaneous Optimization of Rigid-body Displacement and Side-chain Conformations. 
J. Mol. Biol. 331: 281–299. 
3.  Kaufmann, K.W., G.H. Lemmon, S.L. Deluca, J.H. Sheehan, and J. Meiler. 2010. Practically useful: what the 
Rosetta protein modeling suite can do for you. Biochemistry. 49: 2987–98. 
4.  Chaudhury, S., M. Berrondo, B.D. Weitzner, P. Muthu, H. Bergman, and J.J. Gray. 2011. Benchmarking and 
analysis of protein docking performance in Rosetta v3.2. PLoS One. 6: e22477. 
5.  Sgourakis, N.G., O.F. Lange, F. DiMaio, I. André, N.C. Fitzkee, P. Rossi, G.T. Montelione, A. Bax, and D. 
Baker. 2011. Determination of the structures of symmetric protein oligomers from NMR chemical shifts and 
residual dipolar couplings. J. Am. Chem. Soc. 133: 6288–98. 
6.  Kaufmann, K.W., and J. Meiler. 2012. Using RosettaLigand for small molecule docking into comparative 
models. PLoS One. 7: e50769. 
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ABSTRACT 
                                                                                                                                                            
We have performed a benchmark to evaluate the relative success of using small angle X-ray 
scattering (SAXS) data as constrains (hereafter referred to SAXSconstrain) in the RosettaDock 
protocol (hereafter referred to RosettaDockSAXS). For this purpose, we have chosen 38 structures 
from the Benchmark 4.0. The theoretical SAXS data for the protein complexes were calculated 
using CRYSOL (Svergun et al. (1995) J. Appl. 28(6):768-773). The SAXS data were then used as 
SAXSconstrain and added to the protocol in the initial, low resolution docking step allowing fast 
rejection of complexes that violate the shape restrains imposed by the SAXS data. Our results 
indicate that the implementation of SAXSconstrain in general reduces the sampling space of 
possible protein-protein complexes significantly and can indeed increase the probability of finding 
near native protein complexes. The methodology used is based on rigid body docking, and works 
for cases where no major conformational changes occur upon binding of the docking partner. In a 
wider perspective, the strength of RosettaDockSAXS lies in the combination of low-resolution 
structural information of protein complexes in solution from SAXS experiments, and protein-
protein interaction energies obtained from RosettaDock that will allow predicting unknown three-
dimensional atomic structures of protein-protein complexes. 
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INTRODUCTION 
Protein-protein interactions are fundamental to the biological function of all organisms where they 
regulate for instance gene expression, cell growth, proliferation, intercellular communication and 
apoptosis. Their investigation has become one of the major objectives of proteomics, since mapping 
the driving force for complexation is not only crucial for understanding life at the cellular level, but 
also for drug design, which may provide new avenues to produce therapeutics that act as modulators 
of protein-protein interactions (1).  
Traditionally, biochemical methods such as co-immunoprecipitation, protein affinity purification, 
far-Western blotting, dynamic light scattering and fluorescence resonance energy transfer are used 
to study protein-protein interactions. These in-vitro methods have the advantage to be relatively fast 
and inexpensive, but do not provide insight on the molecular level. To obtain a detailed structural 
understanding of protein complexes, more advanced techniques have to be applied. High resolution 
techniques, such as X-ray crystallography, nuclear magnetic resonance (NMR), hydrogen / 
deuterium exchange coupled to mass spectrometry (HDX-MS) (2) are commonly applied, but have 
their limitations either due to failing to obtain crystals (X-ray crystallography) or because high 
molecular weight of the complex (NMR, HDX-MS). Low resolution techniques, such as cryo-
electron microscopy (3) and small angle X-ray scattering (SAXS) (4, 5) provide information about 
the shape of protein complexes. SAXS is used to investigate proteins and protein complexes in 
solution resulting in a resolution of 10-50 Å. In recent years, SAXS has become a very attractive 
technique due to the relative ease of sample preparation and fast data acquisition. Low-resolution ab 
initio model structures can be derived from the scattering data obtained from mono-disperse protein 
solutions using programs such as DAMMIF (6) and GASBOR (7). Rigid body docking using only 
the SAXS data and high resolution structures of the protein docking partners is possible with 
programs such as SASREF (8). All these tools are low resolution methods where the proteins are 
represented as rigid bodies and no information of the energy landscape of protein-protein 
interactions are included.  
The full power of SAXS data can be explored when using SAXS data in combination with 
computational advanced docking programs. The advantage of in-silico modelling lies in its high 
speed, low cost and freedom from experimental limits. However, there are still challenges to 
overcome such as adequate sampling of conformational space of protein-protein complexes. 
Particularly, weak binding affinity and potential multiple binding poses of proteins increase the 
difficulty of predicting their binding poses and energies. Here, SAXS data provide essential 
information to guide the docking by restraining the search space of possible protein-protein 
complexes, whereas the docking program can optimize the complex by exploring the energy 
landscape of protein-protein interactions.  
Although a relatively large number of protein-protein docking programs are available (9), only a 
limited number of these programs may use information from SAXS data to guide the selection of 
protein-protein complexes. Most of them are webserver-based docking programs such as foXSDock 
(10, 11), HADDOCK (12, 13) and pyDockSAXS (14, 15). The energy function (i.e. scoring 
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function) included in foXSDock contains a SAXS score that is based on the pair distribution 
function instead of the scattering intensity to reduce the computational burden. HADDOCK and 
pyDockSAXS do not use SAXS data directly during the docking procedure, but are applied as a 
final scoring constrain utilizing CRYSOL (16) to calculate the scattering data of each pose. Hence, 
false positive docking poses (“decoys”) are discarded first in the final stage. In an earlier approach, 
Grishaev et al. (17) showed how the structure of the two-domain S crystalline solved by NMR 
restrains using the software suite CNS (18), could be improved by the addition of SAXS constrains 
in the protocol. Similarly, Förster and co-workers (19) describe the implementation of SAXS data 
as constrains into their Integrative Modelling Platform that combines information from proteomics 
data during the modelling procedure (20, 21). SAXS constrains have also been implemented in the 
Rosetta modelling suite where SAXS data have been used in conjunction with NMR restrains for 
modelling of symmetric and oligomeric complexes (22, 23). 
The Rosetta modelling suite is a multipurpose software suite originally developed for de novo 
structure prediction (24). It contains a variety of applications for both designing and predicting 
protein structures (25), such as the protein docking tool for docking of non-identical proteins, 
RosettaDock (26, 27). The challenge in using RosettaDock is the difficulties in efficiently 
identifying the native-like complex structure which should be amongst the lowest energy structures. 
For better identification, SAXS constrains can be applied during the docking procedure. As 
discussed by Lensink and Wodak (28), application of SAXS data should only be necessary in the 
initial, low resolution docking step, as SAXS data for closely resembling protein-protein 
conformations do not provide sufficient information to distinguish between them. Therefore, we 
developed a methodology for protein-protein-docking using the traditional RosettaDock suite with 
the implementation of SAXS data as constrains (hereafter referred to RosettaDockSAXS) in the initial 
selection of decoys; i.e. after the low resolution docking step. No benchmarking has been reported 
regarding the relative success of using SAXS data as constrains (hereafter referred to SAXSconstrain) 
in RosettaDock. We have therefore conducted a benchmark, where we have implemented 
SAXSconstrain into the RosettaDock protocol for determining protein complexes of non-identical 
proteins. A pool of protein complex structures were chosen from the docking benchmark, 
Benchmark 4.0 (29), to evaluate the difference between conventional docking and docking 
performed using additionally SAXSconstrain. We demonstrate that the implementation of SAXSconstrain 
reduces the sampling space of possible protein-protein complexes and can improve the accuracy of 
the final complex structure. The strength of the methodology presented here is that it combines 
relatively easily obtainable low-resolution structural information from SAXS experiments and 
protein-protein interaction energies obtained from the Rosetta docking procedure to optimize the 
final complex structure. Particularly, the implementation of SAXSconstrain during the modelling 
procedure will result in complex structures that more closely resembles the solution structure of the 
complexes. In a wider perspective, this strategy will provide an avenue for predicting unknown 
three-dimensional structures of protein-protein complexes.  
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RESULTS AND DISCUSSION 
We have performed a benchmark to evaluate the success of using SAXS data as constrains 
(SAXSconstrain) in RosettaDock. For this purpose, we have chosen 38 structures from the Benchmark 
4.0 (29), where the structures are classified as Rigid Body, Medium difficult and Difficult cases 
reflecting the difficulty level of finding the native complex structure using in-silico docking 
techniques. Our benchmark includes 28 Rigid Body, six Medium difficult and four Difficult cases 
(Table 1). The benchmark consists of structures of a given complex (bound) used for calculating the 
theoretical SAXS data and the structures of the individual proteins (unbound) which are used as 
input for docking in Rosetta. Docking runs were performed with RosettaDock and 
RosettaDockSAXS. In the latter, SAXSconstrain were implemented in the docking protocol after the low 
resolution step as described in the Methods section. In the following discussion, we will indicate the 
docking runs with and without the implementation of SAXSconstrain as SAXS
protocol
 and NO-
SAXS
protocol
, respectively. Theoretical SAXS curves of the complexes were estimated using 
CRYSOL (16). To resemble the experimental SAXS measurements, an error was added to the 
theoretical SAXS data using a method proposed by Williamson et al. and Karaca and Bonvin (13, 
30). The methodology is briefly described in the Methods section.  
 
Figure 6-1 Standard deviations of IRMSD of the top five complexes, NO-SAXS
protocol
 vs. SAXSprotocol. The 
straight line corresponds to the diagonal y=x. Data points lying above the diagonal indicate that docking runs using 
SAXSprotocol perform better than docking runs using NO-SAXSprotocol and vice versa. For 23 complex structures (out of 
38 structures), SAXSprotocol improves the result; STDs (SAXSprotocol) < STDs (NO-SAXSprotocol). For eight complex 
structures, no effect is seen (STDs (SAXSprotocol)  STDs (NO-SAXSprotocol)) and for seven complex structures, NO-
SAXSprotocol yields better results than SAXSprotocol. STDs (SAXSprotocol) > STDs (NO-SAXSprotocol).   
After docking, all decoys were evaluated by the Interface Analyzer (IA) described by Lewis and 
Kuhlman (31). IA calculates a variety of metrics including among other parameters, the interface 
energy (dG) and the interface root mean square displacement (IRMSD), which commonly are used 
to evaluate docking poses. The first analysis was done based on IRMSD calculated between the 
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native (input) complex structure and the output decoys. The poses were sorted according to dG, and 
the mean and standard deviations (STD) of the IRMSD values of the top five structures were 
calculated. STD is a measure of the spread of the best structures, and a small STD indicates that all 
poses are close to the native complex structure. Figure 6-1 presents the STD obtained from NO-
SAXS
protocol
 docking runs as a function of STD obtained from SAXS
protocol
 docking runs. Most of 
the STD values for SAXS
protocol
 are below the STD for NO-SAXS
protocol
 showing that the 
implementation of SAXSconstrain improves the docking results in finding poses close to the native 
complex structure.  
 
Subsequently, a thorough analysis of IRMSD was performed using the bootstrap method on up to 
5000 output decoys from NO-SAXS
protocol
 runs and from SAXS
protocol
 runs. This led to 76 datasets. 
In order to investigate, if SAXSconstrain improve the prediction of poses that are close to the native 
complex structure, we created bootstrap samples (32) for each dataset. 1000 bootstrap samples were 
performed. Prior to the creation of the bootstrap samples, it was necessary to expand the number of 
decoys to be equal to 5000, as not all decoys came out successful from Rosetta. From each 
bootstrap sample, the average of the five best IRMSD was calculated. Based on these 1000 IRMSD 
averages, we calculated the probability estimates (in %) of finding a decoy with a low IRMSD in the 
intervals: below 2 Å, between 2 and 4 Å, and between 4 and 8 Å. The results are given as averaged 
probability ± one standard deviation and presented in Figure 6-2. 
 
The same trend as illustrated in Figure 6-1 is observed in Figure 6-2. The application of 
SAXSconstrain is in general superior to the use of NO-SAXS
protocol
. Even for structures classified as 
Medium difficult and Difficult cases, implementation of SAXSconstrain, in several docking runs, yields 
poses that are closer to the bound (native) complex structures than found when using NO-
SAXS
protocol 
(Table 6-2). On the other hand, there are also some cases, where both protocols work 
equally good and some cases where docking runs using NO-SAXS
protocol
 perform better than 
RosettaDockSAXS (Table 6-2). In the following, we have chosen three examples (PDB IDs: 1BVN, 
1DR6 and 1F34; Table 1). Each of them presents one of the scenarios. For convenience, PDB 
entries will be abbreviated as for instance PDB ID: 1BVN will be referred to 
PDB
1BVN. 
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Figure 6-2 Probability of a structure having an IRMSD in the intervals of: a) 1-2 Å, b) 2-4 Å and c) 4-8 Å based 
on the NO-SAXS
protocol
 (blue) and SAXS
protocol
 (orange) docking runs. The gray areas indicate the structures that are 
classified as Medium difficult cases, and the four structures far to the right are classified as Difficult. The inserted lines 
are shown to guide the eye. 
IMPROVEMENT WITH THE IMPLEMENTATION OF SAXSconstrain  
The success stories show a clear increase in near native structures in the docking results when using 
SAXSconstrain, as compared to regular docking. This works mainly by improving the docking 
landscape by the removal of fake minima and increasing the number of structures similar to the 
bound structure. An example in this category is the structure of α-amylase in complex with 
Tendamistat (
PDB
1BVN) which is classified as a Rigid Body case in Benchmark 4.0. The unbound 
structures used for the docking runs are 
PDB
1PIG (pig Alpha-amylase) and 
PDB
1HOE (Tendamistat; 
alpha-amylase inhibitor HOE-467A) as indicated in Table 1. The traditional way of illustrating the 
results is by plotting the interface energy (dG) versus IRMSD, the docking landscape. For a 
successful docking run, this landscape should show a funnel-like shape indicating a convergence of 
a)
b)
c)
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the most probable structures into a local energy minimum. Figure 6-3 shows the docking landscape 
for 
PDB
1BVN using NO-SAXS
protocol
 (left) and SAXS
protocol
 (right).  
 
Figure 6-3 Rosetta interface energy (dG) as a function of interface root mean square displacement (IRMSD) for 
PDB
1BVN showing the improved result using SAXS
protocol
 (right) vs. NO-SAXS
protocol
 (left). The population density 
of poses is indicated by the color spectrum, where yellow and dark blue indicate high and low population density of 
poses, respectively. REU = Rosetta energy units. 
The population density of poses is indicated by the color spectrum, where yellow and dark blue 
indicate high and low population density of poses, respectively. In the energy landscape obtained 
from the NO-SAXS
protocol
 docking runs, several funnels are observed. In contrast, with SAXSconstrain, 
a clear increase of poses resembling the bound structure (
PDB
1BVN) is observed as seen from the 
more pronounced funnel at low IRMSD. An additional funnel is observed at relatively high IRMSD 
corresponding to a conformation which also agrees with SAXSconstrain but less with the Rosetta 
energy function as reflected by the higher interface energy compared to the energy found for the 
first funnel at low IRMSD. The bimodal profile observed in the docking landscape (Figure 6-3) is 
correlated to the shape restriction imposed by SAXSconstrain as seen in Figure 6-4, where fastsaxs 
values are plotted as a function of IRMSD. Structures resulting in high fastsaxs values (NO-
SAXS
protocol
 docking runs; Figure 6-4, left) are removed when applying SAXSconstrain (SAXS
protocol
 
docking runs; Figure 6-4, right) demonstrating that the conformational search space of possible 
protein-protein complexes during the high resolution docking step is significantly reduced. The 
results also emphasize the importance of the combination of Rosetta’s energy function and the 
fastsaxs term as none of them individually would be able to discern a structure close to the native 
complex structure.  
 
PDB1BVN
NO-SAXSprotocol
PDB1BVN
SAXSprotocol
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Figure 6-4 Fastsaxs values are plotted a function of IRMSD for 
PDB
1BVN using NO-SAXS
protocol
 (colored blue, 
left) or SAXS
protocol 
(colored orange, right) for the docking runs. 
STRUCTURED FUNNEL WITH THE IMPLEMENTATION OF SAXSconstrain  
This classification covers protein complexes where the implementation of SAXSconstrain results in 
driving the docking towards a fake energy minimum in the docking landscape. This could arise 
from loop movements both in the interface area but also loop or domain movements away from the 
area of interaction which results in a wrong overall shape for the correct interface arrangement. One 
such example is the structure of Bovine trypsin bound to the Bowman-Birk inhibitor (
PDB
1D6R) 
which is classified as a Rigid Body case in Benchmark 4.0. The unbound structures are 
PDB
2TGT 
and 
PDB
1K9B, respectively. When applying SAXSconstrain, we overall observe that the docking poses 
have a lower IRMSD than found for the poses from NO-SAXS
protocol
 docking runs (Fig. 5). Looking 
at the energy landscape obtained from the NO-SAXS
protocol
 runs, a funnel is seen at IRMSD 2.5 Å 
with a minimum energy of -8 REU (Fig. 5, left). For the docking runs using SAXSconstrain, a well-
defined funnel is observed, but it appears at IRMSD 6 Å with a minimum energy of -11 REU 
(Fig. 5, right). Based only on the energy, one would select complex structures with relatively high 
IRMSD, and hence structures that are relatively far from the native structure.  
 
A closer look at the structures reveals that this example emphasizes the challenge when 
conformational changes occur during the formation of protein-protein complexes. The structures of 
the native complex (
PDB
1D6R) and the individual (unbound) docking partners (
PDB
2TGT, 
PDB
1K9B) 
are compared in Figure 6-6.  
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 Figure 6-5 Rosetta interface energy (dG) as a function of interface root mean square displacement (IRMSD) for 
PDB
1DR6. The population density of poses is indicated by the color spectrum, where yellow and dark blue indicate high 
and low population density of poses, respectively. Arrow (right Fig.) shows the shift in the high population density from 
the results using NO-SAXSprotocol to SAXSprotocol. REU = Rosetta energy units. 
 
Figure 6-6 Structures of the native complex structure, PDB1D6R, colored in gray and the unbound structures, 
PDB
2TGT and 
PDB
1K9B, colored in orange and yellow are superimposed. The left picture shows the overall 
structures depicting the changes in the overall shape after relaxation of the unbound structures in RosettaDock, 
enhanced by the surface representation of the inhibitor, blue circle. The zoom-in to the right displays part of the protein-
protein interface showing the conformational changes of the two loop regions (indicated by the arrows) observed in the 
bound structures.  
Conformational changes occur both in the protein-protein interface region and the overall complex 
structure. Generally, SAXS data are based on protein complexes in solution, whereas the structures 
of the individual protein docking partners are crystal structures. Depending on the extent of 
conformational changes during complexation, the shape restrain imposed by the SAXS data can 
restrict energy optimization and hence leading to false docking poses (i.e. poses with relatively high 
PDB1D6R
NO-SAXSprotocol
PDB1D6R
SAXSprotocol
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IRMSD). On the other hand, NO-SAXS
protocol
 will allow for optimizing the interfacial energy but 
will lead to complex structures that do not resemble the native complex structure. Hence, both 
criteria, shape restrain and interface energy optimization, cannot be fulfilled simultaneously. In this 
cases, one should consider using a more advanced protocol that includes flexibility of the individual 
docking partners (33, 34). However, the trade-off of such approach would be a significant increase 
in the computational burden of the docking procedure.  
 
MORE THAN ONE SOLUTION WITH THE IMPLEMENTATION OF SAXSconstrain  
Biased results reflect dockings where the implementation of SAXSconstrain results in several funnels 
which do not allow selecting a single solution. An example is the complex structure of Porcine 
pepsin with the Ascaris inhibitor 3 (
PDB
1F34), which classified as a Rigid Body case in Benchmark 
4.0 (Table 1). The implementation of SAXSconstrain increases the amount of poses with a lower 
IRMSD when compared to the docking results obtained from the NO-SAXS
protocol
 docking runs 
(Figure 6-7).  
 
Figure 6-7 Rosetta interface energy (dG) as a function of interface root mean square displacement (IRMSD) for 
PDB
1F34. The population density of poses is indicated by the color spectrum, where yellow and dark blue indicate high 
and low population density of poses, respectively. Circles show the regions of the low energy poses. REU = Rosetta 
energy units. 
Noticeable, when applying SAXSconstrain, there are two highly populated areas of poses (Figure 6-7, 
right). One of them lie at relatively low IRMSD and appears at significantly lower IRMSD than the 
highly populated area of poses seen in the energy landscape obtained from the NO-SAXS
protocol
 
docking runs. The funnel structure is also more structured (sharp) when using SAXSconstrain, while 
the application of NO-SAXS
protocol
 leads to a broad range of poses with similar low energies over an 
IRMSD interval of 10Å (Figure 6-7, left). The challenge in using SAXSconstrain is in this case that 
two funnels appear in the energy landscape at low IRMSD (2Å and 3.5Å) and that the funnel at 
IRMSD 3.5 Å has a lower dG than the one appearing at IRMSD 2Å. The identification of the 
correct funnel might be a challenge when no native structure is available. However, a clear 
improvement of the docking landscape is obtained when using SAXS
protocol
 instead of NO-
SAXS
protocol
.  
PDB1F34
NO-SAXSprotocol
PDB1F34
SAXSprotocol
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REPRODUCIBILITY OF THE DOCKING RESULTS WHEN INCLUDING SAXSconstrain  
 
Each run in Rosetta produced 1000 structures which were repeated 5 times to verify the 
reproducibility of the docking runs. This did show reproducibility, but in order to estimate this 
statistically, the bootstrapping analysis was performed by using the interface energies. The results 
are illustrated by plotting the frequency of an IRMSD value versus IRMSD. This way the areas of 
sampling or the distribution of the final structures from the Rosetta output are observed, instead of 
reflecting the depth of the funnels. Distributions for 
PDB
1BVN, 
PDB
1D6R and 
PDB
1F34 are shown in 
Fig. 8 emphasizing that the improvement obtained by applying SAXSconstrain is statistical significant 
and yields docking poses that are closer to the bound structure than the poses obtained from the 
NO-SAXS
protocol
 docking runs.  
 
Figure 6-8 Bootstrap sampled IRMSD Frequency vs. IRMSD are shown for a) 
PDB
1BVN, b) 
PDB
1D6R and c) 
PDB
1F34 using NO-SAXS
protocol
 (colored blue) or SAXS
protocol
 (colored orange). 
 
 
a) PDB1BVN b) PDB1D6R
c) PDB1F34
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CONCLUDING REMARKS  
SAXS is a simple and increasingly popular method to investigate the structure of macromolecular 
complexes in solution providing information on the overall shape of complexes, and the full power 
of SAXS data can be explored when using SAXS data in combination with in-silico modelling 
techniques such as RosettaDock that explore the energy landscape of protein-protein complexes and 
optimize protein-protein interactions.  
 
To evaluate the success of implementing SAXS data as a constrain during the docking procedure, 
we have performed a benchmark using a pool of 38 protein complex structures from the docking 
benchmark, Benchmark 4.0 (29) classified as Rigid Body (Easy), Medium difficult and Difficult 
cases. SAXSconstrain were implemented at the low-resolution step of the RosettaDock docking 
procedure following the suggestion by Lensink and Wodak (28) who previously pointed out that 
SAXSconstrain would be most efficiently applied in the initial, low resolution docking step, as SAXS 
is a low-resolution method.  
 
Our results indicate that RosettaDockSAXS reduces the conformational search space of protein-
protein complexes (i.e. false positive complexes are discarded at an early stage of the docking 
procedure) and increases the chance of identifying near native protein complexes. Interestingly, this 
was not dependent on the difficulty level of the chosen complex structures from the Benchmark. 
Limitations of the methodology arise when conformational changes both in the protein-protein 
interface and other parts of the proteins occur during binding that potentially can affect the overall 
shape of the molecule and thereby also the shape of the SAXS curve. In this case, relaxation of the 
protein-protein complexes would be necessary, which could be achieved by implementing 
molecular dynamics simulations in the procedure. However, this would increase the computational 
requirements significantly. Alternatively, other proteomics data (e.g. results from mutational 
studies) could be used to select the final complex structure. Despite the limitations in specific cases, 
our results indicated that SAXS
protocol
 is superior to NO-SAXS
protocol
.  
 
RosettaDockSAXS can provide the platform for studying protein-protein complexes, where SAXS 
data of protein complex structures in solution and the three-dimensional structures of the individual 
docking partners obtained by X-ray diffraction or homology modelling are available.  
METHODS  
BENCHMARK SELECTION  
38 complex structures were chosen from the docking benchmark version 4.0 (29), which is a non-
redundant dataset of protein complexes giving both the native complex structure (hereafter referred 
to bound structure) and structures of the individual proteins (hereafter referred to unbound 
structures). All PDB structures have a minimum resolution of 3.25 Å and a minimum chain length 
of 30 residues. NMR structures are only included for unbound proteins. The benchmark set is 
classified into three different categories based on the interface root mean square displacement 
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(IRMSD) between the unbound structures superimposed onto the bound protein complex structure. 
The set is divided according to three difficult levels and includes 121 Rigid Body (Easy), 30 
Medium difficult and 25 Difficult cases. These structures are further subcategorized into 
antibody/antigen (AB), enzymes/inhibitor (E) and others (O). The 38 selected structures represent 
the three difficulty levels and the subcategories E and O. The 38 structures present 28 Rigid Body, 
six Medium difficult and four Difficult cases (Table 1). Only few structures classified Medium 
difficult and Difficult are included in the benchmark, since in these cases, the proteins undergo 
different degrees of conformational changes upon binding. These conformational changes can 
propagate to relatively large differences in the overall shape of the complex. As the SAXS data is a 
restrain on the overall shape of the complex, it is expected that these structures will pose a particular 
difficult problem when implementing SAXSconstrain in the docking protocol.  
STRUCTURE PREPARATION AND SAXS DATA  
Protein structures were obtained from the protein data bank (www.rcsb.org) (35). Ligands and 
cofactors were deleted from all structures. Bound and unbound structures were checked to have the 
same sequence length, to have identical amino acid sequence and hence same molecular weight. 
This is important not only for root mean square displacement (RMSD) calculations but also for the 
use of SAXSconstrain. SAXS data are sensitive to the molecular weight of the investigated proteins, as 
the scattering intensity at the scattering vector 𝑞 = 0 is proportional to the molecular weight of the 
proteins. Each unbound and bound structure were initially minimized using the FastRelax protocol 
(36) with default settings to relax the structure into the Rosetta force field. The unbond structures 
corresponding to a particular bound complex structure were superimposed onto the bound complex 
structure giving the initial input unbound structures for docking.  
The scattering data for the bound complex structures was calculated using the program CRYSOL 
(16), which is part of the ATSAS program package (37). CRYSOL calculates the scattering 
intensity based on the atomic coordinates of the protein and can potentially add the hydration layer 
simplified as a continuous outer envelope. The hydration layer was included in the calculation in 
order to resemble the experimental conditions. Scattering intensities were estimated with default 
values up to 𝑞 = 0.5 Å−1  (0.01 − 0.5 Å
−1
)  with 51 data points. The computational time for using 
the fastsaxs protocol is critical dependent on the number of SAXS data points and the size of the 
protein. In the protocol, RosettaDock was set to only evaluate up to 0.3 Å−1 to further decrease the 
number of data points and increase the efficiency of the calculations.  
DOCKING PROTOCOL AND IMPLEMENTATION OF SAXSconstrain IN ROSETTADOCK  
The method implemented in RosettaDock for calculating a SAXS data was developed by Stovgaard 
et al. (38) and initially described by Sgourakis et al. (22). In short, it is a coarse grain method, where 
the form factors of the individual amino acids are based on calculations from known structures. The 
amino acids are represented by a two body model where one dummy atom represents the backbone 
while another is residue specific. Calculation of the SAXS data is based on the Debye formula (39), 
and does not include contribution from the hydration layer of the protein surface that can contribute 
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to the overall scattering of the protein (40). Förster et al. (19) reported that the inclusion of the 
hydration layer is unnecessary as the error associated with excluding the hydration layer is smaller 
than the experimental error. We have tested the effect of the hydration layer on the outcome of 
docking runs (data not shown) and found that for the complexes studied, the effect is negligible. 
SAXSconstrain were implemented in RosettaDock procedure by modifying the existing docking 
protocol that divides the docking procedure in a low and a high resolution stage. SAXSconstrain were 
applied during the low resolution step by applying the RosettaDock fastsaxs term in the Rosetta 
scoring function 12. An outline of the protocol is provided in SI Methods section, and an overview 
is depicted in Fig. S1.  
ERROR ESTIMATE ADDED TO SAXSconstrain  
In order to simulate experimentally collected data, we added an error which was done following the 
procedure suggested by Williamson and coworkers and interpreted by Karaca and Bonvin (13, 30). 
To estimate experimental error, we chose a 20 mg/mL human serum albumin (HSA) sample 
(measured at MAX IV laboratories, beamline I911-SAXS, Sweden (41), 3*60 seconds exposure 
time). The experimental error-to-intensity ratio, kexp(q) = 𝜎exp(𝑞)/𝐼exp(𝑞), as a function of q were 
fitted to a second-order Gaussian function resulting in Equation 1. 1. The 𝑘calc values were 
subsequently used to estimate the error of the calculated SAXS data using Equation 2.  
 
𝑘calc(𝑞) = (−0.01457 ∗ 𝑒𝑥𝑝 (−(
𝑞 − 1.169
1.175
)
2
) +  0.06833 ∗ 𝑒𝑥𝑝 (−(
𝑞 − 4.438
3.022
)
2
))
∗ √20 
1)  
 
For improving the error estimation, kcal(q) values were randomly chosen within the 95% confidence 
interval of the Gaussian function, and the error was estimated using:   
 
 
𝜎calc(𝑞) = 𝑘calc (𝑞) ∗
𝐼(𝑞)CRYSOL
√concentration
 2)  
 
where 𝜎calc is the calculated 𝑞-dependent error. For comparison with kexp(q), an error of 2% of the 
estimated error (eq. 2) was used to estimate kcal(q). In Figure 6-9, the methodology is verified by 
comparing the calculated 𝜎calc(𝑞)/𝐼calc(𝑞) values for the complex structure 
PDB
1GCQ with the 
experimentally determined 𝜎exp(𝑞)/𝐼exp(𝑞) values determined for the 20 mg/mL HSA solution. 
Good agreement is seen for q > 0.02 Å
-1
.  
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Figure 6-9 𝝈(𝒒)/𝑰(𝒒) vs. q for the SAXS curves calculated from the structure PDB1GCQ and from the 
experimental scattering curve measured for HSA at 20 mg/mL. Note that the scattering curve has 1000 data points, 
while the calculated curve scattering curve has 51 data points. 
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Table 6-1 Overview of structures used from Benchmark 4.0. 
 Complex Receptor Ligand Complex Type Difficult 
levels 
Residues 
P/L 
1 1AVX 1QQU 1BA7 Porcine trypsin/Soybean trypsin inhibitor E Rigid Body 223/173 
2 1AY7 1RGH 1A19 RNase Sa/Barstar E Rigid Body 96/89 
3 1BVN 1PIG 1HOE α-amylase/Tendamistat E Rigid Body 495/71 
4 1CGI 2CGA 1HPT Bovine chymotrypsinogen/PSTI E Rigid Body 245/56 
5 1CLV 1JAE 1QFD α-amylase/α-amylase inhibitor E Rigid Body 470/32 
6 1D6R 2TGT 1K9B Bovine trypsin/Bowman-Birk inhibitor E Rigid Body 223/58 
7 1DFJ 9RSA 2BNH Ribonuclease A/Rnase inhibitor E Rigid Body 455/124 
8 1E6E 1E1N 1CJE Adrenoxin reductase/Adrenoxin E Rigid Body 455/107 
9 1EAW 1EAX 9PTI Matriptase/BPTI E Rigid Body 241/56 
10 1EWY 1GJR 1CZP Ferredoxin reductase/Ferredoxin E Rigid Body 295/98 
11 1EZU 1TRM 1ECZ D102N Trypsin/Ecotin E Rigid Body 280/223 
12 1F34 4PEP 1F32 Porcine pepsin/Ascaris inhibitor 3 E Rigid Body 326/127 
13 1FLE 9EST 2REL Elastase/Elafin E Rigid Body 240/47 
22 1GCQ 1GRI 1GCP GRB2 C-ter SH3 domain/Vav N-ter SH3 domain O Rigid Body 66/57 
14 1GL1 1K2I 1PMC α-chymotrypsin/Protease inhibitor LCMI II E Rigid Body 236/34 
23 1GPW 1THF 1K9V HISF protein/Amidotransferase HISH O Rigid Body 253/200 
24 1H9D 1EAN 1ILF Runx1 domain of CBFα1/Dimerisation domain of CBF-β O Rigid Body 125/114 
15 1HIA 2PKA 1BX8 Kallikrein/Hirustatin E Rigid Body 230/48 
16 1JTG 3GMU 1ZG4 β-lactamase inhibitor protein/β-lactamase TEM-1 E Rigid Body 263/165 
17 1MAH 1J06 1FSC Acetylcholinesterase/Fasciculin E Rigid Body 533/61 
18 1OC0 1B3K 2JQ8 Plasminogen activator inhibitor-1/Vitronectin Somatomedin B domain E Rigid Body 363/36 
19 1OPH 1QLP 1UTQ α-1-antitrypsin/Trypsinogen E Rigid Body 372/223 
20 1PPE 1BTP 1LU0 Bovine trypsin/CMTI-1 squash inhibitor E Rigid Body 223/29 
21 1R0R 1SCN 2GKR Subtilisin carlsberg/OMTKY E Rigid Body 274/51 
25 1RV6 1FZV 1QSZ PIGF receptor binding domain/Flt1 protein domain 2 O Rigid Body 189/92 
26 2AJF 1R42 2GHV ACE2/SARS spike protein receptor binding domain O Rigid Body 597/174 
27 2AYO 2AYN 2FCN Ubiquitin carboxyl-terminal hydrolase 14/Ubiquitin O Rigid Body 337/72 
28 2OOB 2OOA 1YJ1 Ubiquitin ligase/Ubiquitin O Rigid Body 70/41 
        
29 1ACB 2CGA 1EGL Chymotrypsin/Eglin C E M. difficult 238/63 
30 1IJK 1AUQ 1FVU Von Willebrand Factor dom. A1/Botrocetin E M. difficult 257/199 
32 1LFD 5P21  1LXD Ras/RalGDS Ras-interacting domain O M. difficult 166/87 
31 1NW9 1JXQ 2OPY Capase-9/BIR3-XIAP E M. difficult 231/91 
33 1WQ1 6Q21 1WER Ras GTPase/Ras GAP O M. difficult 320/166 
34 1ZM4 1N0V 1XK9 Elongation factor 2/Diphtheria toxin A catalytic domain O M. difficult 823/204 
        
38 1BKD 1CTQ 2II0 Ras GTPase/Son of sevenless O Difficult 438/166 
35 1FQ1 1B39 1FPZ CDK2 kinase/CDK inhibitor 3 E Difficult 287/178 
36 1PXV 1X9Y 1NYC Cystein protease/Cystein protease inhibitor E Difficult 171/111 
37 1ZLI 1KWM 2JTO Carboxypeptidase B/Tick carboxypeptidase inhibitor E Difficult 216/74 
‘ 
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Table 6-2 Bootstrap analysis of IRMSD on up to 5000 output decoys from NO-SAXS
protocol
 and from SAXS
protocol
 
runs. Data are extracted from Fig. 2, and the numbers refer to the number of cases where SAXSprotocol improves the 
docking result (  ), SAXSprotocol is equally good as NO-SAXSprotocol (  ), and NO-SAXSprotocol yields better results 
than SAXSprotocol (  ).  
Interval (Å) Rigid body Medium difficult Difficult 
  /  /   /  /   /  /  
1-2 8 / 15 / 5 2 / 4 / 0 0 / 4 / 0 
2-4 19 / 6 / 3 4 / 1 / 1 1 / 3 / 0 
4-8 15 / 4 / 9 5 / 1 / 0 3 / 0 / 1 
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SUPPLEMENTARY 
S1 METHODS 
DOCKING PROTOCOL AND IMPLEMENTATION OF SAXSCONSTRAIN IN ROSETTADOCK  
An overview of the docking protocol for RosettaDockSAXS is depicted in Figure S1. RosettaDock 
initially translates and orientates one of the input structures randomly, while the other structure is 
kept in place. Changes in rotation and translation are sampled from Gaussian distributions with 
spread of respectively 8° in rotation and 3 Å in translation. In this stage, the proteins are represented 
as centroids, and the docking partner is subjected to rigid body movement where the relative 
position of the partner is optimized and scored (Checkpoint 1). At this stage, we have implemented 
the SAXS constrains as an additional restrain to the RosettaDock scoring function. With this 
additional filter, only structures within a certain Chi squared (𝜒2) threshold are allowed into the 
next high resolution step.  
Comparison between the calculated X-ray scattering of a Rosetta pose (𝐼calc) and the estimated 
solution scattering (𝐼obs), RosettaDock determines the Chi squared (𝜒
2) value between the two 
curves, eq. 4. 𝜒2 is calculated between the input SAXS curve (𝐼obs) and the SAXS curve calculated 
for the current decoy (𝐼calc) using eq. 1. The two curves are initially aligned by estimation of a 
scaling factor according eq. 2. The procedure is similar to that performed by CRYSOL (16), though 
no fitting is performed.  
 
 
𝜒2(𝑞) =  
1
𝑁 ∙ 𝑄
∑[
𝐼obs(𝑞i) − 𝑐 ∙ 𝐼calc(𝑞i)
𝜎(𝑞i)
]
2𝑁∙𝑄
𝑖=1
              1)  
 
 
𝑐 = ∑[
𝐼calc(𝑞i) ∙ 𝐼obs(𝑞i)
𝜎(𝑞i)2
]
𝑁∙𝑄
𝑖=1
∑[
𝐼calc(𝑞i) ∙ 𝐼calc(𝑞i)
𝜎(𝑞i)2
]
𝑁∙𝑄
𝑖=1
⁄          2)  
 
where 𝑁 ∙ 𝑄 is the number of experimental points, and 𝜎 is the experimental error. The energy 
contribution to the overall score from the SAXSconstrain, is called “fastsaxs“, and it is a combination 
of the calculated 𝜒2 and a weight factor assigned to fastsaxs. We have chosen a weight factor of 0.5 
evaluated from a test of different values on a trial set resulting in an energy contribution to the 
scoring function that was within the range of the RosettaDock energies (data not shown). In the 
high resolution optimization stage, the proteins are converted back into full atomic representations 
as sidechains are added from the original unbound conformation. The refinement involves random 
orientation and translation of the protein docking partner. Values are sampled from Gaussian 
distribution with spread of respectively 3° in rotation and 0.1 Å in translation. Following the 
perturbation, the sidechain conformations are optimized. Before energy minimization, a scoring is 
applied in order to filter out decoys which have had a too large energy change (Checkpoint 2). This 
procedure is repeated 50 times for simultaneous optimization with a more rigorous sidechain 
repacking every eight cycle, and the final decoy is now scored (Checkpoint 3) (27). The docking 
procedure was only done in local docking mode, as the main interest was to evaluate whether the 
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implementation of SAXS constrains in RosettaDock could improve the prediction of native protein-
protein complexes.  
 
 
Figure S1: Overview of RosettaDockSAXS which combines low and high resolution steps. The low resolution step 
is a rigid body Monte Carlo search in coarse-grain mode where the amino acids are represented as centroids. In the high 
resolution step, the representation is full-atomic, and both the rigid body orientation and the sidechain conformations 
are simultaneously optimized (26, 27). Implementation of SAXSconstrain is done in the initial low resolution docking 
step. 
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 Conclusion and perspective 7
 
 
The study on the self-interaction of HSA in different solution systems, show how the solution 
properties of HSA is dependent on the excipients in the solution. Overall HSA show a repulsive 
behaviour due to is high surface charge. At high concentration the electrostatic repulsion dominate 
the protein-protein interaction which could result in an increasing order of the HSA molecules. It is 
proposed that this behaviour could result in the formation of a HSA network. HSA ability to 
stabilize other proteins at high concentration could then be by partitioning of the proteins into this 
network, hereby shielding the proteins from each other and avoiding aggregation. Studies on binary 
systems of HSA and other proteins at high concentrations will help shed light on the feasibility of 
this proposed model. We have shown that the tonicity is an important parameter for shielding of 
electrostatic interaction and the effect of salt on stability of the binary systems need to addressed as 
well. 
Half-life extension by interaction with HSA was investigated for two different systems. One where 
the interaction with HSA is mediated by a fatty acid moiety conjugated to a GLP-1 analogue 
(liraglutide) and second where aGLP-1 was chemically conjugated to Cys34 of HSA variants. 
Liraglutide is a concentration-independent oligomer in the present buffer system of probable 
heptameric size, as concluded from SAXS and MD simulations. The oligomer seems to be 
stabilized by interaction of the FA moieties. The binding of liraglutide to HSA was investigated by 
SLS and SAXS, but as the binding was observed to be weak, the complex is only present at low 
concentration. Whether this complex consists of monomer or oligomer binding to HSA is 
speculative. The SAXS result indicate that only 3 components are present in solution and 
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combining this with the most stable oligomer from the MD simulations, the Heptamer, it is probable 
that it is the heptameric form which binds via the free fatty acid chain. Both liraglutide and HSA 
show repulsive interaction in the present buffer systems and decreasing this repulsion could 
possibly increase the complex formation. Increasing the ionic strength too much could destabilize 
liraglutide, as this could increase inter-particle attraction due to the FA’s and an intermediate 
situation need to be established. SANS studies could be a way to gain insight to the role of the FA’s 
in both liraglutide oligomerization and possibly in complex formation through the use of contrast 
variation. As peptide and fatty acids has different chemical compositions this could be a very 
interesting approach.    
Conjugation of GLP-1 to Cys34 of HSA did not affect the in-vitro binding kinetics to FcRn while a 
decrease in half-life compared to WT albumin was observed in mice. This could be due to an 
increase in clearance in mice resulting from decreased FcRn affinity, though in-vivo steric 
hindrance of the conjugate cannot be ruled out. The conjugates had a decreased affinity for GLP-
1R, probably due to steric hindrance from HSA. SAXS derived structural models show that the 
GLP-1 protrudes out from the albumin molecules with a small degree of flexibility inferred by the 
linker. Combining SAXS results with modelling using crystal structures, confirms the findings that 
conjugation has limited effect on the interaction with FcRn in-vitro, and describes how albumin 
interference decreases the affinity for GLP-1R. The decrease in GLP-1R affinity should be more 
than compensated for by the increased half-life, increasing the availability of the peptide drug. 
These results confirm the importance of utilizing higher affinity albumin variants when conjugating 
to albumin and show that the use of PEG as a stand-in for peptide drugs does not necessarily 
provide the correct picture. The use of albumin variants has many applications for both half-life 
extension and drug-delivery. An important issue is to keep the immunogenicity low for these 
variants. 
Finally a benchmark of using SAXS as a constrain to identify native-like protein complexes using 
RosettaDock has been presented. Overall we observe an improvement of the docking energy 
landscape by an increase in near native structures, which should make a positive identification more 
accessible. As the benchmark is based on a rigid body approach, limited backbone conformational 
change is accepted. This give rise to problems for complexes where conformational changes affect 
the overall shape of the complex such that the shape constrain induced by SAXS works against the 
energy function.  
The flexibility of the Rosetta protocols allow for incorporation of small molecules and potentially 
fatty acids. This could be a way to model the complexes and conjugates of this thesis where more 
detailed chemical information is taken into account. The liraglutide oligomer were probed by MD 
simulations but the HSA systems are too large for MD simulations.  The Rosetta program suite is an 
attractive approach to model unknown compounds and by identifying the potential pitfalls and 
advantages of combining this with SAXS, a first step has been taken to utilize the power of the 
combined approach. 
 
